U.S. patent application number 11/326221 was filed with the patent office on 2006-07-13 for heteroaromatic quinoline compounds.
This patent application is currently assigned to Pfizer Inc. Invention is credited to Christopher J. Helal, Dennis J. Hoover, John M. Humphrey, Patrick R. Verhoest.
Application Number | 20060154931 11/326221 |
Document ID | / |
Family ID | 36589327 |
Filed Date | 2006-07-13 |
United States Patent
Application |
20060154931 |
Kind Code |
A1 |
Verhoest; Patrick R. ; et
al. |
July 13, 2006 |
Heteroaromatic quinoline compounds
Abstract
The invention pertains to heteroaromatic compounds that serve as
effective phosphodiesterase (PDE) inhibitors. In particular, the
invention relates to said compounds which are selective inhibitors
of PDE10. The invention also relates to intermediates for
preparation of said compounds; pharmaceutical compositions
comprising said compounds; and the use of said compounds in a
method for treating certain central nervous system (CNS) or other
disorders.
Inventors: |
Verhoest; Patrick R.; (Old
Lyme, CT) ; Helal; Christopher J.; (East Lyme,
CT) ; Hoover; Dennis J.; (Mysic, CT) ;
Humphrey; John M.; (Mystic, CT) |
Correspondence
Address: |
PFIZER INC
150 EAST 42ND STREET
5TH FLOOR - STOP 49
NEW YORK
NY
10017-5612
US
|
Assignee: |
Pfizer Inc
|
Family ID: |
36589327 |
Appl. No.: |
11/326221 |
Filed: |
January 5, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60642058 |
Jan 7, 2005 |
|
|
|
Current U.S.
Class: |
514/249 ;
514/252.04; 514/256; 514/314; 544/238; 544/333; 544/353;
546/167 |
Current CPC
Class: |
A61P 25/22 20180101;
A61P 25/30 20180101; A61P 15/08 20180101; A61P 25/28 20180101; A61P
25/24 20180101; A61P 25/36 20180101; A61P 9/10 20180101; A61P 25/16
20180101; A61P 43/00 20180101; A61P 25/14 20180101; C07D 413/14
20130101; A61P 3/04 20180101; A61P 25/18 20180101; C07D 401/14
20130101; A61P 25/32 20180101; A61P 25/00 20180101; A61P 25/08
20180101 |
Class at
Publication: |
514/249 ;
514/256; 514/314; 544/333; 544/353; 546/167; 514/252.04;
544/238 |
International
Class: |
A61K 31/506 20060101
A61K031/506; A61K 31/498 20060101 A61K031/498; A61K 31/4709
20060101 A61K031/4709; C07D 403/14 20060101 C07D403/14; C07D 401/14
20060101 C07D401/14 |
Claims
1. A compound of formula I or a pharmaceutical acceptable salt
thereof, ##STR31## wherein Z is ##STR32## R.sup.1 is each
independently selected from a group consisting of hydrogen,
halogen, hydroxyl, cyano, C.sub.1 to C.sub.8 alkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8
alkoxy, C.sub.1 to C.sub.8 haloalkyl, C.sub.3 to C.sub.8
cycloalkyl, C.sub.3 to C.sub.8 cycloalkyl-C.sub.1 to C.sub.8 alkyl,
4 to 7 membered heterocycloalkyl, C.sub.1 to C.sub.8 alkylthio,
--NR.sup.3R.sup.3--O--CF.sub.3, --S(O).sub.n--R.sup.3,
C(O)--NR.sup.3R.sup.3, and C.sub.1 to C.sub.8 alkyl substituted
with a heteroatom wherein the heteroatom is selected from a group
consisting of nitrogen, oxygen and sulfur and wherein the
heteroatom may be further substituted with a substituent selected
from a group consisting of hydrogen, C.sub.1 to C.sub.8 alkyl,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2
to C.sub.8 alkynyl, and C.sub.1 to C.sub.8 haloalkyl; each R.sup.3
is independently selected from a group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to
C.sub.8 alkynyl, C.sub.1 to C.sub.8 haloalkyl, C.sub.3 to C.sub.8
cycloalkyl; R.sup.2 is selected from a group consisting of
hydrogen, C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl,
C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8 haloalkyl and
C.sub.3 to C.sub.8 cycloalkyl; HET.sup.1 is selected from a group
consisting of a monocyclic heteroaryl and a bicyclic heteroaryl,
wherein the monocyclic and bicyclic heteroaryl may be optionally
substituted with at least one R.sup.4; R.sup.4 is selected from a
group consisting of halogen, hydroxyl, cyano, C.sub.1 to C.sub.8
alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl,
C.sub.1 to C.sub.8 alkoxy, C.sub.3 to C.sub.8 cycloalkyl, C.sub.3
to C.sub.8 cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8
alkylthiol and C.sub.1 to C.sub.8 alkyl substituted with a
substituent selected from a group consisting of --OR.sup.8,
--NR.sup.8R.sup.8, and --SR.sup.8, wherein R.sup.8 is independently
selected from a group consisting of hydrogen and C.sub.1 to C.sub.8
alkyl; HET.sup.2 is a monocyclic or bicyclic heteroaryl, wherein
the monocyclic and bicyclic heteroaryl may be substituted with at
least one R.sup.5, with the proviso that HET.sup.2 is not
tetrazole; R.sup.5 is independently selected from a group
consisting of halogen, hydroxyl, cyano, C.sub.1 to C.sub.8 alkyl,
C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to
C.sub.8 alkoxy, C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkylthio,
--NR7R7, and C.sub.1 to C.sub.8 haloalkyl; B.sup.1 and B.sup.2 are
adjacent atoms in Het.sup.1 which are independently selected from a
group consisting of carbon and nitrogen; bond j is a covalent bond
between Z and B.sup.2; bond k is a bond in Het.sup.1 between
B.sup.1 and B.sup.2; X and X.sup.1 are each independently selected
from a group consisting of oxygen, sulfur, C(R.sub.2).sub.2 and
NR.sub.2; provided that at least one of X and X.sup.1 is carbon; Y
is selected from a group consisting of carbon and nitrogen,
provided that when Y is carbon it is substituted with R.sup.6;
wherein each R.sup.6 is independently selected from a group
consisting of hydrogen, halogen, hydroxyl, cyano, C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to C.sub.8 cycloalkyl,
C.sub.1 to C.sub.8 alkylthio, C.sub.1 to C.sub.8 haloalkyl,
NR.sup.7R.sup.7--O--CF.sub.3, --S(O)m-R.sup.7, and
C(O)--NR.sup.7R.sup.7, C.sub.1 to C.sub.8 alkyl substituted with a
heteroatom wherein the heteroatom is selected from a group
consisting of nitrogen, oxygen and sulfur and wherein the
heteroatom may be further substituted with a substituent selected
from a group consisting of hydrogen, C.sub.1 to C.sub.8 alkyl,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl,
C.sub.2 to C.sub.8 alkynyl, and C.sub.1 to C.sub.8 haloalkyl;
wherein each R.sup.7 is independently selected from a group
consisting of hydrogen and C.sub.1-C.sub.8alkyl; p is 1,2 or 3; n
is 0, 1 or 2; and m is 0, 1 or 2.
2. The compound of claim 1, wherein HET.sub.1 is a 5 membered
heterocyclic aromatic ring.
3. The compound of claim 1, wherein HET.sub.1 is selected from a
group consisting of pyrazole, isoxazole, triazole, oxazole,
thiazole and imidazole.
4. The compound of claim 1, wherein HET.sub.2 is selected from a
group consisting of 4-pyridyl, 4-pyridazine and isoxazole.
5. The compound of claim 1, wherein HET.sub.2 is 4-pyridyl.
6. The compound of claim 1, wherein the compound is selected from a
group consisting of: ##STR33##
7. The compound of claim 1, wherein the compound of formula I has
the following structure: ##STR34##
8. The compound of claim 1, wherein the compound of formula I has
the following structure: ##STR35##
9. The compound of claim 1, wherein Y is selected from a group
consisting of carbon and nitrogen, provided that not more than one
Y is nitrogen.
10. The compound of claim 1, wherein X.sup.1 is carbon and X is
oxygen.
11. The compound of claim 1, wherein all Y's are carbon.
12. A compound of formula I or a pharmaceutical salt thereof,
##STR36## wherein Z is ##STR37## R.sup.1 is each independently
selected from a group consisting of hydrogen, halogen, hydroxyl,
cyano, C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl,
C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to
C.sub.8 haloalkyl, C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to
C.sub.8 cycloalkyl-C.sub.1 to C.sub.8 alkyl, 4 to 7 membered
heterocycloalkyl, C.sub.1 to C.sub.8 alkylthio,
--NR.sup.3R.sup.3--O--CF.sub.3, --S(O).sub.n--R.sup.3,
C(O)--NR.sup.3R.sup.3, and C.sub.1 to C.sub.8 alkyl substituted
with a heteroatom wherein the heteroatom is selected from a group
consisting of nitrogen, oxygen and sulfur and wherein the
heteroatom may be further substituted with a substituent selected
from a group consisting of hydrogen, C.sub.1 to C.sub.8 alkyl,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2
to C.sub.8 alkynyl, and C.sub.1 to C.sub.8 haloalkyl; each R.sup.3
is independently selected from a group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to
C.sub.8 alkynyl, C.sub.1 to C.sub.8 haloalkyl, C.sub.3 to C.sub.8
cycloalkyl; R.sup.2 is selected from the group consisting of
hydrogen and C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl,
C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8 haloalkyl and
C.sub.3 to C.sub.8 cycloalkyl; HET.sup.1 is selected from a group
consisting of a monocyclic heteroaryl and a bicyclic heteroaryl,
wherein the monocyclic and bicyclic heteroaryl is substituted with
at least one R.sup.4; R.sup.4 is a C.sub.1 to C.sub.8 haloalkyl;
HET.sup.2 is a monocyclic or bicyclic heteroaryl, wherein the
monocyclic and bicyclic heteroaryl and may be substituted with at
least one R.sup.5; R.sup.5 is independently selected from a group
consisting of halogen, hydroxyl, cyano, C.sub.1 to Ca alkyl,
C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to
C.sub.8 alkoxy, C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl , C.sub.1 to C.sub.8 alkylthio,
--NR.sup.7R.sup.7and C.sub.1 to C.sub.8 haloalkyl; B.sup.1 and
B.sup.2 are adjacent atoms in Het.sup.1 which are independently
selected from a group consisting of carbon and nitrogen; bond j is
a covalent bond between Z and B.sup.2; bond k is a bond in
Het.sup.1 between B.sup.1 and B.sup.2; X and X.sup.1 are each
independently selected from the group consisting of oxygen, sulfur,
C(R.sub.2).sub.2 and NR.sub.2; provided that at least one of X or
X.sup.1 is carbon; Y is selected from a group consisting of carbon
and nitrogen, provided that when Y is carbon it is substituted with
R.sup.6; wherein each R.sup.6 is independently selected from a
group consisting of hydrogen, halogen, hydroxyl, cyano, C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to C.sub.8 cycloalkyl,
C.sub.3to C.sub.8 cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to
C.sub.8 alkylthio, C.sub.1 to C.sub.8 haloalkyl, --NR.sup.7R.sup.7,
--O--CF.sub.3, --S(O)m-R.sup.7, and C(O)--NR.sup.7R.sup.7C.sub.1 to
C.sub.8 alkyl substituted with a heteroatom wherein the heteroatom
is selected from a group consisting of nitrogen, oxygen and sulfur
and wherein the heteroatom may be further substituted with a
substituent selected from the group consisting of hydrogen, C.sub.1
to C.sub.8 alkyl, C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to C.sub.8
alkenyl, C.sub.2 to C.sub.8 alkynyl, and C.sub.1 to C.sub.8
haloalkyl; wherein each R.sup.7 is independently selected from the
group consisting of hydrogen and C.sub.1-C.sub.8alkyl; p is 1, 2 or
3; n is 0, 1 or 2; and m is 0, 1 or 2.
13. The compound of claim 1, wherein said compound is selected from
a group consisting of:
2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(2-Methyl-4-pyridin4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(2-Ethyl-4-pyridin4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(1-Ethyl-4-pyridin4-yl-1H-pyrazol-3-yl
)-phenoxymethyl]-quinoline;
Dimethyl-(2-{4-pyridin4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1--
yl}-ethyl)-amine;
Dimethyl-(2-{4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-
-yl}-ethyl)-amine;
1-{4-Pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-propa-
n-2-ol;
1-{4-Pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-y-
l}-propan-2-ol;
2-[4-(2-Isopropyl-4-pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinolin-
e; 2-[4-(4-Pyridin-4yl-isoxazol-5-yl)-phenoxymethyl]-quinoline;
2-[4-(5-Pyridin-4-yl-pyrimidin-4-yl)-phenoxymethyl]-quinoline;
2-[4-(2-Methyl-5-pyridin-4-yl-pyrimidin-4-yl)-phenoxymethyl]-quinoline;
2-[4-(2-Methyl-6-pyridin4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-phenoxymethyl-
]-quinoline;
2-[4-(2-Methyl-6-pyridin4-yl-[1,2,4]triazolo[1.5-a]pyrimidin-7-yl)-phenox-
ymethyl]-quinoline
2-[4-(4-Pyridazin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(1-Methyl-4-pyridazin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline-
;
2-[4-(2-Methyl-4-pyridazin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoli-
ne;
2-[4-(4-Pyrimidin-4yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(4-Pyridazin-3-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline;
2-{4-[4-(3-Methyl-isoxazol-5-yl)-2H-pyrazol-3-yl]-phenoxymethyl}-quinolin-
e; 2-{4-[2-Methyl4-(3-methyl-isoxazol-5-yl
)-2H-pyrazol-3-yl]-phenoxymethyl}-quinoline;
2-{4-[1-Methyl4-(3-methyl-isoxazol-5-yl)-1H-pyrazol-3-yl]-phenoxymethyl}--
quinoline;
2-{4-[2-Methyl-5-(3-methyl-isoxazol-5-yl)-pyrimidin4-yl]-phenoxymethyl}-q-
uinoline;
2-[4-(2-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(3-Methyl-5-pyridin-4-yl[1
,2,4]triazol-4-yl)-phenoxymethyl]-quinoline;
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoxaline
7-Chloro-2-[4-(1-methyl4-pyridin-4-yl-1H-pyrazol-3-yl
)-phenoxymethyl]-quinoline hydrogen chloride;
6-Fluoro-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qu-
inoline hydrogen chloride;
2-[2-Fluoro4-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[2-Fluoro4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline;
2-[2,3-Difluoro-4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-pheno-
xymethyl]-quinoline;
2-[3-Fluoro-4-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[4-(5-Pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline;
2-[4-(1-Methyl-5-pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline
2-[4-(1-Methyl-3-pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline;
2-Methyl-1-{4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1--
yl}-propan-2-ol;
2-Methyl-1-{4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1--
yl}-propan-2-ol;
(R)-1-{4-Pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-p-
ropan-2-ol;
(S)-1-{4-Pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-p-
ropan-2-ol;
2-[4-(1-Isopropyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinolin-
e;
2-[4-(1-Isobutyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinol-
ine;
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-[1.8]n-
aphthyridine;
2-{2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline;
2-{2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenyl]-ethyl}-quinolin-
e;
2-{4-[4-(2-Chloro-pyridin-4-yl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinol-
ine;
2-{4-[4-(2-Chloro-pyridin-4-yl)-1-methyl-1H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoline;
2-{4-[1-Methyl-4-(2-methyl-pyridin-4-yl)-1H-pyrazol-3-yl]-phenoxymethyl}--
quinoline;
Dimethyl-(4-{1-methyl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-1H-pyrazol-4-yl-
}-pyridin-2-yl)-amine;
2-[4-(5-Pyridin-4-yl-pyrazol-1-yl)-phenoxymethyl]-quinoline;
2-[4-(3-Methyl-5-pyridin-4-yl-pyrazol-1-yl)-phenoxymethyl]-quinoline;
2-[2-Chloro-4-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline;
2-[2-Chloro4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline; 2-[4-(4-Pyridin-4-yl-4H-[1,2,4]triazol-3-yl
)-phenoxymethyl]-quinoline;
2-[4-(5-Pyridin-4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinoline;
2-[4-(3-Methyl-5-pyridin-4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinoli-
ne;
2-[4-(2-Pyridin-4-yl-2H-[1,2,4]triazol-3-yl)-phenoxymethyl]-quinoline-
;
2-[4-(5-Methyl-2-pyridin-4-yl-2H-[1,2,4]triazol-3-yl)-phenoxymethyl]-qu-
inoline;
8-Methoxy-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-
methyl]-quinoline;
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-pyrido[1,2--
a]pyrimidin-4-one;
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinazoline-
;
2-[3-Fluoro4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-q-
uinoline;
4-Chloro-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-
methyl]-quinoline;
4-Methoxy-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-q-
uinoline; Dimethyl-{2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl
)-phenoxymethyl]-quinolin-4-yl}-amine;
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-benzyloxy]-quinoline
di-succinic acid;
2-((4-(5-(pyridin-4-yl)oxazol-4-yl)phenoxy)methyl)quinoline;
2-((4-(2-methyl-5-(pyridin-4-yl)oxazol-4-yl)phenoxy)methyl)quinoline;
2-((4-(3-Methyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline-
;
2-((4-(1,3-dimethyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)qui-
noline;
2-((4-(1,5-dimethyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)meth-
yl)quinoline;
2-(1-(4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)ethyl)quinolin-
e;
2-((4-(5-(pyridin-4-yl)-1,2,3-triazol-4-yl)phenoxy)methyl)quinoline;
2-((4-(2-methyl-5-(pyridin-4-yl)-2H-1,2,3-triazol-4-yl)phenoxy)methyl)qui-
noline;
2-((4-(3-methyl-5-(pyridin-4-yl)-3H-1,2,3-triazol-4-yl)phenoxy)me-
thyl)quinoline;
2-((4-(1-(pyridin-4-yl)-1H-imidazol-2-yl)phenoxy)methyl)quinoline;
2-((4-(5-(pyridin-4-yl)-1H-imidazol-1-yl)phenoxy)methyl)quinoline;
2-((4-(2-methyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)phenoxy)methyl)quinolin-
e; 2-((4-(2-ethyl-5-(pyridin-4-yl
)-1H-imidazol-1-yl)phenoxy)methyl)quinoline; 2-((4-(2-(pyridin-4-yl
)-1H-imidazol-1-yl)phenoxy)methyl )quinoline; and pharmecutical
acceptable salts thereof.
14. The compound of claim 12, wherein said compound is selected
from a group consisting of:
2-{4-[-Pyridin-4-yl-2-(2,2,2-trifluoro-ethyl)-2H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoline;
2-{4-[-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoline;
2-{3-Fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]--
phenoxymethyl}-quinoline;
2-3-Fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-p-
henoxymethyl}-quinoxaline;
2-{4-[4-Pyridin4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoxaline; and pharmecutical acceptable salts thereof.
15. A process for forming the compound of Formula I in claim 1,
comprising a step of reacting a compound of formula IV ##STR38##
with dimethoxymethyl-dimethyl amine and hydrazine or substituted
hydrazine.
16. A process for forming the compound of Formula I in claim 1,
comprising a step of reacting a compound of formula V ##STR39##
with a compound of formula VI ##STR40## wherein Q is a hydroxyl or
a halide.
17. A pharmaceutical composition for treating psychotic disorders,
delusional disorders and drug induced psychosis; anxiety disorders,
movement disorders, mood disorders, neurodegenerative disorders,
obesity, and drug addiction, comprising an amount of a compound of
formula I according to claim 1 or claim 12 effective in treating
said disorder or condition.
18. A method of treating a disorder selected from psychotic
disorders, delusional disorders and drug induced psychosis; anxiety
disorders, movement disorders, mood disorders, obesity, and
neurodegenerative disorders, which method comprises administering
an amount of a compound of claim 1 or claim 12 effective in
treating said disorder.
19. The method of claim 18, wherein said disorder is selected from
the group consisting of: dementia, Alzheimer's disease,
multi-infarct dementia, alcoholic dementia or other drug-related
dementia, dementia associated with intracranial tumors or cerebral
trauma, dementia associated with Huntington's disease or
Parkinson's disease, or AIDS-related dementia; delirium; amnestic
disorder; post-traumatic stress disorder; mental retardation; a
learning disorder, for example reading disorder, mathematics
disorder, or a disorder of written expression;
attention-deficit/hyperactivity disorder; age-related cognitive
decline, major depressive episode of the mild, moderate or severe
type; a manic or mixed mood episode; a hypomanic mood episode; a
depressive episode with atypical features; a depressive episode
with melancholic features; a depressive episode with catatonic
features; a mood episode with postpartum onset; post-stroke
depression; major depressive disorder; dysthymic disorder; minor
depressive disorder; premenstrual dysphoric disorder;
post-psychotic depressive disorder of schizophrenia; a major
depressive disorder superimposed on a psychotic disorder comprising
a delusional disorder or schizophrenia; a bipolar disorder
comprising bipolar I disorder, bipolar II disorder, cyclothymic
disorder, Parkinson's disease; Huntington's disease; dementia,
Alzheimer's disease, multi-infarct dementia, AIDS-related dementia,
Fronto temperal Dementia; neurodegeneration associated with
cerebral trauma; neurodegeneration associated with stroke;
neurodegeneration associated with cerebral infarct;
hypoglycemia-induced neurodegeneration; neurodegeneration
associated with epileptic seizure; neurodegeneration associated
with neurotoxin poisoning; multi-system atrophy, paranoid,
disorganized, catatonic, undifferentiated or residual type;
schizophreniform disorder; schizoaffective disorder of the
delusional type or the depressive type; delusional disorder;
substance-induced psychotic disorder, psychosis induced by alcohol,
amphetamine, cannabis, cocaine, hallucinogens, obesity, inhalants,
opioids, or phencyclidine; personality disorder of the paranoid
type; and personality disorder of the schizoid type.
20. A method of treating psychotic disorders, delusional disorders
and drug induced psychosis; anxiety disorders, movement disorders,
mood disorders, neurodegenerative disorders, obesity, and drug
addiction which method comprises administering an amount of the
compound of claim 1 or claim 12 effective in inhibiting PDE10.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] The present application claims benefit of U.S. Ser. No.
60/642,058 filed on Jan. 7, 2005 which is incorporated by reference
herein in its entirety.
FIELD OF THE INVENTION
[0002] The invention pertains to heteroaromatic compounds that
serve as effective phosphodiesterase (PDE) inhibitors. The
invention also relates to compounds which are selective inhibitors
of PDE10. The invention further relates to intermediates for
preparation of such compounds; pharmaceutical compositions
comprising such compounds; and the use of such compounds in methods
for treating certain central nervous system (CNS) or other
disorders. The invention relates also to methods for treating
neurodegenerative and psychiatric disorders, for example psychosis
and disorders comprising deficient cognition as a symptom.
BACKGROUND OF INVENTION
[0003] Phosphodiesterases (PDEs) are a class of intracellular
enzymes involved in the hydrolysis of the nucleotides cyclic
adenosine monophosphate (cAMP) and cyclic guanosine monophosphates
(cGMP) into their respective nucleotide monophosphates. The cyclic
nucleotides cAMP and cGMP are synthesized by adenylyl and guanylyl
cyclases, respectively, and serve as secondary messengers in
several cellular pathways.
[0004] The cAMP and cGMP function as intracellular second
messengers regulating a vast array of intracellular processes
particularly in neurons of the central nervous system. In neurons,
this includes the activation of cAMP and cGMP-dependent kinases and
subsequent phosphorylation of proteins involved in acute regulation
of synaptic transmission as well as in neuronal differentiation and
survival. The complexity of cyclic nucleotide signaling is
indicated by the molecular diversity of the enzymes involved in the
synthesis and degradation of cAMP and cGMP. There are at least ten
families of adenylyl cyclases, two of guanylyl cyclases, and eleven
of phosphodiesterases. Furthermore, different types of neurons are
known to express multiple isozymes of each of these classes, and
there is good evidence for compartmentalization and specificity of
function for different isozymes within a given neuron.
[0005] A principal mechanism for regulating cyclic nucleotide
signaling is by phosphodiesterase-catalyzed cyclic nucleotide
catabolism. There are 11 known families of PDEs encoded by 21
different genes. Each gene typically yields multiple splice
variants that further contribute to the isozyme diversity. The PDE
families are distinguished functionally based on cyclic nucleotide
substrate specificity, mechanism(s) of regulation, and sensitivity
to inhibitors. Furthermore, PDEs are differentially expressed
throughout the organism, including in the central nervous system.
As a result of these distinct enzymatic activities and
localization, different PDEs' isozymes can serve distinct
physiological functions. Furthermore, compounds that can
selectively inhibit distinct PDE families or isozymes may offer
particular therapeutic effects, fewer side effects, or both.
[0006] PDE10 is identified as a unique family based on primary
amino acid sequence and distinct enzymatic activity. Homology
screening of EST databases revealed mouse PDE10A as the first
member of the PDE10 family of PDEs (Fujishige et al., J. Biol.
Chem. 274:18438-18445, 1999; Loughney, K. et al., Gene 234:109-117,
1999). The murine homologue has also been cloned (Soderling, S. et
al., Proc. Natl. Acad. Sci. USA 96:7071-7076, 1999)and N-terminal
splice variants of both the rat and human genes have been
identified (Kotera, J. et al., Biochem. Biophys. Res. Comm.
261:551-557, 1999; Fujishige, K. et al., Eur. J. Biochem.
266:1118-1127, 1999). There is a high degree of homology across
species. The mouse PDE10A1 is a 779 amino acid protein that
hydrolyzes both cAMP and cGMP to AMP and GMP, respectively. The
affinity of PDE10 for cAMP (Km=0.05 .mu.M) is higher than for cGMP
(Km=3 .mu.M). However, the approximately 5-fold greater Vmax for
cGMP over cAMP has lead to the suggestion that PDE10 is a unique
cAMP-inhibited cGMPase (Fujishige et al., J. Biol. Chem.
274:18438-18445, 1999).
[0007] The PDE 10 family of polypeptides shows a lower degree of
sequence homology as compared to previously identified PDE families
and has been shown to be insensitive to certain inhibitors that are
known to be specific for other PDE families. U.S. Pat. No.
6,350,603, incorporated herein by reference.
[0008] PDE10 also is uniquely localized in mammals relative to
other PDE families. mRNA for PDE10 is highly expressed only in
testis and brain (Fujishige, K. et al., Eur J Biochem.
266:1118-1127, 1999; Soderling, S. et al., Proc. Natl. Acad. Sci.
96:7071-7076, 1999; Loughney, K. et al., Gene 234:109-117, 1999).
These initial studies indicated that within the brain PDE10
expression is highest in the striatum (caudate and putamen), n.
accumbens, and olfactory tubercle. More recently, a detailed
analysis has been made of the expression pattern in rodent brain of
PDE10 mRNA (Seeger, T. F. et al., Abst. Soc. Neurosci. 26:345.10,
2000) and PDE10 protein (Menniti, F. S., Stick, C. A., Seeger, T.
F., and Ryan, A. M., Immunohistochemical localization of PDE10 in
the rat brain. William Harvey Research Conference
`Phosphodiesterase in Health and Disease`, Porto, Portugal, Dec.
5-7, 2001).
[0009] A variety of therapeutic uses for PDE inhibitors has been
reported including obtrusive lung disease, allergies, hypertension,
angina, congestive heart failure, depression and erectile
dysfunction (WO 01/41807 A2, incorporated herein by reference).
[0010] The use of selected benzimidazole and related heterocyclic
compounds in the treatment of ischemic heart conditions has been
disclosed based upon inhibition of PDE associated cGMP activity.
U.S. Pat. No. 5,693,652, incorporated herein by reference.
[0011] United States Patent Application Publication No.
2003/0032579 discloses a method for treating certain neurologic and
psychiatric disorders with the selective PDE10 inhibitor
papaverine. In particular, the method relates to psychotic
disorders such as schizophrenia, delusional disorders and
drug-induced psychosis; to anxiety disorders such as panic and
obsessive-compulsive disorder; and to movement disorders including
Parkinson's disease and Huntington's disease.
SUMMARY OF THE INVENTION
[0012] The present invention provides for compounds of formula I or
pharmaceutical salts thereof, ##STR1## wherein Z is ##STR2##
[0013] R.sub.1 is each independently selected from a group
consisting of hydrogen, halogen, hydroxyl, cyano, C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to C.sub.8 haloalkyl,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, 4 to 7 membered
heterocycloalkyl, C.sub.1 to C.sub.8 alkylthio, --NR.sup.3R.sup.3,
--O--CF.sub.3, --S(O).sub.n--R.sup.3, C(O)--NR.sup.3R.sup.3, and
C.sub.1 to C.sub.8 substituted with a heteroatom wherein the
heteroatom is selected from a group consisting of nitrogen, oxygen
and sulfur and wherein the heteroatom may be further substituted
with a substituent selected from a group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, and C.sub.1 to C.sub.8
haloalkyl;
[0014] each R.sup.3 is independently selected from a group
consisting of hydrogen, C.sub.1 to C.sub.8 alkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8
haloalkyl, C.sub.3 to C.sub.8 cycloalkyl;
[0015] R.sup.2 is selected from the group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8 cycloalkyl-C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 haloalkyl and C.sub.3 to C.sub.8
cycloalkyl;
[0016] HET.sup.1 is selected from a group consisting of a
monocyclic heteroaryl and a bicyclic heteroaryl, wherein the
monocyclic and bicyclic heteroaryl may be optionally substituted
with at least one R.sup.4 and;
[0017] R.sup.4 is selected from a group consisting of halogen,
hydroxyl, cyano, C.sub.1 to C.sub.8 alkyl, C.sub.2 to C.sub.8
alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8 alkoxy,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkylthio,
and C.sub.1 to C.sub.8 alkyl substituted with a substituent is
selected from the group consisting of --OR.sup.8,
--NR.sup.8R.sup.8, and --SR.sup.8, wherein R.sup.8 is independently
selected from the group consisting of hydrogen and C.sub.1 to
C.sub.8 alkyl
[0018] HET.sup.2 is a monocyclic or bicyclic heteroaryl, wherein
the monocyclic and bicyclic heteroaryl optionally substituted with
at least one R.sup.5, with the proviso that HET.sup.2 is not
tetrazole;
[0019] R.sup.5 is independently selected from a group consisting of
halogen, hydroxyl, cyano, C.sup.1 to C.sub.8 alkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8
alkoxy, C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkylthio,
--NR.sup.7R.sup.7 and C.sub.1 to C.sub.8 haloalkyl;
[0020] B.sup.1 and B.sup.2 are adjacent atoms in Het.sup.1 which
are independently selected from a group consisting of carbon and
nitrogen;
[0021] bond j is a covalent bond between Z and B.sup.2;
[0022] bond k is a covalent bond in Het.sup.1 between B.sup.1 and
B.sup.2;
[0023] X and X.sup.1 are each independently selected from the group
consisting of oxygen, sulfur, C(R.sub.2).sub.2 and NR.sub.2;
provided that at least one of X or X.sup.1 is carbon;
[0024] Y is selected from a group consisting of carbon and
nitrogen, provided that when Y is carbon it is substituted with
R.sup.6;
[0025] wherein each R.sup.6 is independently selected from a group
consisting of hydrogen, halogen, hydroxyl, cyano, C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to C.sub.8 cycloalkyl,
C.sub.3 to C.sub.8 cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to
C.sub.8 alkylthio, C.sub.1 to C.sub.8 haloalkyl, --NR.sup.7R.sup.7,
--O--CF.sub.3, --S(O)m-R.sup.7, and C(O)--NR.sup.7R.sup.7, C.sub.1
to C.sub.8 alkyl substituted with a heteroatom wherein the
heteroatom is selected from a group consisting of nitrogen, oxygen
and sulfur and wherein the heteroatom may be further substituted
with a substituent selected from the group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl and C.sub.1 to C.sub.8
haloalkyl;
[0026] wherein each R.sup.7 is independently selected from the
group consisting of hydrogen and C.sub.1-C.sub.8 alkyl; p is 1, 2
or 3; n is 0, 1 or 2; and m is 0, 1 or 2.
[0027] In another embodiment, the present invention provides for
compounds of formula I or pharmaceutical salts thereof; ##STR3##
wherein Z is ##STR4##
[0028] R.sup.1 is each independently selected from a group
consisting of hydrogen, halogen, hydroxyl, cyano, C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to C.sub.8 haloalkyl,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, 4 to 7 membered
heterocycloalkyl, C.sub.1 to C.sub.8 alkylthio, --NR.sup.3R.sup.3,
--O--CF.sub.3, --S(O).sub.n--R.sup.3, C(O)--NR.sup.3R.sup.3, and
C.sub.1 to C.sub.8 alkyl substituted with a heteroatom wherein the
heteroatom is selected from a group consisting of nitrogen, oxygen
and sulfur and wherein the heteroatom may be further substituted
with a substituent selected from a group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, and C.sub.1 to C.sub.8
haloalkyl;
[0029] each R.sup.3 is independently selected from a group
consisting of hydrogen, C.sub.1 to C.sub.8 alkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8
haloalkyl, C.sub.3 to C.sub.8 cycloalkyl;
[0030] R.sup.2 is selected from the group consisting of hydrogen,
C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.8 cycloalkyl-C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl C.sub.2 to C.sub.8 alkenyl, C.sub.1 to C.sub.8 haloalkyl
and C.sub.3 to C.sub.8 cycloalkyl;
[0031] HET.sup.1 is selected from a group consisting of a
monocyclic heteroaryl and a bicyclic heteroaryl, wherein the
monocyclic and bicyclic heteroaryl may be optionally substituted
with at least one R.sup.4;
[0032] R.sup.4 is selected from a group consisting of C.sub.1 to
C.sub.8 haloalkyl;
[0033] HET2 is a monocyclic or bicyclic heteroaryl, wherein the
monocyclic and bicyclic heteroaryl and may be substituted with at
least one R.sup.5;
[0034] R.sup.5 is independently selected from a group consisting of
halogen, hydroxyl, cyano, C.sub.1 to C.sub.8 alkyl, C.sub.2 to
C.sub.8 alkenyl, C.sub.2 to C.sub.8 alkynyl, C.sub.1 to C.sub.8
alkoxy, C.sub.3 to C.sub.8 cycloalkyl, C.sub.3 to C.sub.8
cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to C.sub.8 alkylthio,
--NR.sup.7R.sup.7, and C.sub.1 to C.sub.8 haloalkyl;
[0035] B.sup.1 and B.sup.2 are adjacent atoms in Het.sup.1 which
are independently selected from a group consisting of carbon and
nitrogen;
[0036] bond j is a covalent bond between Z and B.sup.2;
[0037] bond k is a bond in Het.sup.1 between B.sup.1 and
B.sup.2;
[0038] X and X.sup.1 are each independently selected from the group
consisting of oxygen, sulfur, C(R.sub.2).sub.2 and NR.sub.2,
provided that at least one of X or X.sup.1 is carbon;
[0039] Y is selected from a group consisting of carbon and
nitrogen, provided that when Y is carbon it is substituted with
R.sup.6;
[0040] wherein each R.sub.6 is independently selected from a group
consisting of hydrogen, halogen, hydroxyl, cyano, C.sub.1 to
C.sub.8 alkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2 to C.sub.8
alkynyl, C.sub.1 to C.sub.8 alkoxy, C.sub.1 to C.sub.8 cycloalkyl,
C.sub.3 to C.sub.8 cycloalkyl-C.sub.1 to C.sub.8 alkyl, C.sub.1 to
C.sub.8 alkylthio, C.sub.1 to C.sub.8 haloalkyl,
NR.sup.7R.sup.7--O--CF.sub.3, --S(O)m-R.sup.7, and
C(O)--NR.sup.7R.sup.7. C.sub.1 to C.sub.8 alkyl substituted with a
heteroatom wherein the heteroatom is selected from a group
consisting of nitrogen, oxygen and sulfur and wherein the
heteroatom may be further substituted with a substituent selected
from the group consisting of hydrogen, C.sub.1 to C.sub.8 alkyl,
C.sub.3 to C.sub.8 cycloalkyl, C.sub.2 to C.sub.8 alkenyl, C.sub.2
to C.sub.8 alkynyl, and C.sub.1 to C.sub.8 haloalkyl;
[0041] wherein each R.sup.7 is independently selected from the
group consisting of hydrogen and C.sub.1-C.sub.8alkyl; p is 1, 2 or
3; n is 0, 1 or 2 and m is 0, 1 or 2.
[0042] In one aspect of the present invention, Y is selected from a
group consisting of carbon and nitrogen, provided that not more
than one Y is nitrogen.
[0043] In another aspect of the present invention, X.sup.1 is
carbon and X is oxygen.
[0044] In another aspect of the present invention all Y's are
carbon (i.e., the heteroaryl is quinoline).
[0045] The present invention also provides compounds of formula I
or pharmaceutical salts thereof, wherein HET.sup.1 is a 5 membered
heteroaryl group. Preferably, HET.sup.1 is selected from a group
consisting of pyrazole, isoxazole, triazole, oxazole, thiazole and
imidazole.
[0046] The present invention also provides subgenera providing for
number of ring members for HET.sup.2 of formula I wherein HET.sup.2
is selected from a group consisting of 4-pyridyl, 4-pyridazine and
isoxazole. More preferably, HET.sup.2 is 4-pyridyl.
[0047] In a preferred embodiment, the invention is directed to a
compound of formula I(a)-I(k): ##STR5## wherein j, k, Z
HET.sup.2and R.sup.4 are as defined above. More preferably, the
compounds of formula I have the following general structure:
##STR6##
[0048] Most preferably, the compounds of formula I have the
following general structure: ##STR7##
[0049] In another aspect, for the above compounds of Formula I,
HET.sup.1 is not tetrazole.
[0050] Compounds of the Formula I may have optical centers and
therefore may occur in different enantiomeric and diastereomeric
configurations. The present invention includes all enantiomers,
diastereomers, and other stereoisomers of such compounds of the
Formula I, as well as racemic compounds and racemic mixtures and
other mixtures of stereoisomers thereof.
[0051] Pharmaceutically acceptable salts of the compounds of
Formula I include the acid addition and base salts thereof.
[0052] Suitable acid addition salts are formed from acids which
form non-toxic salts. Examples include, but are not limited to, the
acetate, adipate, aspartate, benzoate, besylate,
bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate,
citrate, cyclamate, edisylate, esylate, formate, fumarate,
gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate,
hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide,
isethionate, lactate, malate, maleate, malonate, mandelates
mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate,
nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen
phosphate/dihydrogen phosphate, pyroglutamate, salicylate,
saccharate, stearate, succinate, sulfonate, stannate, tartrate,
tosylate, trifluoroacetate and xinofoate salts.
[0053] Suitable base salts are formed from bases which form
non-toxic salts. Examples include, but are not limited to, the
aluminium, arginine, benzathine, calcium, choline, diethylamine,
diolamine, glycine, lysine, magnesium, meglumine, olamine,
potassium, sodium, tromethamine and zinc salts.
[0054] Hemisalts of acids and bases may also be formed, for
example, hemisulphate and hemicalcium salts.
[0055] For a review on suitable salts, see Handbook of
Pharmaceutical Salts: Properties, Selection, and Use by Stahl and
Wermuth (Wiley-VCH, 2002).
[0056] Pharmaceutically acceptable salts of compounds of Formula I
may be prepared by one or more of three methods:
[0057] (i) by reacting the compound of Formula I with the desired
acid or base;
[0058] (ii) by removing an acid- or base-labile protecting group
from a suitable precursor of the compound of Formula I or by
ring-opening a suitable cyclic precursor, for example, a lactone or
lactam, using the desired acid or base; or
[0059] (iii) by converting one salt of the compound of Formula I to
another by reaction with an appropriate acid or base or by means of
a suitable ion exchange column.
[0060] All three reactions are typically carried out in solution.
The resulting salt may precipitate out and be collected by
filtration or may be recovered by evaporation of the solvent. The
degree of ionization in the resulting salt may vary from completely
ionised to almost non-ionised.
[0061] The compounds of the invention may exist in a continuum of
solid states ranging from fully amorphous to fully crystalline. The
term `amorphous` refers to a state in which the material lacks long
range order at the molecular level and, depending upon temperature,
may exhibit the physical properties of a solid or a liquid.
Typically such materials do not give distinctive X-ray diffraction
patterns and, while exhibiting the properties of a solid, are more
formally described as a liquid. Upon heating, a change from solid
to liquid properties occurs which is characterised by a change of
state, typically second order (`glass transition`). The term
`crystalline` refers to a solid phase in which the material has a
regular ordered internal structure at the molecular level and gives
a distinctive X-ray diffraction pattern with defined peaks. Such
materials when heated sufficiently will also exhibit the properties
of a liquid, but the change from solid to liquid is characterised
by a phase change, typically first order (`melting point`).
[0062] The compounds of the invention may also exist in unsolvated
and solvated forms. The term `solvate` is used herein to describe a
molecular complex comprising the compound of the invention and one
or more pharmaceutically acceptable solvent molecules, for example,
ethanol. The term `hydrate` is employed when said solvent is
water.
[0063] A currently accepted classification system for organic
hydrates is one that defines isolated site, channel, or metal-ion
coordinated hydrates--see Polymorphism in Pharmaceutical Solids by
K. R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995). Isolated
site hydrates are ones in which the water molecules are isolated
from direct contact with each other by intervening organic
molecules. In channel hydrates, the water molecules lie in lattice
channels where they are next to other water molecules. In metal-ion
coordinated hydrates, the water molecules are bonded to the metal
iron.
[0064] When the solvent or water is tightly bound, the complex will
have a well-defined stoichiometry independent of humidity. When,
however, the solvent or water is weakly bound, as in channel
solvates and hygroscopic compounds, the water/solvent content will
be dependent on humidity and drying conditions. In such cases,
non-stoichiometry will be the norm.
[0065] The compounds of the invention may also exist in a
mesomorphic state (mesophase or liquid crystal) when subjected to
suitable conditions. The mesomorphic state is intermediate between
the true crystalline state and the true liquid state (either melt
or solution). Mesomorphism arising as the result of a change in
temperature is described as `thermotropic` and that resulting from
the addition of a second component, such as water or another
solvent, is described as `lyotropic`. Compounds that have the
potential to form lyotropic mesophases are described as
`amphiphilic` and consist of molecules which possess an ionic (such
as --COO.sup.-Na.sup.+, --COO.sup.-K.sup.+, or
--SO.sub.3.sup.-Na.sup.+) or non-ionic (such as
--N.sup.-N.sup.+(CH.sub.3).sub.3) polar head group. For more
information, see Crystals and the Polarizing Microscope by N. H.
Hartshorne and A. Stuart, 4.sup.th Edition (Edward Arnold,
1970).
[0066] Hereinafter all references to compounds of Formula I include
references to salts, solvates, multi-component complexes and liquid
crystals thereof and to solvates, multi-component complexes and
liquid crystals of salts thereof.
[0067] The compounds of the invention include compounds of Formula
I as hereinbefore defined, including all polymorphs and crystal
habits thereof, prodrugs and isomers thereof (including optical,
geometric and tautomeric isomers) as hereinafter defined and
isotopically-labeled compounds of Formula I.
[0068] As indicated, so-called `prodrugs` of the compounds of
Formula I are also within the scope of the invention. Thus certain
derivatives of compounds of Formula I which may have little or no
pharmacological activity themselves can, when administered into or
onto the body, be converted into compounds of Formula I having the
desired activity, for example, by hydrolytic cleavage. Such
derivatives are referred to as `prodrugs`. Further information on
the use of prodrugs may be found in Pro-drugs as Novel Delivery
Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella)
and Bioreversible Carriers in Drug Design, Pergamon Press, 1987
(Ed. E. B. Roche, American Pharmaceutical Association).
[0069] Prodrugs in accordance with the invention can, for example,
be produced by replacing appropriate functionalities present in the
compounds of Formula I with certain moieties known to those skilled
in the art as `pro-moieties` as described, for example, in Design
of Prodrugs by H. Bundgaard (Elsevier, 1985).
[0070] Some examples of prodrugs in accordance with the invention
include, but are not limited to,
[0071] (i) where the compound of Formula I contains a carboxylic
acid functionality (--COOH), an ester thereof, for example, a
compound wherein the hydrogen of the carboxylic acid functionality
of the compound of Formula (I) is replaced by
(C.sub.1-C.sub.8)alkyl;
[0072] (ii) where the compound of Formula I contains an alcohol
functionality (--OH), an ether thereof, for example, a compound
wherein the hydrogen of the alcohol functionality of the compound
of Formula I is replaced by (C.sub.1-C.sub.6)alkanoyloxymethyl;
and
[0073] (iii) where the compound of Formula I contains a primary or
secondary amino functionality (--NH.sub.2 or --NHR where
R.noteq.H), an amide thereof, for example, a compound wherein, as
the case may be, one or both hydrogens of the amino functionality
of the compound of Formula I is/are replaced by
(C.sub.1-C.sub.10)alkanoyl.
[0074] Further examples of replacement groups in accordance with
the foregoing examples and examples of other prodrug types may be
found in the aforementioned references.
[0075] Moreover, certain compounds of Formula I may themselves act
as prodrugs of other compounds of Formula I.
[0076] Also included within the scope of the invention are
metabolites of compounds of Formula I, that is, compounds formed in
vivo upon administration of the drug. Some examples of metabolites
in accordance with the invention include, but are not limited
to,
[0077] (i) where the compound of Formula I contains a methyl group,
an hydroxymethyl derivative thereof
(--CH.sub.3.fwdarw.--CH.sub.2OH):
[0078] (ii) where the compound of Formula I contains an alkoxy
group, an hydroxy derivative thereof (--OR.fwdarw.--OH);
[0079] (iii) where the compound of Formula I contains a tertiary
amino group, a secondary amino derivative thereof
(--NR.sup.1R.sup.2.fwdarw.--NHR.sup.1 or --NHR.sup.2);
[0080] (iv) where the compound of Formula I contains a secondary
amino group, a primary derivative thereof
(--NHR.sup.1.fwdarw.--NH.sub.2);
[0081] (v) where the compound of Formula I contains a phenyl
moiety, a phenol derivative thereof (-Ph.fwdarw.-PhOH); and
[0082] (vi) where the compound of Formula I contains an amide
group, a carboxylic acid derivative thereof
(--CONH.sub.2.fwdarw.COOH);
[0083] (vii) where the compound contains an aromatic nitrogen atom
or an tetrtiary aliphatic amine function, an N-oxide derivative
thereof.
[0084] Compounds of Formual I having a nitrogen atom in a tertiary
amine functional group may be further substituted with oxygen
(i.e., an N-oxide);
[0085] Compounds of Formula I containing one or more asymmetric
carbon atoms can exist as two or more stereoisomers. Where a
compound of Formula I contains an alkenyl or alkenylene group,
geometric cis/trans (or Z/E) isomers are possible. Where structural
isomers are interconvertible via a low energy barrier, tautomeric
isomerism (`tautomerism`) can occur. This can take the form of
proton tautomerism in compounds of Formula I containing, for
example, an imino, keto, or oxime group, or so-called valence
tautomerism in compounds that contain an aromatic moiety. It
follows that a single compound may exhibit more than one type of
isomerism.
[0086] Included within the scope of the present invention are all
stereoisomers, geometric isomers and tautomeric forms of the
compounds of Formula I, including compounds exhibiting more than
one type of isomerism, and mixtures of one or more thereof. Also
included are acid addition or base salts wherein the counterion is
optically active, for example, d-lactate or l-lysine, or racemic,
for example, dl-tartrate or dl-arginine.
[0087] Cis/trans isomers may be separated by conventional
techniques well known to those skilled in the art, for example,
chromatography and fractional crystallisation.
[0088] Conventional techniques for the preparation/isolation of
individual enantiomers include chiral synthesis from a suitable
optically pure precursor or resolution of the racemate (or the
racemate of a salt or derivative) using, for example, chiral high
pressure liquid chromatography (HPLC).
[0089] Alternatively, the racemate (or a racemic precursor) may be
reacted with a suitable optically active compound, for example, an
alcohol, or, in the case where the compound of Formula I contains
an acidic or basic moiety, a base or acid such as
1-phenylethylamine or tartaric acid. The resulting diastereomeric
mixture may be separated by chromatography and/or fractional
crystallization and one or both of the diastereoisomers converted
to the corresponding pure enantiomer(s) by means well known to a
skilled person.
[0090] Chiral compounds of the invention (and chiral precursors
thereof) may be obtained in enantiomerically-enriched form using
chromatography, typically HPLC, on an asymmetric resin with a
mobile phase consisting of a hydrocarbon, typically heptane or
hexane, containing from 0 to 50% by volume of isopropanol,
typically from 2% to 20%, and from 0 to 5% by volume of an
alkylamine, typically 0.1% diethylamine. Concentration of the
eluate affords the enriched mixture.
[0091] When any racemate crystallises, crystals of two different
types are possible. The first type is the racemic compound (true
racemate) referred to above wherein one homogeneous form of crystal
is produced containing both enantiomers in equimolar amounts. The
second type is the racemic mixture or conglomerate wherein two
forms of crystal are produced in equimolar amounts each comprising
a single enantiomer.
[0092] While both of the crystal forms present in a racemic mixture
have identical physical properties, they may have different
physical properties compared to the true racemate. Racemic mixtures
may be separated by conventional techniques known to those skilled
in the art--see, for example, Stereochemistry of Organic Compounds
by E. L. Eliel and S. H. Wilen (Wiley, 1994).
[0093] The present invention includes all pharmaceutically
acceptable isotopically-labelled compounds of Formula I wherein one
or more atoms are replaced by atoms having the same atomic number,
but an atomic mass or mass number different from the atomic mass or
mass number which predominates in nature.
[0094] Examples of isotopes suitable for inclusion in the compounds
of the invention include, but are not limited to, isotopes of
hydrogen, such as .sup.2H and .sup.3H, carbon, such as .sup.11C,
.sup.13C and .sup.14C, chlorine, such as .sup.36Cl, fluorine, such
as .sup.18F, iodine, such as .sup.123I and .sup.125I, nitrogen,
such as .sup.13N and .sup.15N, oxygen, such as .sup.15O, .sup.17O
and .sup.18O, phosphorus, such as .sup.32P, and sulphur, such as
.sup.35S.
[0095] Certain isotopically-labelled compounds of Formula I, for
example, those incorporating a radioactive isotope, are useful in
drug and/or substrate tissue distribution studies. The radioactive
isotopes tritium, i.e. .sup.3H, and carbon-14, i.e. .sup.14C, are
particularly useful for this purpose in view of their ease of
incorporation and ready means of detection.
[0096] Substitution with heavier isotopes such as deuterium, i.e.
.sup.2H, may afford certain therapeutic advantages resulting from
greater metabolic stability, for example, increased in vivo
half-life or reduced dosage requirements, and hence may be
preferred in some circumstances.
[0097] Substitution with positron emitting isotopes, such as
.sup.11C, .sup.18F, .sup.15O and .sup.13N, can be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy.
[0098] Isotopically-labeled compounds of Formula I can generally be
prepared by conventional techniques known to those skilled in the
art or by processes analogous to those described in the
accompanying Examples and Preparations using an appropriate
isotopically-labeled reagent in place of the non-labeled reagent
previously employed.
[0099] Pharmaceutically acceptable solvates in accordance with the
invention include those wherein the solvent of crystallization may
be isotopically substituted, e.g. D.sub.2O, d.sub.6-acetone,
d.sub.6-DMSO.
[0100] Specific embodiments of the present invention include the
compounds exemplified in the Examples below and their
pharmaceutically acceptable salts, complexes, solvates, polymorphs,
steroisomers, metabolites, prodrugs, and other derivatives
thereof;
[0101] This invention also pertains to a pharmaceutical composition
for treatment of certain psychotic disorders and conditions such as
schizophrenia, delusional disorders and drug induced psychosis; to
anxiety disorders such as panic and obsessive-compulsive disorder;
and to movement disorders including Parkinson's disease and
Huntington's disease, comprising an amount of a compound of formula
I effective in inhibiting PDE 10.
[0102] In another embodiment, this invention relates to a
pharmaceutical composition for treating psychotic disorders and
condition such as schizophrenia, delusional disorders and drug
induced psychosis; anxiety disorders such as panic and
obsessive-compulsive disorder; and movement disorders including
Parkinson's disease and Huntington's disease, comprising an amount
of a compound of formula I effective in treating said disorder or
condition.
[0103] Examples of psychotic disorders that can be treated
according to the present invention include, but are not limited to,
schizophrenia, for example of the paranoid, disorganized,
catatonic, undifferentiated, or residual type; schizophreniform
disorder; schizoaffective disorder, for example of the delusional
type or the depressive type; delusional disorder; substance-induced
psychotic disorder, for example psychosis induced by alcohol,
amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids,
or phencyclidine; personality disorder of the paranoid type; and
personality disorder of the schizoid type.
[0104] Examples of movement disorders that can be treated according
to the present invention include but are not limited to selected
from Huntington's disease and dyskinesia associated with dopamine
agonist therapy, Parkinson's disease, restless leg syndrome, and
essential tremor.
[0105] Other disorders that can be treated according to the present
invention are obsessive/compulsive disorders, Tourette's syndrome
and other tic disorders.
[0106] In another embodiment, this invention relates to a method
for treating an anxiety disorder or condition in a mammal which
method comprises administering to said mammal an amount of a
compound of formula I effective in inhibiting PDE 10.
[0107] This invention also provides a method for treating an
anxiety disorder or condition in a mammal which method comprises
administering to said mammal an amount of a compound of formula I
effective in treating said disorder or condition.
[0108] Examples of anxiety disorders that can be treated according
to the present invention include, but are not limited to, panic
disorder; agoraphobia; a specific phobia; social phobia;
obsessive-compulsive disorder; post-traumatic stress disorder;
acute stress disorder; and generalized anxiety disorder.
[0109] This invention further provides a method of treating a drug
addiction, for example an alcohol, amphetamine, cocaine, or opiate
addiction, in a mammal, including a human, which method comprises
administering to said mammal an amount of a compound of formula I
effective in treating drug addiction.
[0110] This invention also provides a method of treating a drug
addiction, for example an alcohol, amphetamine, cocaine, or opiate
addiction, in a mammal, including a human, which method comprises
administering to said mammal an amount of a compound of formula I
effective in inhibiting PDE10.
[0111] A "drug addiction", as used herein, means an abnormal desire
for a drug and is generally characterized by motivational
disturbances such a compulsion to take the desired drug and
episodes of intense drug craving.
[0112] This invention further provides a method of treating a
disorder comprising as a symptom a deficiency in attention and/or
cognition in a mammal, including a human, which method comprises
administering to said mammal an amount of a compound of formula I
effective in treating said disorder.
[0113] This invention also provides a method of treating a disorder
or condition comprising as a symptom a deficiency in attention
and/or cognition in a mammal, including a human, which method
comprises administering to said mammal an amount of a compound of
formula I effective in inhibiting PDE10.
[0114] This invention also provides a method of treating a disorder
or condition comprising as a symptom a deficiency in attention
and/or cognition in a mammal, including a human, which method
comprises administering to said mammal an amount of a compound of
formula I effective in treating said disorder or condition.
[0115] The phrase "deficiency in attention and/or cognition" as
used herein in "disorder comprising as a symptom a deficiency in
attention and/or cognition" refers to a subnormal functioning in
one or more cognitive aspects such as memory, intellect, or
learning and logic ability, in a particular individual relative to
other individuals within the same general age population.
"Deficiency in attention and/or cognition" also refers to a
reduction in any particular individual's functioning in one or more
cognitive aspects, for example as occurs in age-related cognitive
decline.
[0116] Examples of disorders that comprise as a symptom a
deficiency in attention and/or cognition that can be treated
according to the present invention are dementia, for example
Alzheimer's disease, multi-infarct dementia, alcoholic dementia or
other drug-related dementia, dementia associated with intracranial
tumors or cerebral trauma, dementia associated with Huntington's
disease or Parkinson's disease, or AIDS-related dementia; delirium;
amnestic disorder; post-traumatic stress disorder; mental
retardation; a learning disorder, for example reading disorder,
mathematics disorder, or a disorder of written expression;
attention-deficit/hyperactivity disorder; and age-related cognitive
decline.
[0117] This invention also provides a method of treating a mood
disorder or mood episode in a mammal, including a human, comprising
administering to said mammal an amount of a compound of formula I
effective in treating said disorder or episode.
[0118] This invention also provides a method of treating a mood
disorder or mood episode in a mammal, including a human, comprising
administering to said mammal an amount of a compound of formula I
effective in inhibiting PDE10.
[0119] Examples of mood disorders and mood episodes that can be
treated according to the present invention include, but are not
limited to, major depressive episode of the mild, moderate or
severe type, a manic or mixed mood episode, a hypomanic mood
episode; a depressive episode with atypical features; a depressive
episode with melancholic features; a depressive episode with
catatonic features; a mood episode with postpartum onset;
post-stroke depression; major depressive disorder; dysthymic
disorder; minor depressive disorder; premenstrual dysphoric
disorder; post-psychotic depressive disorder of schizophrenia; a
major depressive disorder superimposed on a psychotic disorder such
as delusional disorder or schizophrenia; a bipolar disorder, for
example bipolar I disorder, bipolar II disorder, and cyclothymic
disorder.
[0120] This invention further provides a method of treating a
neurodegenerative disorder or condition in a mammal, including a
human, which method comprises administering to said mammal an
amount of a compound of formula I effective in treating said
disorder or condition.
[0121] This invention further provides a method of treating a
neurodegenerative disorder or condition in a mammal, including a
human, which method comprises administering to said mammal an
amount of a compound of formula I effective in inhibiting
PDE10.
[0122] As used herein, and unless otherwise indicated, a
"neurodegenerative disorder or condition" refers to a disorder or
condition that is caused by the dysfunction and/or death of neurons
in the central nervous system. The treatment of these disorders and
conditions can be facilitated by administration of an agent which
prevents the dysfunction or death of neurons at risk in these
disorders or conditions and/or enhances the function of damaged or
healthy neurons in such a way as to compensate for the loss of
function caused by the dysfunction or death of at-risk neurons. The
term "neurotrophic agent" as used herein refers to a substance or
agent that has some or all of these properties.
[0123] Examples of neurodegenerative disorders and conditions that
can be treated according to the present invention include, but are
not limited to, Parkinson's disease; Huntington's disease;
dementia, for example Alzheimer's disease, multi-infarct dementia,
AIDS-related dementia, and Fronto temperal Dementia;
neurodegeneration associated with cerebral trauma;
neurodegeneration associated with stroke, neurodegeneration
associated with cerebral infarct; hypoglycemia-induced
neurodegeneration; neurodegeneration associated with epileptic
seizure; neurodegeneration associated with neurotoxin poisoning;
and multi-system atrophy.
[0124] In one embodiment of the present invention, the
neurodegenerative disorder or condition comprises neurodegeneration
of striatal medium spiny neurons in a mammal, including a
human.
[0125] In a further embodiment of the present invention, the
neurodegenerative disorder or condition is Huntington's
disease.
[0126] This invention also provides a pharmaceutical composition
for treating psychotic disorders, delusional disorders and drug
induced psychosis; anxiety disorders, movement disorders, mood
disorders, neurodegenerative disorders, obesity, and drug
addiction, comprising an amount of a compound of formula I
effective in treating said disorder or condition.
[0127] This invention also provides a method of treating a disorder
selected from psychotic disorders, delusional disorders and drug
induced psychosis; anxiety disorders, movement disorders, obesity,
mood disorders, and neurodegenerative disorders, which method
comprises administering an amount of a compound of formula I
effective in treating said disorder.
[0128] This invention also provides a method of treating disorders
selected from the group consisting of: dementia, Alzheimer's
disease, multi-infarct dementia, alcoholic dementia or other
drug-related dementia, dementia associated with intracranial tumors
or cerebral trauma, dementia associated with Huntington's disease
or Parkinson's disease, or AIDS-related dementia; delirium;
amnestic disorder; post-traumatic stress disorder; mental
retardation; a learning disorder, for example reading disorder,
mathematics disorder, or a disorder of written expression;
attention-deficit/hyperactivity disorder; age-related cognitive
decline, major depressive episode of the mild, moderate or severe
type; a manic or mixed mood episode; a hypomanic mood episode; a
depressive episode with atypical features; a depressive episode
with melancholic features; a depressive episode with catatonic
features; a mood episode with postpartum onset; post-stroke
depression; major depressive disorder; dysthymic disorder; minor
depressive disorder; premenstrual dysphoric disorder;
post-psychotic depressive disorder of schizophrenia; a major
depressive disorder superimposed on a psychotic disorder comprising
a delusional disorder or schizophrenia; a bipolar disorder
comprising bipolar I disorder, bipolar II disorder, cyclothymic
disorder, Parkinson's disease; Huntington's disease; dementia,
Alzheimer's disease, multi-infarct dementia, AIDS-related dementia,
Fronto temperal Dementia; neurodegeneration associated with
cerebral trauma; neurodegeneration associated with stroke;
neurodegeneration associated with cerebral infarct;
hypoglycemia-induced neurodegeneration; neurodegeneration
associated with epileptic seizure; neurodegeneration associated
with neurotoxin poisoning; multi-system atrophy, paranoid,
disorganized, catatonic, undifferentiated or residual type;
schizophreniform disorder; schizoaffective disorder of the
delusional type or the depressive type; delusional disorder;
substance-induced psychotic disorder, psychosis induced by alcohol,
amphetamine, cannabis, cocaine, hallucinogens, obesity, inhalants,
opioids, or phencyclidine; personality disorder of the paranoid
type; and personality disorder of the schizoid type, which method
comprises administering an amounot of a compound of Formula I
effecting in said disorders.
[0129] This invention also provides a method of treating psychotic
disorders, delusional disorders and drug induced psychosis; anxiety
disorders, movement disorders, mood disorders, neurodegenerative
disorders, obesity, and drug addiction which method comprises
administering an amount of a compound of formula I effective in
inhibiting PDE10.
[0130] The term "alkyl", as used herein, unless otherwise
indicated, includes saturated monovalent hydrocarbon radicals
having straight or branched moieties. Examples of alkyl groups
include, but are not limited to, methyl, ethyl, propyl, isopropyl,
and t-butyl.
[0131] The term "alkenyl", as used herein, unless otherwise
indicated, includes alkyl moieties having at least one
carbon-carbon double bond wherein alkyl is as defined above.
Examples of alkenyl include, but are not limited to, ethenyl and
propenyl.
[0132] The term "alkynyl", as used herein, unless otherwise
indicated, includes alkyl moieties having at least one
carbon-carbon triple bond wherein alkyl is as defined above.
Examples of alkynyl groups include, but are not limited to, ethynyl
and 2-propynyl.
[0133] The term "alkoxy", as used herein, unless otherwise
indicated, as employed herein alone or as part of another group
refers to an alkyl, groups linked to an oxygen atom.
[0134] The term "alkylthio" as used herein, unless otherwise
indicated, employed herein alone or as part of another group
includes any of the above alkyl groups linked through a sulfur
atom.
[0135] The term "halogen" or "halo" as used herein alone or as part
of another group refers to chlorine, bromine, fluorine, and
iodine.
[0136] The term "haloalkyl" as used herein, unless otherwise
indicated, refers to at least one halo group, linked to an alkyl
group. Examples, of haloalkyl groups include, but are not limited,
to trifluoromethyl, trifluoroethyl, difluoromethyl and fluoromethyl
groups.
[0137] The term "cycloalkyl", as used herein, unless otherwise
indicated, includes non-aromatic saturated cyclic alkyl moieties
wherein alkyl is as defined above. Examples of cycloalkyl include,
but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, and cycloheptyl.
[0138] The term "aryl", as used herein, unless otherwise indicated,
includes an organic radical derived from an aromatic hydrocarbon by
removal of one hydrogen, such as phenyl, naphthyl, indenyl, and
fluorenyl. "Aryl" encompasses fused ring groups wherein at least
one ring is aromatic.
[0139] The terms "heterocyclic", "heterocycloalkyl", and like
terms, as used herein, refer to non-aromatic cyclic groups
containing one or more heteroatoms, prefereably from one to four
heteroatoms, each preferably selected from oxygen, sulfur and
nitrogen. The heterocyclic groups of this invention can also
include ring systems substituted with one or more oxo moieties.
Examples of non-aromatic heterocyclic groups are aziridinyl,
azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl,
1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl,
tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl,
morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl,
2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl,
dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl,
imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl,
3-azabicyclo[4.1.0]heptanyl, quinolizinyl, quinuclidinyl,
1,4-dioxaspiro[4.5]decyl, 1,4-dioxaspiro[4.4]nonyl,
1,4-dioxaspiro[4.3]octyl, and 1,4-dioxaspiro[4.2]heptyl.
[0140] The term "heteroaryl", as used herein, refers to aromatic
groups containing one or more heteroatoms (preferably oxygen,
sulfur and nitrogen), preferably from one to four heteroatoms. A
multicyclic group containing one or more heteroatoms wherein at
least one ring of the group is aromatic is a "heteroaryl" group.
The heteroaryl groups of this invention can also include ring
systems substituted with one or more oxo moieties. Heteroaryl
groups containing a tertiary nitrogen may also be further
substituted with oxygen (i.e., an N-oxide). Examples of heteroaryl
groups are pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl,
pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl,
furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl,
pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl,
indazolyl, indolizinyl, phthalazinyl, triazinyl, isoindolyl,
purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl,
benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl,
quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl,
tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl,
benzofuryl, furopyridinyl, pyrolopyrimidinyl, and azaindolyl. For
clarity, the term heteroaryl includes the heteroaryl structure in
substituent Z in Formula I (i.e., the heteroaryl structure
containing Y).
[0141] Unless otherwise indicated, the term "one or more"
substituents, or "at least one" substituent as used herein, refers
to from one to the maximum number of substituents possible based on
the number of available bonding sites.
[0142] Unless otherwise indicated, all the foregoing groups derived
from hydrocarbons may have up to about 1 to about 20 carbon atoms
(e.g. C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl,
C.sub.3-C.sub.20 cycloalkyl, 3-20 membered heterocycloalkyl;
C.sub.6-C.sub.20 aryl, 5-20 membered heteroaryl, etc.) or 1 to
about 15 carbon atoms (e.g., C.sub.1-C.sub.15 alkyl,
C.sub.2-C.sub.15 alkenyl, C.sub.3-C.sub.15 cycloalkyl, 3-15
membered heterocycloalkyl, C.sub.6-C.sub.15 aryl, 5-15 membered
heteroaryl, etc.) , or 1 to about 12 carbon atoms, or 1 to about 8
carbon atoms, or 1 to about 6 carbon atoms.
[0143] "Neurotoxin poisoning" refers to poisoning caused by a
neurotoxin. A neurotoxin is any chemical or substance that can
cause neural death and thus neurological damage. An example of a
neurotoxin is alcohol, which, when abused by a pregnant female, can
result in alcohol poisoning and neurological damage known as Fetal
Alcohol Syndrome in a newborn. Other examples of neurotoxins
include, but are not limited to, kainic acid, domoic acid, and
acromelic acid; certain pesticides, such as DDT; certain
insecticides, such as organophosphates; volatile organic solvents
such as hexacarbons (e.g. toluene); heavy metals (e.g. lead,
mercury, arsenic, and phosphorous); aluminum; certain chemicals
used as weapons, such as Agent Orange and Nerve Gas; and neurotoxic
antineoplastic agents.
[0144] As used herein, the term "selective PDE10 inhibitor" refers
to a substance, for example an organic molecule, that effectively
inhibits an enzyme from the PDE10 family to a greater extent than
enzymes from the PDE 1-9 families or PDE11 family. In one
embodiment, a selective PDE10 inhibitor is a substance, for example
an organic molecule, having a K.sub.i for inhibition of PDE10 that
is less than or about one-tenth the K.sub.i that the substance has
for inhibition of any other PDE enzyme. In other words, the
substance inhibits PDE10 activity to the same degree at a
concentration of about one-tenth or less than the concentration
required for any other PDE enzyme.
[0145] In general, a substance is considered to effectively inhibit
PDE10 activity if it has a K.sub.i of less than or about 10 .mu.M,
preferably less than or about 0.1 .mu.M.
[0146] A "selective PDE10 inhibitor" can be identified, for
example, by comparing the ability of a substance to inhibit PDE10
activity to its ability to inhibit PDE enzymes from the other PDE
families. For example, a substance may be assayed for its ability
to inhibit PDE10 activity, as well as PDE1A, PDE1B, PDE1C, PDE2,
PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, PDE6, PDE7, PDE8,
PDE9, and PDE11.
[0147] The term "treating", as in "a method of treating a
disorder", refers to reversing, alleviating, or inhibiting the
progress of the disorder to which such term applies, or one or more
symptoms of the disorder. As used herein, the term also
encompasses, depending on the condition of the patient, preventing
the disorder, including preventing onset of the disorder or of any
symptoms associated therewith, as well as reducing the severity of
the disorder or any of its symptoms prior to onset. "Treating" as
used herein refers also to preventing a recurrence of a
disorder.
[0148] For example, "treating schizophrenia, or schizophreniform or
schizoaffective disorder" as used herein also encompasses treating
one or more symptoms (positive, negative, and other associated
features) of said disorders, for example treating, delusions and/or
hallucination associated therewith. Other examples of symptoms of
schizophrenia and schizophreniform and schizoaffecctive disorders
include disorganized speech, affective flattening, alogia,
anhedonia, inappropriate affect, dysphoric mood (in the form of,
for example, depression, anxiety or anger), and some indications of
cognitive dysfunction.
[0149] The term "mammal", as used herein, refers to any member of
the class "Mammalia", including, but not limited to, humans, dogs,
and cats.
[0150] The compound of the invention may be administered either
alone or in combination with pharmaceutically acceptable carriers,
in either single or multiple doses. Suitable pharmaceutical
carriers include inert solid diluents or fillers, sterile aqueous
solutions and various organic solvents. The pharmaceutical
compositions formed thereby can then be readily administered in a
variety of dosage forms such as tablets, powders, lozenges, liquid
preparations, syrups, injectable solutions and the like. These
pharmaceutical compositions can optionally contain additional
ingredients such as flavorings, binders, excipients and the like.
Thus, the compound of the invention may be formulated for oral,
buccal, intranasal, parenteral (e.g. intravenous, intramuscular or
subcutaneous), transdermal (e.g. patch) or rectal administration,
or in a form suitable for administration by inhalation or
insufflation.
[0151] For oral administration, the pharmaceutical compositions may
take the form of, for example, tablets or capsules prepared by
conventional means with pharmaceutically acceptable excipients such
as binding agents (e.g. pregelatinized maize starch,
polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers
(e.g. lactose, microcrystalline cellulose or calcium phosphate);
lubricants (e.g. magnesium stearate, talc or silica); disintegrants
(e.g. potato starch or sodium starch glycolate); or wetting agents
(e.g. sodium lauryl sulphate). The tablets may be coated by methods
well known in the art. Liquid preparations for oral administration
may take the form of, for example, solutions, syrups or
suspensions, or they may be presented as a dry product for
constitution with water or other suitable vehicle before use. Such
liquid preparations may be prepared by conventional means with
pharmaceutically acceptable additives such as suspending agents
(e.g. sorbitol syrup, methyl cellulose or hydrogenated edible
fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous
vehicles (e.g. almond oil, oily esters or ethyl alcohol); and
preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic
acid).
[0152] For buccal administration, the composition may take the form
of tablets or lozenges formulated in conventional manner.
[0153] The compounds of the invention may be formulated for
parenteral administration by injection, including using
conventional catheterization techniques or infusion. Formulations
for injection may be presented in unit dosage form, e.g. in ampules
or in multi-dose containers, with an added preservative. They may
take such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and may contain formulating agents such as
suspending, stabilizing and/or dispersing agents. Alternatively,
the active ingredient may be in powder form for reconstitution with
a suitable vehicle, e.g. sterile pyrogen-free water, before
use.
[0154] When a product solution is required, it can be made by
dissolving the isolated inclusion complex in water (or other
aqueous medium) in an amount sufficient to generate a solution of
the required strength for oral or parenteral administration to
patients. The compounds may be formulated for fast dispersing
dosage forms (fddf), which are designed to release the active
ingredient in the oral cavity. These have often been formulated
using rapidly soluble gelatin-based matrices. These dosage forms
are well known and can be used to deliver a wide range of drugs.
Most fast dispersing dosage forms utilize gelatin as a carrier or
structure-forming agent. Typically, gelatin is used to give
sufficient strength to the dosage form to prevent breakage during
removal from packaging, but once placed in the mouth, the gelatin
allows immediate dissolution of the dosage form. Alternatively,
various starches are used to the same effect.
[0155] The compounds of the invention may also be formulated in
rectal compositions such as suppositories or retention enemas, e.g.
containing conventional suppository bases such as cocoa butter or
other glycerides.
[0156] For intranasal administration or administration by
inhalation, the compound of the invention is conveniently delivered
in the form of a solution or suspension from a pump spray container
that is squeezed or pumped by the patient or as an aerosol spray
presentation from a pressurized container or a nebulizer, with the
use of a suitable propellant, e.g. dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
or other suitable gas. In the case of a pressurized aerosol, the
dosage unit may be determined by providing a valve to deliver a
metered amount. The pressurized container or nebulizer may contain
a solution or suspension of the active compound. Capsules and
cartridges (made e.g. from gelatin) for use in an inhaler or
insulator may be formulated containing a powder mix of a compound
of the invention and a suitable powder base such as lactose or
starch.
[0157] Aerosol formulations for treatment of the conditions
referred to above (e.g. migraine) in the average adult human are
preferably arranged so that each metered dose or "puff" of aerosol
contains about 20 mg to about 1000 mg of the compound of the
invention. The overall daily dose with an aerosol will be within
the range of about 100 mg to about 10 mg. Administration may be
several times daily, e.g. 2, 3, 4 or 8 times, giving for example,
1, 2 or 3 doses each time.
[0158] A proposed daily dose of the compound of the invention for
oral, parenteral, rectal or buccal administration to the average
adult human for the treatment of the conditions referred to above
is from about 0.01 mg to about 2000 mg, preferably from about 0.1
mg to about 200 mg of the active ingredient of formula I per unit
dose which could be administered, for example, 1 to 4 times per
day.
[0159] Assay methods are available to screen a substance for
inhibition of cyclic nucleotide hydrolysis by the PDE 10 and the
PDEs from other gene families. The cyclic nucleotide substrate
concentration used in the assay is 1/3 of the K.sub.m
concentration, allowing for comparisons of IC.sub.50 values across
the different enzymes. PDE activity is measured using a
Scintillation Proximity Assay (SPA)-based method as previously
described (Fawcett et al., 2000). The effect of PDE inhibitors is
determined by assaying a fixed amount of enzyme (PDEs 1-11) in the
presence of varying substance concentrations and low substrate,
such that the IC.sub.50 approximates the K.sub.i (cGMP or cAMP in a
3:1 ratio unlabelled to [.sup.3H]-labeled at a concentration of 1/3
Km). ). The final assay volume is made up to 100 .mu.l with assay
buffer [50 mM Tris-HCl pH 7.5, 8.3 mM MgCl.sub.2, 1 mg/ml bovine
serum albumin]. Reactions are initiated with enzyme, incubated for
30-60 min at 30.degree. C. to give <30% substrate turnover and
terminated with 50 .mu.l yttrium silicate SPA beads (Amersham)
(containing 3 mM of the respective unlabelled cyclic nucleotide for
PDEs 9 and 11). Plates are re-sealed and shaken for 20 min, after
which the beads were allowed to settle for 30 minutes in the dark
and then counted on a TopCount plate reader (Packard, Meriden,
Conn.). Radioactivity units can be converted to percent activity of
an uninhibited control (100%), plotted against inhibitor
concentration and inhibitor IC.sub.50 values can be obtained using
the "Fit Curve` Microsoft Excel extension.
[0160] Using such assay, compounds of the present invention were
determined to have an IC.sub.50 for inhibiting PDE10 activity of
less than about 10 micromolar.
[0161] This invention also pertains to the preparation of compounds
of formula I. The present invention also provides for methods for
the synthesis compounds of formula I. For example, the present
invention provides for a process for forming the compound of
formula I, comprising a step of reacting a compound of formula II
##STR8## with dimethoxymethyl-dimethyl amine and hydrazine or
substituted hydrazine (e.g., such as R.sub.20--NHNH.sub.2 where
R.sub.20 is alkyl).
[0162] The present invention also provides for a process for
forming the compound of formula I, comprising a step of reacting a
compound of formula III ##STR9## with dimethyl oxalate and a
hydrazine of formula HET.sup.2-NHNH.sub.2.
[0163] The present invention also provides for a process for
forming the compound of formula I, comprising a step of reacting a
compound of formula IV ##STR10## with dimethoxymethyl-dimethyl
amine and hydrazine or substituted hydrazine.
[0164] The present invention also provides for a process for
forming the compound of formula I, comprising a step of reacting a
compound of formula V ##STR11## with a compound of formula VI
##STR12## wherein Q is a hydroxyl or a halide.
DETAILED DESCRIPTION OF THE INVENTION
[0165] Scheme 1 depicts the preparation of the pyrazole class of
compounds of this invention. Alkylation of a substituted phenol
with 2-methyl chloro quinoline provides the desired ether.
Hydrolysis of the ester and treatment with thionyl chloride
provides the desired acid chloride. Addition of O,N-dimethyl
hydroxyl amine hydrochloride provides the Weinreb amide for
coupling (Weinreb et al, Tet Lett., 1981, 22(39) 3815). Anion
generation with 4-picoline and LDA followed by addition of the
Weinreb amide affords the ketone. The ketone can then be treated
with dimethoxymethyl-dimethyl amine at reflux to form the enaminone
intermediate. Treatment with various hydrazines affords the
pyrazole analogues. A variety of ratios of the two isomers were
obtained. These isomers were separated via, crystallization,
Biotage MPLC, preparative TLC or preparative HPLC. This reaction
scheme is general for a variety of starting substituted phenols,
substituted quinolines and substituted hydrazines. ##STR13##
[0166] Alternatively, the substituted pyrazole compounds can be
prepared by alkylation of the NH pyrazole. One set of conditions is
the utilization of cesium carbonate as the base with an alkyl
halide as the electrophile in a solvent such as dimethyl formamide.
Some reactions require heating. ##STR14##
[0167] As depicted in Scheme 3, a variety of heterocycles can be
prepared from the enaminone intermediate. Pyrimidines can be
prepared by heating with substituted formamides in the presence of
ethanol and sodium ethoxide. Isoxazoles are prepared by heating the
enaminone with hydroxyl amine in methanol/acetic acid. Only one
isomer in the isoxazole case is formed. By heating with amino
pyroles, amino imidazoles or amino triazoles, 6-5 bicyclic systems
can be formed. ##STR15##
[0168] A variety of 4-pyridyl heterocyclic replacements can be
prepared according to scheme 4. Methyl heterocycles such as
3,5-dimethyl isoxazole and methyl pyridazine can be deprotated with
lithium diisopropyl amide and added to a Weinreb amide (Weinreb et
al, Tet Lett., 1981, 22(39) 3815) to provide the desired ketone.
Sequential treatment with dimethoxymethyl-dimethyl amine and a
hydrazine provides the heterocyclic pyrazoles. Pyrimidines and
isoxazoles can also be prepared as described in Scheme 3.
##STR16##
[0169] N-pyridyl pyrazoles can be prepared according to Scheme 5.
The starting ketones are prepared by alkylation of the phenol as
depicted in Scheme 1. Treatment of the ketone with
dimethoxymethyl-dimethyl amine followed by addition of 4-pyridyl
hydrazine (see J. Med. Chem. 2002, 45(24) 5397) provides the
desired compounds. Other heterocyclic replacements for 4-pyridyl
can be prepared by using the requisite hydrazine. ##STR17##
[0170] As depicted in Scheme 6, 3-substituted-N-pyridyl pyrazoles
can be prepared by literature methods. (see J. Med. Chem. 2004, 47,
2180). Treatment of the acetophenone (prepared according to scheme
1) with sodium methoxide and dimethyl oxalate provides the ester
intermediate. Addition of 4-pyridyl hydrazine (see J. Med. Chem.
2002, 45(24) 5397) provides the pyrazole with an ester at the
3-position. This ester can be converted to amides by hydrolysis and
coupling with amines. It can be converted to ethers by reduction to
the alcohol and alkylation. Amine formation is capable by amide
formation followed by reduction or conversion to the aldehyde
followed by reductive amination. All of these transformations can
be carried out by those skilled in the art of organic chemistry.
##STR18##
[0171] The benzyl intermediates can be prepared by the method shown
in scheme 1. The benzyl ether can be removed via treatment with
hydrogen gas over a palladium catalyst such as palladium on carbon
or palladium hydroxide in a variety of solvents. The phenol can
then be alkylated using a benzylic chloride in acetone heating with
potassium carbonate. Also Mitsunobu chemistry (Hughes, D. L., The
Mitsunobu Reaction. Organic Reactions. Vol. 42. 1992, New York.
335-656.) can be applied to couple the phenol with alcohols.
##STR19##
[0172] Many benzylic halides or alcohols are commericially
available or are known in the literature. General ways to make
these intermediates by those skilled in the art are reduction of an
ester, acid or aldehyde to form an alcohol. One general procedure
is the oxidation of a benylic site with selenium dioxide to provide
an aldehyde that is subsequentially reduced with sodium
borohydride. Benzylic halide can be formed vial halogenation (see
Syn. Comm. 1995, 25(21) 3427-3434). ##STR20##
[0173] Triazole analogues can be prepared in many ways. One way is
depicted in Scheme 9. Treatment of a hydrazide with dimethyl
formamide dimethyl acetal to form an intermediate, which is
subsequently treated with an amine or aniline with the addition of
heat and acetic acid provides the 1,2,4 triazoles (see Org. Lett,
2004, 6(17), 2969-2971). The regioisomeric triazoles can be
prepared by interchanging the functionality of the starting
materials. ##STR21##
[0174] Other triazole isomers can be prepared according to scheme
10 by starting with the carboxyamides and treating with dimethyl
formamide dimethyl acetal followed by the addition of aromatic
hydrazines. The regioisomeric triazoles can be prepared by
interchanging the functionality of the starting materials.
##STR22##
[0175] The inverted ketone isomer can be prepared according to
Scheme 11. (Bunting et al. JACS, 1988, 110, 4008.) The starting
aldehyde is coupled with a phosphonate to provide the enaminone.
The enaminone is hydrolyzed to provide the desired ketone. The
ketone can then be utilized according to Scheme 1,2 and 3 to
provide the desired compounds ##STR23##
[0176] Scheme 12 depicts a method for synthesizing a 4,5-diaryl
oxazole. In the illustrated case, 4-benzyloxy-benzaldehyde and
4-methylbenzenesulfinic acid are heated with formamide to generate
a substituted formamide as shown. This transformation is known in
the literature. [J. Med Chem., 2002, 45, 1697] Dehydration of the
formamide in a reaction mediated by POCl3 gives a tosylmethyl
isocyanate. This class of compound can be treated with an aldehyde
and a base to yield an oxazole. In the illustrated case, the
tosylmethylisocyanate is treated with isonicotinaldehyde and
potassium carbonate. The product of this reaction is an oxazole
possessing a 4-benzyloxyphenyl group at the 4-position of the
oxazole ring, and a 4-pyridyl substituent at the 5-position. These
substituents can be substituted with other aryl groups simply by
utilizing different aryl-aldehydes for steps one and three of the
sequence. Cleavage of the benzyloxy group is achieved by the
standard method of catalytic hydrogenation, and the resultant
phenol is easily alkylated by treatment with an alkyl halide, such
as 2-(chloromethyl)quinoline, and cesium fluoride in DMF. The
method is not limited to the illustrated case as the relative
positions of the phenyl and pyridyl rings can be switched, and said
rings may comprise a variety of aryl groups displaying various
substitution patterns. ##STR24## ##STR25##
[0177] Scheme 13 depicts a method for preparing 4,5-substituted
oxazoles possessing alkyl group substitution in the 2-position of
the oxazole ring. In the illustrated case,
1-(4-Benzyloxy-phenyl)-2-pyridin-4-yl-ethanone is brominated by
treatment with bromine in acetic acid according to traditional
methods. The resultant .alpha.-bromoketone is then treated with
ammonium acetate and sodium acetate in acetic acid, which yields
the methyl-substituted oxazole ring as disclosed in the patent
literature (WO 9513067). The methyl group can be replaced by other
alkyl groups. For example, substitution of ammonium ethanoate,
sodium ethanoate, and ethanoic acid acid would yield ethyl group
substitution. Cleavage of the benzyloxy group is achieved by the
standard method of catalytic hydrogenation, and the resultant
phenol is easily alkylated by treatment with an alkyl halide as
described above. The method is not limited to the illustrated case
as the relative positions of the phenyl and pyridyl rings can be
switched, and said rings may comprise a variety of aryl groups
displaying various substitution patterns. ##STR26##
[0178] Step 1 of Scheme 14 is an imine formation/heterocycle
formation. A compound of formula 2A wherein R1 is alkyl, benzyl, or
allyl, is condensed with 4-pyridine carboxaldehyde in solvent such
as toluene and is heated to reflux with a Dean-Stark apparatus
attached to remove water for about 40 hours. After removal of
toluene, the crude imine is mixed with tosylmethylisocyanide and a
base such as potassium carbonate, in a solvent mixture of
1,2-dimethoxyethane and methanol, and is heated at reflux for about
3 hours to afford 3A.
[0179] Step 2 of Scheme 14 is a phenol dealkylation. If R1 is
methyl, the dealkylation can be effected with boron tribromide
(BBr3) in a non-coordinating solvent such as methylene chloride at
about 20-40.degree. C. for about 3-48 hours, where about 24 hours
is preferred to yield 4A. If R2 is benzyl, the dealkylation can be
effected with in neat trifluoracetic acid with anisole at a
temperature of about 75.degree. C. for about 3-48 hours, where
about 24 hours is preferred to yield 4A. If R1 is allyl, the
dealkylation can be effected with a palladium catalyst, such as
dichloropalladium bis(triphenylphosphine) of palladium acetate,
where dichloropalladium bis(triphenylphosphine) is preferred, with
a reducing agent such as n-butylammonium formate, in a solvent such
as tetrahydrofuran, 1,2-dichloroethane, methylene chloride, or an
alkanol, where 1,2-dichloroethane is preferred, in a temperature
range from about 20.degree. C. to 75.degree. C., to yield 4A.
[0180] Step 3 of Scheme 14 is a phenol alkylation. Treatment of 4A
with a base such as potassium carbonate, sodium carbonate, cesium
carbonate, sodium hydride, or potassium hydride, where cesium
carbonate or sodium hydride are preferred, in a solvent such as
tetrahydrofuran, 1,2-dimethoxyethane, N,N-dimethylformamide,
dimethylacetamide, N-methylpyrrolidinone, or dimethylsulfoxide,
where dimethylsulfoxide or N,N-dimethylformamide are preferred, at
a temperature from about 20.degree. C. to 70.degree. C., where
about 23.degree. C. is preferred, for about 3-48 hours, where about
24 hours is preferred, affords 1A.
[0181] Step 4 of Scheme 14 is an imidazole
deprotonation/electrophilic trapping. Treatment of 3A with a base
such as lithium diisopropyl amide or lithium
2,2,6,6-tetramethylpiperidine, where lithium diisopropylamide is
preferred, in a solvent such as tetrahydrofuran, at a temperature
from about -78.degree. C. to 0.degree. C., where about -20.degree.
C. is preferred, for about 5 minutes to 30 minutes, where about 10
minutes is preferred, followed by addition of the desired
electrophile R3-1, affords 3B.
[0182] Step 5 of Scheme 14 is a phenol dealkylation and uses the
same methods as described for Step 2 above to produce 4B.
[0183] Step 6 of Scheme 14 is a phenol alkylation and uses the same
methods as described for Step 3 above to produce 1B. ##STR27##
[0184] Step 1 of Scheme 15 is an acylation of an amine to form an
amide. Compound 2A, wherein R1 can be methyl, benzyl, or allyl, is
treated with an acid chloride or a carboxylic acid in the presence
of a coupling reagent, such as tri-n-propylphosphonic anhydride or
dicyclohexyl carbodiimide, where tri-n-propylphosphonic anhydride
is preferred, in the presence of a base such as sodium hydroxide,
potassium or sodium carbonate, triethylamine, or
diisopropylethylamine, where diisopropylethylamine is preferred, in
a solvent system such as water/methylene chloride, water/ethyl
acetate, ethyl acetate, tetrahydrofuran, or methylene chloride,
where ethyl acetate is preferred, at a temperature from about
0.degree. C. to 50.degree. C., where about 20.degree. C. to
30.degree. C. is preferred, to yield 5A.
[0185] Step 2 consists of a chlorination to form an iminochloride,
reaction with an amine to form an amidine, followed by treatment
with acid to form an imidazole. Compound 5A is treated with a
chlorinating agent such as PCl.sub.5/POCl.sub.3 at a temperature of
about 120.degree. C. for about 4 hours. The chlorinating agent is
removed in vacuo and an excess of 1,1-diethoxy-2-ethylamine in a
solvent such as isopropanol is added and the mixture is stirred for
about 5-24 hours at about 23.degree. C. The solvent is removed in
vacuo and concentrated hydrochloric acid and isopropanol is added
and the mixture is heated to about 90.degree. C. for about 24 hours
to yield 6A.
[0186] Step 3 of Scheme 15 is a phenol dealkylation. If R1 is
methyl, the dealkylation can be effected with boron tribromide
(BBr3) in a non-coordinating solvent such as methylene chloride at
about 20-40.degree. C. for about 3-48 hours, where about 24 hours
is preferred to yield 7A. If R2 is benzyl, the dealkylation can be
effected with in neat trifluoracetic acid with anisole at a
temperature of about 75.degree. C. for about 3-48 hours, where
about 24 hours is preferred to yield 7A. If R1 is allyl, the
dealkylation can be effected with a palladium catalyst, such as
dichloropalladium bis(triphenylphosphine) of palladium acetate,
where dichloropalladium bis(triphenylphosphine) is preferred, with
a reducing agent such as n-butylammonium formate, in a solvent such
as tetrahydrofuran, 1,2-dichloroethane, methylene chloride, or an
alkanol, where 1,2-dichloroethane is preferred, in a temperature
range from about 20.degree. C. to 75.degree. C., to yield 7A.
[0187] Step 4 of Scheme 15 is a phenol alkylation. Treatment of 7A
with a base such as potassium carbonate, sodium carbonate, cesium
carbonate, sodium hydride, or potassium hydride, where cesium
carbonate is preferred, in a solvent such as tetrahydrofuran,
1,2-dimethoxyethane, N,N-dimethylformamide, dimethylacetamide,
N-methylpyrrolidinone, or dimethylsulfoxide, where
dimethylsulfoxide is preferred, at a temperature from about
20.degree. C. to 70.degree. C., where about 23.degree. C. is
preferred, for about 3-48 hours, where about 24 hours is preferred,
affords 1C. ##STR28##
[0188] The quinolyl benzaldehyde can be coupled with the ketone in
the presence of refluxing piperidine to provide the desired olefin.
Treatment with hydrazine affords the NH-pyrazole. This can be
further elaborated by treatment with sodium hydride and an
electrophile such as methyl iodide to provide substituted
pyrazoles. ##STR29##
[0189] As depicted in scheme 17, the alkyne and iodide can be
coupled via a Sonagashira coupling and the methyl ether deprotected
with boron tribromide in dichloromethane. Alkylation of the phenol
with 2-chloromethylquinoline according to the methods described
above provides the penultimate intermediate. Treatment with
trimethyl silyl azide in a sealed tube at 70-190.degree. C.,
preferably about 150.degree. C., for 24-72 h, provides the desired
triazole. ##STR30##
General Experimental
[0190] Organic solutions were dried with magnesium or sodium
sulfate if not otherwise specified. Room temperature is abbreviated
as RT. HPLC-MS system 1 consisted of Zorbax Bonus-RP.TM.
4.6.times.150 mm column, 1.0 mL/min, solvent A=MeCN, solvent B=0.1%
aqueous formic acid, linear gradient of 1:9 A:B to 95:5 A:B over 10
min, using a Hewlett-Packard 1100 HPLC system equipped with diode
array and mass detectors. HPLC system 2 used a linear gradient of
3:7 A:B to 95:5 A:B over 15 min. When purification by RP-HPLC is
indicated, a Shimadzu preparative HPLC instrument equipped with
X-Terra.TM. 50.times.50 mm column, solvent A=acetonitrile, solvent
B=water, each containing either 0.1% trifluoroacetic acid ("acidic
conditions") or 0.1% concentrated ammonium hydroxide ("basic
conditions"), linear gradient of 25%-85% A:B over 10 min.
[0191] The following Examples illustrate the present invention. It
is to be understood, however, that the invention, as fully
described herein and as recited in the claims, is not intended to
be limited by the details of the following Examples.
Experimental Procedures
Preparation 1
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester
[0192] To a solution of 2-Chloromethyl quinoline. (2 g, 9.3 mmole)
in acetone (47 ml, 0.2M) was added 4-hydroxy benzoic acid methyl
ester (1.42 g, 1.0 eq.) and potassium carbonate (3.86 g, 3 eq.).
The reaction mixture was heated at 60.degree. C. for 16 h under
N.sub.2 atmosphere, cooled to ambient temperature and poured into
1N sodium hydroxide (50 ml)/ethyl acetate (100 ml). The layers were
separated and the organic layer dried magnesium sulfate, filtered
and concentrated. Biotage MPLC was run using a 5-30% ethyl
acetate/hexane gradient on a 40 M column to provide the title
compound as a white solid (1.66 g, 61%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.18 (d, J=8.7 Hz, 1 H), 8.07 (d, J=8.3 Hz, 1
H), 7.95 (M, 2H), 7.82 (d, J=7.9 Hz, 1 H), 7.74 (dt, J=7.1, 1.7 Hz,
1 H), 7.62 (d, J=8.3 Hz, 1 H), 7.55 (dt, J=7.9, 1.2 Hz, 1 H), 7.03
(d, J=9.1, 2 H), 5.41 (s, 2 H), 3.84 (s, 3 H); MS: (M.sup.+H
m/z=294.2).
Preparation 2
4-(Quinolin-2-ylmethoxy)-benzoic acid
[0193] To a solution of 4-(Quinolin-2-ylmethoxy)-benzoic acid
methyl ester (500 mg, 1.7 mmole) in tetrahydrofuran (8.5 ml) and
methanol (3 ml) was added 1N NaOH (3.4 ml, 2 eq.). The reaction
mixture was stirred at ambient temperature for 16 h. To the
reaction mixture was added 50 ml of brine and the pH was adjusted
to 3 with 1N HCl to provide a white precipitate which was filtered
and dried to provide the title compound as a white solid (463 mg,
98%). .sup.1H NMR (400 MHz, DMSO) .delta. 8.39 (d, J=8.3 Hz, 1 H),
7.99 (m, 2 H), 7.81 (M, 2H), 7.76 (dt, J=8.3, 1.7 Hz, 1 H), 7.64
(d, J=8.3 Hz, 1 H), 7.60 (dt, J=7.9, 1.3 Hz, 1 H), 7.12 (M, 2 H),
5.41 (s, 2 H); MS: (M.sup.+H m/z=280.2).
Preparation 3
N-Methoxy-N-methyl4-(quinolin-2-ylmethoxy)-benzamide
[0194] To a solution of 4-(Quinolin-2-ylmethoxy)-benzoic acid
(25.98 g, 93 mmole) was added 250 ml of thionyl chloride under
N.sub.2. The reaction mixture stirred 3 h and the excess thionyl
chloride was removed under vacuum. The acid chloride was dissolved
in tetrahydrofuran (450 ml) and triethylamine (50 ml, 4 eq.) was
slowly added. O,N-dimethyl hydroxyl amine hydrochloride (27 g, 3
eq.) was added and the reaction stirred 18 h. The reaction mixture
was placed on a rotovap to remove the solvent, partitioned between
1N NaOH and methylene chloride, separated, dried magnesium sulfate,
filtered and concentrated. The crude product was filtered through
silica gel eluting with 30-70% ethyl acetate/hexane to proved the
title compound as a brown oil (26.26 g, 87%); .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.17 (d, J=8.7 Hz, 1 H), 8.06 (d, J=8.3 Hz, 1
H), 7.81 (d, J=8.3 Hz, 1H), 7.67 (m, 3 H), 7.63 (d, J=8.3 Hz, 1 H),
7.52 (m, 1 H), 7.01 (M, 2 H), 5.39 (s, 2 H), 3.52 (s, 3 H) 3.31 (s,
2H); MS: (M.sup.+H m/z=323.2).
Preparation 4
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
[0195] To a solution of Lithium diisopropyl amide (1.0M) in
tetrahydrofuran was added 4-picoline dropwise (7.55 ml, 5 eq.) at
0.degree. C. under N.sub.2. After 30 min the anion was cooled to
-78.degree. C. In a separate round bottom flask
N-Methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide (5.0, 15.5
mmole) was dissolved in tetrahydrofuran (77 ml, 0.2M) and cooled to
-78.degree. C. under N.sub.2. 1.2 eq. of the 4-picoline anion was
added dropwise to the amide solution. After 45 min, 1 eq. more of
the 4-picoline anion was added. After an addition 30 min, acetic
acid (40 ml) was added dropwise and the reaction was slowly warmed
to ambient temperature. The solid product (acetate salt) was
filtered and partitioned between saturated sodium bicarbonate and
dichloromethane. The layers were separated, dried magnesium sulfate
filtered and concentrated to provide the title compound as a tan
solid (4.41 g, 80%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.52
(d, J=5.8 Hz, 2 H), 8.19 (d, J=8.7 Hz, 1 H), 8.07 (d, J=8.7 Hz,
1H), 7.93 (m, 2 H), 7.82 (d, J=8.3 Hz, 1 H), 7.75 (m, 1 H), 7.61
(d, J=8.3 Hz, 1 H), 7.54 (dt, J=7.9, 1.0 Hz, 1 H), 7.23 (m, 2 H)
7.07 (m, 2H), 5.42 (s, 2H), 4.19 (s, 2H); MS: (M.sup.+H
m/z=355.2).
Preparation 5
3-Dimethylamino-2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl}-propeno-
ne
[0196] To
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone (4.0 g,
11.3 mmole) was added dimethoxymethyl-dimethyl amine (10 ml) and
the reaction mixture was heated at reflux for 1 hr. Concentrated to
give a quantitative yield of the title compound which was used as
is in the next step. LC/MS: RT=1.4 min, MS: (M.sup.+H
m/z=410.2).
EXAMPLE 1
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0197] To a solution of
3-Dimethylamino-2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl}-propen-
one (9.57 g, 27 mmole) in methanol was added hydrazine hydrate
(3.33 g, 40.5 mmole) and the reaction mixture was heated at reflux
for 1 h. The solvent was evaporated to yield a white solid. The
solid was washed with water and ethyl ether. The solid was
recystallized from hot ethanol/ethylacetate (10 ml/g) to give 8.34
g of the title compound (82%). .sup.1H NMR (400 MHz, DMSO) .delta.
8.41 (m, 3 H), 8.16 (s, 1 H), 7.97 (m, 2H), 7.86 (s, 1 H), 7.75 (t,
J=7.9 Hz, 1 H), 7.68 (d, J=8.3 Hz, 1 H), 7.60 (t, J=7.5 Hz, 1 H),
7.33 (m, 2 H), 7.18 (m, 2 H) 7.15 (d, J=8.3 Hz, 1H), 7.06 (d, J=8.3
Hz, 1H), 5.38 (s, 2H); MS: (M.sup.+H m/z=379.2).
EXAMPLE 2
2-[4-(2-Methyl-4-pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0198] To a solution of
2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline
(1.72 g) in ethanol (20 ml) was added methyl hydrazine (3.5 ml, 1.5
eq.) and concentrated sulfuric acid (0.1 ml). The reaction mixture
was stirred 1 h at ambient tempature and solvent evaporated. The
reaction mixture was partitioned between methylene chloride and
saturated sodium bicarbonate. The layers were separated and the
organic layer dried magnesium sulfate, filtered and concentrated.
Preparative HPLC chromatography provided the title compound (minor
isomer) as a white solid (0.30 g, 17%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.31 (d, J=5.4 Hz, 2 H), 8.21 (d, J=8.7 Hz, 1
H), 7.80 (d, J=8.3 Hz, 1H), 7.77 (s, 1 H), 7.66 (m, 3 H), 7.53 (m,
1H), 7.19 (d, J=8.7 Hz, 2 H), 7.11 (d, J=8.7 Hz, 2H), 7.01 (d,
J=6.2 Hz, 2H) 5.40 (s, 2H), 3.69 (s, 3H); MS: (M.sup.+H
m/z=393.3).
EXAMPLE 3
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0199] To a solution of
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline
(1.72 g) in ethanol (20 ml) was added methyl hydrazine (3.5 ml, 1.5
eq.) and concentrated sulfuric acid (0.1 ml). The reaction mixture
was stirred 1 h at ambient temperature and solvent evaporated. The
reaction mixture was partitioned between methylene chloride and
saturated sodium bicarbonate. The layers were separated and the
organic layer dried magnesium sulfate, filtered and concentrated.
Preparative HPLC chromatography provided the title compound (major
isomer) as a clear oil (0.97 g, 56%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.44 (d, J=5.0 Hz, 2 H), 8.17 (d, J=8.7 Hz, 1
H), 8.05 (d, J=8.3 Hz, 1H), 7.81 (d, J=7.9 Hz, 1 H), 7.70 (m, 1 H),
7.66 (d, J=8.7 Hz, 1H), 7.54 (s, 1H), 7.53 (m, 1H), 7.37 (d, J=8.7
Hz, 2H) 7.15 (d, J=5.0, 2H), 7.00 (d, J=8.7 Hz, 2H), 5.38 (s, 2H),
3.93 (s, 3H); MS: (M.sup.+H m/z=393.3).
EXAMPLE 4
2-[4-(2-Ethyl-4-pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0200] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting ethyl hydrazine provided the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.35 (bs, 2H), 8.23 (d,
J=8.3 Hz, 1 H), 8.08 (d, J=8.3 Hz, 1 H), 7.85 (d, J=7.4 Hz, 1H),
7.83 (s, 1 H), 7.74 (m, 2 H), 7.57 (t, J=7.9 Hz, 1H), 7.21 (d,
J=8.7 Hz, 2 H), 7.14 (d, J=9.1 Hz, 2 H), 7.04 (m, 2H) 5.42 (s, 2H),
4.03 (q, J=7.5 Hz, 2H), 1.36 (t, J=7.5 Hz, 3H); MS: (M.sup.+H
m/z=407.3).
EXAMPLE 5
2-[4-(1-Ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0201] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting ethyl hydrazine provided the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.35 (bs, 2H), 8.19 (d,
J=8.3 Hz, 1 H), 8.07 (d, J=9.1 Hz, 1 H), 7.82 (d, J=7.9 Hz, 1H),
7.73 (t, J=8.3 Hz, 1H), 7.67 (d, J=8.3 Hz, 2 H), 7.62 (s, 1H), 7.55
(t, J=7.9 Hz, 1 H), 7.37 (d, J=9.1 Hz, 2H), 7.21 (bs, 2 H), 7.01
(d, J=8.7 Hz, 2H) 5.39 (s, 2H), 4.24 (q, J=7.5 Hz, 2H), 1.56 (t,
J=7.5 Hz, 3H); MS: (M.sup.+H m/z=407.3).
EXAMPLE 6
Dimethyl-(2-4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-y-
l}-ethyl)-amine
[0202] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting (2-hydrazino-ethyl)-dimethyl-amine provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.44 (dd,
J=4.6, 1.7, Hz, 2 H), 8.18 (d, J=8.3 Hz, 1 H), 8.06 (d, J=8.3 Hz,
1H), 7.82 (d, J=8.7 Hz, 1 H), 7.71 (m 2H), 7.55 (t, J=7.1 Hz, 1H),
7.38 (d, J=8.7 Hz, 2H), 7.15 (d, J=6.2 Hz, 2H) 7.00 (d, J=8.7 Hz,
2H), 5.38 (s, 2H), 4.25 (t, J=6.6 Hz, 2H), 2.82 (t, J=6.6 Hz, 2H),
2.28 (s, 6H); MS: (M.sup.+H m/z=450.4).
EXAMPLE 7
Dimethyl-(2-{4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1--
yl}-ethyl)-amine
[0203] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting (2-hydrazino-ethyl)-dimethyl-amine provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.35 (d,
J=6.2 Hz, 2 H), 8.22 (d, J=8.3 Hz, 1 H), 8.08 (d, J=8.7 Hz, 1H),
7.85 (m, 2 H), 7.73 (m 2H), 7.57 (t, J=7.1 Hz, 1H), 7.23 (m, 2H),
7.17 (d, J=9.1 Hz, 2H) 7.00 (d, J=6.2 Hz, 2H), 5.42 (s, 2H), 4.05
(t, J=6.6 Hz, 2H), 2.66 (t, J=7.1 Hz, 2H), 2.10 (s, 6H); MS:
(M.sup.+H m/z=450.4).
EXAMPLE 8
2-{4-[-Pyridin4-yl-2-(2,2,2-trifluoro-ethyl)-2H-pyrazol-3-yl]-phenoxymethy-
l}-quinoline
[0204] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting (2,2,2-trifluoro-ethyl)-hydrazine provided the
title compound. MS: (M.sup.+H m/z=461.2).
EXAMPLE 9
2-{4-[-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymeth-
yl}-quinoline
[0205] To a solution of
2-[4-(4-Pyridin4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline (26.5
g) in dimethyl formamide (140 mL) was added
1,1,1-Trifluoro-2-iodo-ethane (21 mL, 2.0 eq.) and cesium carbonate
(68.3 g, 3 eq.) and the reaction mixture heated at 60.degree. C.
for 24 h. The reaction mixture was diluted with water, extracted
3.times. methylene chloride, dried with magnesium sulfate, filtered
and concentrated. Purification via flash chromatography eluting
with 5% methanol/70% ethyl acetate/hexanes provided the title
compound 20.85 g as an 8:1 regioisomeric mixture. Preparative HPLC
eluting with acetonitile/methanol (98:2) on a chiralpak AD column
with a flow rate of 430 ml/Min provided the pure title compound as
a free base 13.4 g. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.45
(m, 2 H), 8.16 (d, J=8.3 Hz, 1 H), 8.04 (d, J=8.3 Hz, 1H), 7.96 (s,
1H), 7.79 (d, J=8.3 Hz, 1 H), 7.69 (m, 1 H), 7.64 (d, J=8.3 Hz, 1
H), 7.50 (m, 1H), 7.36 (d, J=8.7 Hz, 2 H), 7.14 (d, J=6.2 Hz, 2H),
6.98 (d, J=9.1 Hz, 2 H), 5.35 (s, 2H), 4.75 (q, J=8.3 Hz, 2 H); MS:
(M.sup.+H m/z=427.1).MS: (M.sup.+H m/z=461.2).
EXAMPLE 10
1-{4-Pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-propan-
-2-ol
[0206] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting 1-hydrazino-propan-2-ol provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.44 (bs, 2 H),
8.20 (d, J=8.3 Hz, 1 H), 8.08 (d, J=8.3 Hz, 1H), 7.83 (d, J=8.3 Hz,
1 H), 7.75 (m 2H), 7.67 (d, J=8.3 Hz, 1H), 7.56 (t, J=8.3 Hz, 1H),
7.36 (d, J=8.7 Hz, 2H) 7.30 (m, 2H), 7.03 (d, J=9.1 Hz, 2 H), 5.40
(s, 2H), 4.49 (m, 1H), 4.23 (m, 1H), 4.02 (m, 1H), 1.83 (m, 1H),
1.28 (d, J=6.2 Hz, 3H); MS: (M.sup.+H m/z=437.2).
EXAMPLE 11
1-4-Pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-propan--
2-ol
[0207] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting 1-hydrazino-propan-2-ol provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.37 (d, J=6.2
Hz, 2 H), 8.23 (d, J=8.7 Hz, 1 H), 8.08 (d, J=8.3 Hz, 1H), 7.84 (m,
2 H), 7.75 (m 2H), 7.57 (t, J=6.6 Hz, 1H), 7.20 (d, J=9.1 Hz, 2H),
7.13 (d, J=8.7 Hz, 2H) 7.00 (dd, J=6.2, 1.7 Hz, 2H), 5.42 (s, 2H),
4.17 (m, 1H), 3.94 (m, 2H), 3.86 (m, 1H), 1.12 (d, J=6.6 Hz, 3H);
MS: (M.sup.+H m/z=437.3).
EXAMPLE 12
2-[4-(2-Isopropyl-4-pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0208] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting isopropyl hydrazine provided the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.33 (bs, 2 H), 8.24 (d,
J=8.3 Hz, 1 H), 8.08 (d, J=8.3 Hz, 1H), 7.86 (s, 1H) 7.83 (m, 1 H),
7.72 (m 2H), 7.58 (t, J=7.9 Hz, 1H), 7.20 (d, J=8.7 Hz, 2H), 7.15
(d, J=9.1 Hz, 2H) 7.04 (m, 2H), 5.43 (s, 2H), 4.31 (m, 1H), 1.43
(d, J=6.6 Hz), 6H); MS: (M.sup.+H m/z=421.2).
EXAMPLE 13
2-[4-(4-Pyridin-4yl-isoxazol-5-yl)-phenoxymethyl]-quinoline
[0209] 2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
(200 mg, 0.56 mmole) was heated at reflux in
dimethoxymethyl-dimethyl amine (1 ml) for 1 h and concentrated. The
crude product was dissolved in methanol/water (3:1, 4 ml) and
hydroxyl amine hydrochloride (43 mg, 1.1 eq.) was added. After 1 h,
acetic acid was added (0.016 ml) and the reaction was heated at
reflux for 1h. Cooled to ambient temperature poured into saturated
sodium bicarbonate, extracted with methylene chloride, dried
magnesium sulfate, filtered and concentrated. Biotage MPLC was run
on a 25S column elution with 3% methanol/1% ammonium
hydroxide/ethyl acetate 50% in hexanes to provide the title
compound as a tan solid (94 mg, 45%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.59(dd, J=6.2, 1.7 Hz, 2 H), 8.36 (s, 1H),
8.20 (d, J=8.3 Hz, 1H), 8.07 (d, J=8.7 Hz, 1 H), 7.82 (d, J=9.1 Hz,
1H), 7.73 (dt, J=7.1, 1.7 Hz, 1H), 7.64 (d, J=8.3 Hz, 1H), 7.54 (m,
3H), 7.28 (d, J=4.2 Hz, 2H) 7.05 (d, J=9.1, 2H), 5.40 (s, 2H); MS:
(M.sup.+H m/z=380.2).
EXAMPLE 14
2-[4-(5-Pyridin-4-yl-pyrimidin-4-yl)-phenoxymethyl]-quinoline
[0210] 2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
(200 mg) was heated at reflux in dimethoxymethyl-dimethyl amine (1
ml) for 1 h and concentrated. The crude reaction mixture was
dissolved in ethanol (3 ml) and formamidine hydrochloride (90 mg, 2
eq.) was added. In a separate flask sodium (40 mg) was added to
ethanol 3 ml and stirred 10 min. The sodium ethoxide solution was
added to the reaction mixture and was heated at reflux for 1 h. The
reaction mixture was concentrated and purified via Biotage MPLC
chromatography on a 25S column eluting with 40-100% ethyl
acetate/hexane to provide the title compound (83 mg, 38%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.53(m, 3 H), 8.14 (d, J=8.7 Hz,
1H), 8.03 (d, J=8.3 Hz, 1H), 7.79 (d, J=7.9 Hz, 1 H), 7.70 (m, 1
H), 7.58 (d, J=8.7 Hz, 1H), 7.50 (m, 1H), 7.33 (d, J=9.1 Hz, 2H)
7.10 (d, J=6.2, 2H), 6.91(d, J=9.1 Hz, 2H), 5.34 (s, 2H) 2.77 (s,
3H); MS: (M.sup.+H m/z=391.2).
EXAMPLE 15
2-[4-(2-Methyl-5-pyridin-4-yl-pyrimidin-4-yl)-phenoxymethyl]-quinoline
[0211] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-pyrimidin-4-yl)-phenoxymethyl]-quinoline but
substituting acetamidine hydrochloride provide the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.21 (s, 1H), 8.63 (S,
1H), 8.58(m, 2 H), 8.17 (d, J=8.7 Hz, 1H), 8.04 (d, J=8.7 Hz, 1H),
7.81 (d, J=8.3 Hz, 1 H), 7.70 (m, 1 H), 7.60 (d, J=8.3 Hz, 1H),
7.52 (m, 1H), 7.37 (m, 2H) 7.15 (d, J=6.2, 2H), 6.93 (d, J=9.1 Hz,
2H), 5.35 (s, 2H); MS: (M.sup.+H m/z=405.2).
EXAMPLE 16
2-[4-(2-Methyl-6-pyridin-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-phenoxymethyl-
]-quinoline
[0212] To a solution of
3-Dimethylamino-2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl}-propen-
one (229 mg, 0.56 mmole) in ethanol (3 ml) was added piperidine (2
eq.) and 5-methyl-2H-pyrazol-3-ylamine (108 mg, 2 eq.) and the
reaction mixture was heated at reflux for 3 h. The reaction mixture
was cooled to RT, filtered and product washed with ethanol and
hexane to provide the title compound (96 mg, 39%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.51 (d, J=7.9 Hz, 2H), 8.46 (S, 1H),
8.30(m, 1 H), 8.18 (m, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.78 (m, 1 H),
7.71 (m, 1 H), 7.60 (m, 1 H), 7.41 (d, J=8.7, 2H), 7.21 (m, 2H)
7.07 (d, J=8.7, 2H), 6.60 (s, 1H), 5.50 (s, 2H) 2.48 (s, 3H); MS:
(M.sup.+H m/z=444.2).
EXAMPLE 17
2-[4-(2-Methyl-6-pyridin-4-yl-[1,2,4]triazolo[1.5-a]pyrimidin-7-yl)-phenox-
ymethyl]-quinoline
[0213] Following the procedure for the preparation of
2-[4-(2-Methyl-6-pyridin-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl)-phenoxymethy-
l]-quinoline but substituting 5-Methyl-2H-[1,2,4]-triazol-3ylamine
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.75 (s, 1H), 8.55 (m, 2H), 8.21(d, J=8.3 Hz, 1 H), 8.06
(d, J=7.5 Hz, 1H), 7.84 (d, J=7.1 Hz, 1H), 7.73 (m, 1H), 7.64 (d,
J=8.3 Hz, 1 H), 7.55 (m, 1H), 7.42 (d, J=8.7, 2H), 7.08 (m, 4H),
5.39 (s, 2H) 2.60 (s, 3H); MS: (M.sup.+H m/z=445.2).
Preparation 6
2-Pyridazin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
[0214] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting 4-methyl pyridazine for 4-picoline provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.12 (d, J=5.4
Hz, 1 H), 9.08 (d, J=8.7 Hz, 2.1 H), 8.20 (d, J=8.3 Hz, 1H), 8.07
(d, J=8.3 Hz, 1 H), 7.96 (m, 2 H), 7.83 (d, J=7.9 Hz, 1 H), 7.76
(m, 1 H), 7.62 (d, J=8.3 Hz, 1 H), 7.55 (m, 1 H) 7.38 (dd, J=5.4,
2.5 Hz, 1H), 7.09 (m, 2H), 5.44 (s, 2H) 4.23 (s, 2H); MS: (M.sup.+H
m/z=356.2).
Preparation 7
3-Dimethylamino-2-pyridazin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-prope-
none
[0215] Following the procedure for the preparation of
3-Dimethylamino-2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl}-propen-
one but substituting
2-Pyridazin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
provided the title compound. LC/MS: RT=1.8 min, MS: (M.sup.+H
m/z=411.2).
EXAMPLE 18
2-[4-(4-Pyridazin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0216] Following the procedure for the preparation of
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline but
substituting
3-Dimethylamino-2-pyridazin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-prop-
enone provided the title compound as a white solid. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.11 (s, 1H), 9.01 (d, J=5.0 Hz, 1H),
8.34(d, J=8.7 Hz, 1 H), 8.25 (d, J=8.7 Hz, 1H), 7.89 (m 2H), 7.81
(d, J=8.3 Hz, 1 H), 7.79 (m, 2 H), 7.61 (t, J=7.6 Hz, 1H), 7.34 (m,
1H), 7.31 (d, J=8.7 Hz, 2H), 7.05 (d, J=8.7, 2H), 5.49 (s, 2H); MS:
(M.sup.+H m/z=380.2).
EXAMPLE 19
2-[4-(1-Methyl-4-pyridazin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0217] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting
3-Dimethylamino-2-pyridazin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-prop-
enone provided the title compound as a white solid. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.11 (d, J=2.5 Hz, 1H), 8.96 (d,
J=5.4 Hz, 1H), 8.19(d, J=8.7 Hz, 1H), 8.06 (d, J=8.3 Hz, 1H), 7.82
(d, J=7.9 Hz, 1H), 7.73 (t, J=7.1 Hz, 1 H), 7.67 (m, 2H), 7.55 (t,
J=7.1 Hz, 1H), 7.34 (d, J=9.1 Hz, 2H), 7.24 (m, 1H), 7.02 (d, J=6.6
Hz, 2H), 5.39 (s, 2H) 3.97 (s, 3H); MS: (M.sup.+H m/z=394.2).
EXAMPLE 20
2-[4-(2-Methyl-4-pyridazin4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0218] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting
3-Dimethylamino-2-pyridazin4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-prope-
none provided the title compound as a white solid. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.99 (d, J=2.5 Hz, 1H), 8.90 (d, J=5.4 Hz,
1H), 8.24(d, J=8.7 Hz, 1H), 8.08 (d, J=8.7 Hz, 1H), 7.89 (s, 1H),
7.85 (d, J=8.3 Hz, 1 H), 7.75 (t, J=7. 1 Hz, 1 H), 7.70 (d, J=8.3
Hz, 1H), 7.57 (t, J=7.1 Hz, 1H), 7.21 (d, J=8.7 Hz, 2H), 7.15 (d,
J=9.1 Hz, 2H), 7.11 (m, 1 H), 5.43 (s, 2H) 3.73 (s, 3H); MS:
(M.sup.+H m/z=394.2).
EXAMPLE 21
2-[-4-(4-Pyrimidin-4yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0219] Following the procedure for the preparation of
2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline and
making the necessary chemical substitutions provided the title
compound as a white solid. LC/MS: RT=1.8 min, MS: (M.sup.+H
m/z=380.2).
EXAMPLE 22
2-[4-(4-Pyridazin-3-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0220] Following the procedure for the preparation of
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline and
making the necessary chemical substitutions provided the title
compound as a white solid. LC/MS: RT=1.7 min, MS: (M.sup.+H
m/z=380.2).
Preparation 8
2-(3-Methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
[0221] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting 3,5-dimethyl isoxazole for 4-picoline provided the
title compound. LC/MS: RT=2.3 min, MS: (M.sup.+H m/z=359.2).
Preparation 9
3-Dimethylamino-2-(3-methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-phe-
nyl]-propenone
[0222] Following the procedure for the preparation of
3-Dimethylamino-2-pyridin4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl}-propeno-
ne but
2-(3-Methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-etha-
none provided the title compound. LC/MS: RT=2.1 min, MS: (M.sup.+H
m/z=414.2).
EXAMPLE 23
2-{4-[4-(3-Methyl-isoxazol-5-yl)-2H-pyrazol-3-yl]-phenoxymethyl}-quinoline
[0223] Following the procedure for the preparation of
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline but
substituting
3-Dimethylamino-2-(3-methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-ph-
enyl]-propenone provided the title compound. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.23 (d, J=8.7 Hz, 1H), 8.12 (d, J=8.7 Hz, 1H),
7.94(s, 1 H), 7.84 (d, J=7.1 Hz, 1H), 7.74 (m, 1H), 7.69 (d, J=8.3
Hz, 1 H), 7.57 (t, J=6.6 Hz, 2 H), 7.46 (d, J=8.87 Hz, 2H), 7.08
(d, J=8.7 Hz, 2H), 5.88 (s, 1H), 5.42 (s, 2H), 2.23 (s, 3H); MS:
(M.sup.+H m/z=383.2).
EXAMPLE 24
2-{4-[2-Methyl-4-(3-methyl-isoxazol-5-yl)-2H-pyrazol-3-yl]-phenoxymethyl)--
quinoline
[0224] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting
3-Dimethylamino-2-(3-methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-ph-
enyl]-propenone provided the title compound as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.25 (d, J=8.7 Hz, 1H),
8.12 (d, J=8.3 Hz, 1H), 7.89(s, 1 H), 7.85 (d, J=8.3 Hz, 1H), 7.74
(m, 2H), 7.57 (t, J=7.1 Hz, 1 H), 7.28 (s, 1 H), 7.26 (d, J=10.4
Hz, 2H), 7.16 (d, J=8.7 Hz, 2H), 5.45 (s, 2H), 3.71 (s, 3H), 2.16
(s, 3H); MS: (M.sup.+H m/z=397.2).
EXAMPLE 25
2-{4-[1-Methyl-4-(3-methyl-isoxazol-5-yl)-1H-pyrazol-3-yl]-phenoxymethyl}--
quinoline
[0225] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting
3-Dimethylamino-2-(3-methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-ph-
enyl]-propenone provided the title compound as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.18 (d, J=8.3 Hz, 1H),
8.07 (d, J=8.7 Hz, 1H), 7.81(d, J=7.1 Hz, 1 H), 7.77 (s, 1H), 7.74
(t, J=7.1 Hz, 1H), 7.67 (d, J=8.7 Hz, 1 H), 7.54 (t, J=7.1 Hz, 1H),
7.48 (d, 8.7 Hz, 2 H), 7.07 (d, J=8.7 Hz, 2H), 5.81 (s, 1H), 5.41
(s, 2H), 3.92 (s, 3H), 2.20 (s, 3H); MS: (M.sup.+H m/z=397.2).
EXAMPLE 26
2-(4-[2-Methyl-5-(3-methyl-isoxazol-5-yl)-pyrimidin-4-yl]-phenoxymethyl}-q-
uinoline
[0226] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-pyrimidin-4-yl)-phenoxymethyl]-quinoline but
substituting acetamidine hydrochloride and
3-Dimethylamino-2-(3-methyl-isoxazol-5-yl)-1-[4-(quinolin-2-ylmethoxy)-ph-
enyl]-propenone provided the title compound as the hydrochloride
salt. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.87 (s, 1H), 8.18
(d, J=8.3 Hz, 1H), 8.06 (d, J=8.3 Hz, 1H), 7.82(d, J=8.3 Hz, 1 H),
7.72 (t, J=7.1 Hz, 1H), 7.63 (d, J=8.7 Hz, 1H), 7.53 t, J=6.6 Hz, 1
H), 7.45 (d, J=9.1 Hz, 2H), 7.05 (d, J=9.1 Hz, 2H), 5.79 (s, 1H),
5.40 (s, 2H), 2.78 (s, 3H), 2.23 (s, 3H); MS: (M.sup.+H
m/z=409.2).
Preparation 10
1-[4-(Quinolin-2-ylmethoxy)-phenyl]-ethanone
[0227] To a solution of 2-Chloromethyl quinoline (2.5 g, 14 mmole)
in acetone (47 ml) was added 4-hydroxy acetophenone (1.92 g, 1.0
eq.) and potassium carbonate (2.5 g, 2 eq.). The reaction mixture
was heated at 60.degree. C. for 16 h under N.sub.2 atmosphere,
cooled to ambient temperature and poured into 1N sodium hydroxide
(50 ml)/ethyl acetate (100 ml). The layers were separated and the
organic layer dried magnesium sulfate, filtered and concentrated.
Biotage MPLC was run using a 5-40% ethyl acetate/hexane gradient on
a 40 M column to provide the title compound as a white solid (2.75
g, 71%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.19 (d, J=8.7
Hz, 1 H), 8.07 (d, J=8.7, 1H), 7.91 (m, 2H), 7.82 (dd, J=8.3, 1.3
1H), 7.73 (t, J=7.1 Hz, 1 H), 7.62 (d, J =8.3 Hz, 1 H), 7.54 (t,
J=7.1 Hz, 1 H), 7.06 (m, 2H), 5.42 (s, 2 H), 2.51 (s, 3 H); MS:
(M.sup.+H m/z=278.3).
Preparation 11
3-Dimethylamino-1-[4-(quinolin-2-ylmethoxy)-phenyl]-propenone
[0228] 1-[4-(Quinolin-2-ylmethoxy)-phenyl]-ethanone (1.0 g, 3.61
mmole) was stirred in dimethoxymethyl-dimethyl amine (5 ml) and
heated at reflux for 18 h. The reaction mixture was cooled to RT
and a tan precipitate formed. It was filtered and washed with ethyl
ether to provide the title compound 840 mg, 71%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.39 (d, J=8.3 Hz, 1 H), 7.97 (m, 2H),
7.91 (m, 2H), 7.84 (m, 2H), 7.75 (t, J=6.6 Hz, 1 H), 7.62 (m, 3H),
7.05 (d, J=8.7 Hz, 2 H), 5.77 (d, J=12.0, 1H), 5.40 (s, 2 H), 3.07
(bs, 3 H), 2.84 (bs, 3H); MS: (M.sup.+H m/z=333.3).
EXAMPLE 27
2-[4-(2-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0229] To a solution of
3-Dimethylamino-1-[4-(quinolin-2-ylmethoxy)-phenyl]-propenone (46
mg) in ethanol (0.7 ml) was added water (0.7 ml), acetic acid
(0.05ml) and 4-pyridyl hydrazine (25 mg, 1 eq.). The reaction
mixture was heated at 100.degree. C. for 3 h, cooled to RT, poured
into 1 N NaOH, extracted with chloroform, dried magnesium sulfate,
filtered and concentrated. Biotage MPLC was run on a 25S column
eluting with 20-80% ethyl acetate/hexane to provide the title
compound as a tan solid (31 mg, 61%). .sup.1H NMR (400 MHz,
CDCl.sub.3) 8.51 (bs, 2H), 8.24 (d, J=8.7 Hz, 1 H), 8.11 (d, J=8.7,
2H), 7.84 (d, J=8.3 Hz, 1H), 7.74 (m, 2H), 7.69 (d, J=8.7 Hz, 1 H),
7.58 (t, J=7.1, 1H), 7.32 (bs, 2H), 7.19 (d, J=6.6 Hz, 2H), 7.04
(d, J=6.6, 2H), 5.40 (s, 2 H), 6.45 (s, 1H), 5.42 (s, 2H); MS:
(M.sup.+H m/z=379.2).
EXAMPLE 28
2-[4-(3-Methyl-5-pyridin-4-yl
[1,2,4]triazol-4-yl)-phenoxymethyl]-quinoline
[0230] To a solution of isonicotinic hydrazide (1.04 g, 1.12 eq.)
in acetonitrile (30 ml) was added N,N-dimethylacetamide dimethyl
acetal (1.1 eq.) and the reaction mixture was heated at 50.degree.
C. for 3 h. The reaction mixture was cooled to ambient temperature
and concentrated. 4-(Quinolin-2-ylmethoxy)-phenylamine (1.70 g) was
added along with acetic acid (30 ml) and the reaction mixture was
heated at reflux for 3 h, and cooled to ambient temperature. The
reaction mixture was concentrated on a rotovap and purified via
combiflash MPLC to provide the title compound as a tan solid (56%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.51 (d, J=6.2 Hz, 2H),
8.24 (d, J=8.7 Hz, 1 H), 8.08 (d, J=8.7, 1H), 7.85 (d, J=7.9 Hz,
1H), 7.76 (t, J=8.3 Hz, 1H), 7.67 (d, J=8.7 Hz, 1 H), 7.58 (t,
J=7.1, 1H), 7.29 (d, J=6.2 Hz, 2 H), 7.17 (d, J=9.1 Hz, 2H), 7.12
(d, J=9.1 Hz, 2 H), 5.43 (s, 2 H), 2.31 (s, 3H); MS: (M.sup.+H
m/z=394.3).
Preparation 12
4-benzyloxy-N-methoxy-N -methyl-benzamide
[0231] Following the procedure for the preparation of
N-Methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide but
substituting 4-benzyloxy benzoic acid provided the title compound
as a waxy solid. MS: (M.sup.+H m/z=272.3).
Preparation 13
1-(4-Benzyloxy-phenyl)-2-pyridin-4-yl-ethanone
[0232] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting 4-benzyloxy-N-methoxy-N-methyl-benzamide provided the
title compound. MS: (M.sup.+H m/z=304.2).
Preparation 14
4-[3-(4-Benzyloxy-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyridine
[0233] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting 1-(4-Benzyloxy-phenyl)-2-pyridin-4-yl-ethanone
provided the title compound. MS: (M.sup.+H m/z=342.2).
Preparation 15
4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenol
[0234] To a solution of
4-[3-(4-Benzyloxy-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyridine (1.28
g) in ethanol (50 ml)/ethyl acetate (50 ml) in a parr bottle was
added Palladium hydroxide (500 mg). The parr bottle was charged to
40 psi on a shaker for 6 h. The reaction mixture was filtered and
concentrated. MPLC biotage chromatography eluting with methanol
(1-7%)/chloroform provided the title compound (860 mg, 91%).
.sup.1H NMR (400 MHz, DMSO) .delta. 9.53 (s, 1H), 8.39 (d, J=5.8
Hz, 2 H), 7.15 (m, 4H), 6.72 (d, J=8.7 Hz, 1H), 3.84 (s, 3H); MS:
(M.sup.+H m/z=252.2).
EXAMPLE 29
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoxaline
[0235] To a solution of
4-(1-Methyl4-pyridin-4-yl-1H-pyrazol-3-yl)-phenol (50 mg) in
dioxane (2 ml) was added triphenylphosphine (84 mg),
quinoxaline-2-yl-methanol (48 mg) and di-t-butyl-aza-dicarboxylate
(73 mg) and the reaction mixture was heated at 60.degree. C. for 18
h. The reaction mixture was poured into 1N NaOH, extracted 3.times.
methylene chloride, dried magnesium sulfate, filtered and
concentration Purification via MPLC biotage chromatography provided
the title compound (54 mg, 67%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.09 (s, 1H), 8.45 (d, J=6.2 Hz, 2H), 8.10 (m, 2 H), 7.77
(m, 2H), 7.55 (s, 1H), 7.37 (d, J=9.1 Hz, 2H), 7.10 (d, J=6.9 Hz, 2
H), 7.01 (d, J=8.7, 2H), 5.41 (s, 2 H), 3.94 (s, 3H); MS: (M.sup.+H
m/z=394.4).
EXAMPLE 30
7-Chloro-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline hydrogen chloride
[0236] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenol and
7-chloro-2-chloromethyl-quinoline provided the title compound.
.sup.1H NMR (400 MHz, DMSO) =67 8.66 (d, J=6.6 Hz, 2H), 8.54 (s, 1
H), 8.47 (d, J=8.3, 2H), 8.04 (m, 2H), 7.70 (m, 2H), 7.65 (m, 1H),
7.36 (d, J=8.7 Hz, 2H), 7.12 (d, J=8.7, 2H), 5.38 (s, 2H), 3.90 (s,
3 H); MS: (M.sup.+H m/z=427.1).
EXAMPLE 31
6-Fluoro-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline hydrogen chloride
[0237] Following the procedure for the preparation of
7-Chloro-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qu-
inoline hydrogen chloride but substituting
2-chloromethyl-6-fluoro-quinoline provided the title compound.
.sup.1H NMR (400 MHz, DMSO) .delta. 8.67 (d, J=6.6 Hz, 2H), 8.55
(s, 1 H), 8.42 (d, J=8.3, 1H), 8.04 (m, 1H), 7.82 (m, 1H), 7.71 (m,
4H), 7.36 (d, J=8.7 Hz, 2H), 7.12 (d, J=8.7, 2H), 5.37 (s, 2H),
3.91 (s, 3 H); MS: (M.sup.+H m/z=411.2).
Preparation 16
3-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid quinolin-2-ylmethyl
ester
[0238] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
3-fluoro-4-hydroxy-benzoic acid provided the title compound. MS:
(M.sup.+H m/z=439.0).
Preparation 17
3-Fluoro-4-(quinolin-Z-ylmethoxy)-benzoic acid
[0239] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid but substituting
3-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid quinolin-2-ylmethyl
ester provided the title compound. MS: (M.sup.+H m/z=298.2).
Preparation 18
3-Fluoro-N-methoxyl-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide
[0240] Following the procedure for the preparation of
N-Methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide but
substituting 3-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid
provided the title compound. MS: (M.sup.+H m/z=341.2).
Preparation 19
1-[3-Fluoro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
[0241] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting
3-Fluoro-N-methoxyl-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide
provided the title compound. MS: (M.sup.+H m/z=373.1).
EXAMPLE 32
2-[2-Fluoro-4-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0242] Following the procedure for the preparation of
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline but
substituting
1-[3-Fluoro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.47 (bs, 2H), 8.19 (d, J=8.7 Hz, 1H), 8.05 (d, J=8.3 Hz, 1
H), 7.71 (m, 4H), 7.54 (t, J=7.1 Hz, 1H), 7.18 (m, 3H), 7.07 (m, 2
H), 5.42 (s, 2 H); MS: (M.sup.+H m/z=397.0).
EXAMPLE 33
2-[2-Fluoro-4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline
[0243] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting
1-[3-Fluoro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.47 (d, J=6.2 Hz, 2H), 8.21 (d, J=8.3 Hz, 1H), 8.05 (d,
J=8.7 Hz, 1 H), 7.83 (d, J=7.9 Hz, 2H), 7.72 (m, 2H), 7.55 (m, 2H),
7.16 (m, 2 H), 7.07 (m, 1H), 6.99 (m, 2H), 5.45 (s, 2 H), 3.95 (s,
3H); MS: (M.sup.+H m/z=411.0).
Preparation 20
2,3-Difluoro-4-(quinolin-2-ylmethoxy)-benzoic acid quinolin-2-yl
methyl ester
[0244] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
2,3-difluoro-4-hydroxy-benzoic acid provided the title compound.
MS: (M.sup.+H m/z=457.1).
Preparation 21
2,3-Difluoro-4-(quinolin-2-ylmethoxy)-benzoic-acid
[0245] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid but substituting
2,3-Difluoro-4-(quinolin-2-ylmethoxy)-benzoic acid quinolin-2-yl
methyl ester provided the title compound. MS: (M.sup.+H
m/z=316.1).
Preparation 22
2,3-Difluoro-N-methoxy-N
-methyl-4-(quinolin-2-ylmethoxy)-benzamide
[0246] Following the procedure for the preparation of
N-Methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide but
substituting 2,3-Difluoro-4-(quinolin-2-ylmethoxy)-benzoic acid
provided the title compound. MS: (M.sup.+H m/z=359.1).
Preparation 23
1-[2,3-Difluoro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
[0247] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting
2,3-Difluoro-N-methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide
provided the title compound. MS: (M.sup.+H m/z=391.1).
EXAMPLE 34
2-[2,3-Difluoro-4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-
-quinoline
[0248] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting
1-[2,3-Difluoro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.44 (bs, 2H), 8.22 (d, J=8.7 Hz, 1H), 8.06 (d, J=8.7 Hz, 1
H), 7.84 (d, J=7.9 Hz, 1H), 7.70 (m, 2 H), 7.66 (s, 1H), 7.56 (t,
J=7.9 Hz, 1H), 7.08 (m, 3H), 6.88 (m, 1H), 5.48 (s, 2H); MS:
(M.sup.+H m/z=429.1).
Preparation 24
2-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid quinolin-2-ylmethyl
ester
[0249] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
2-fluoro-4-hydroxy-benzoic acid provided the title compound. MS:
(M.sup.+H m/z=439.0).
Preparation 25
2-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid
[0250] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid but substituting
2-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid quinolin-2-yl methyl
ester provided the title compound. MS: (M.sup.+H m/z=298.2).
Preparation 26
2-Fluoro-n-methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide
[0251] Following the procedure for the preparation of
N-Methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide but
substituting 2-Fluoro-4-(quinolin-2-ylmethoxy)-benzoic acid
provided the title compound. MS: (M.sup.+H m/z =341.2).
Preparation 27
1-{2-Fluoro-4-(quinolin-2-ylmethoxy)-phenyl}-2-pyridin-4-yl-ethanone
[0252] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting
2-Fluoro-n-methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide
provided the title compound. MS: (M.sup.+H m/z=373.0).
EXAMPLE 35
2-[3-Fluoro-4-(4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0253] Following the procedure for the preparation of
2-[-4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl}-quinoline but
substituting
1-{2-Fluoro-4-(quinolin-2-ylmethoxy)-phenyl}-2-pyridin-4-yl-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.47 (d, J=6.5 Hz, 2H), 8.22 (d, J=8.3 Hz, 1H), 8.08 (d,
J=8.7 Hz, 1 H), 7.84 (s, 1H), 7.82 (m, 1H), 7.74 (m, 1H), 7.65 (d,
J=8.7 Hz, 1 H), 7.55 (m, 1 H), 7.25 (m, 1 H), 7.18 (d, J=6.2 HZ,
2H), 6.85 (d, J=10.9, 2 H), 5.38 (s, 2 H); MS: (M.sup.+H
m/z=397.2).
Preparation 28
4-(Quinolin-2-ylmethoxy)-benzaldehyde
[0254] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
4-Hydroxy-benzaoldehyde provided the title compound. MS: (M.sup.+H
m/z=264.2).
Preparation 29
1-Pyridin-4-yl-2-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
[0255] To a solution of 4-pyridine carboxaldehyde (10.8 g) in
2-propanol (50 ml) was added aniline (9.3 g). After 15 min, the
phenyl-pyridin-4-ylmethylene-amine product (68%) was filtered and
used crude. To a solution of the imine in ethoanol (35 ml) was
added diphenyl phosphite (13.1 ml) and stirred 1 h. Ethyl ether
(200 mL) was added and the
(Phenylamino-pyridin-4-yl-methyl-phosphonic acid diphenyl ester
(5.06 g) was filtered. The phophonic ester (0.98 g) in THF (25 ml)
was stirred at -40.degree. C. under N.sub.2. A solution of
KOH/methanol (0.146 g/10%) was added followed by
4-(Quinolin-2-ylmethoxy)-benzaldehyde (0.62 g). The crude reation
mixture was warmed to ambient temperature for 1 h and concentrated.
The crude product was stirred in acetonitrile (1 mL)/1 ml conc. HCl
for 1 h, quenched with sat'd sodium bicarbonate, extracted with
chloroform, dried magnesium sulfate, filtered and concentrated.
Purification via MPLC combiflash provided the title compound. MS:
(M.sup.+H m/z=355.1).
EXAMPLE 36
2-[4-(5-Pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline
[0256] 1-Pyridin-4-yl-2-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
(168 mg) was heated in diethoxymethyl-dimethyl amine (1 ml) at
reflux for 2 hours. The reaction mixture was concentrated and
dissolved in methanol (1 ml) and hydrazine hydrate (0.023 ml) was
added and the reaction mixture was heated at 65.degree. C. for 1 h.
The reaction mixture was concentrated and purified by combiflash
MPLC chromatography to provide the title compound (90%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.37 (bs, 2H), 8.18 (d, J=8.7 Hz,
1 H), 7.99 (d, J=8.7 Hz, 1H), 7.78 (d, J=8.3 Hz, 1 H), 7.66 (m, 2
H), 7.54 (s, 1 H), 7.48 (m, 1 H), 7.36 (m, 2 H), 7.11 (d, J=7.1 Hz,
2H), 6.94 (d, J=8.3 Hz, 2H), 5.29 (s, 2H); MS: (M.sup.+H
m/z=379.2).
EXAMPLE 37
2-[4-(1-Methyl-5-pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline
[0257] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline but
substituting methyl hydrazine provided the title compound and
2-[4-(1-Methyl-3-pyridin-4-yl-1H-pyrazol4-yl)-phenoxymethyl]-quinoline.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.66 (bs, 2 H), 8.17 (d,
J=8.7 Hz, 1H), 8.05 (d, J=7.9 Hz, 1 H), 7.81 (d, J=8.3 Hz, 1H),
7.70 (m, 1 H), 7.63 (m, 2 H), 7.53 (t, J=7.1 Hz, 1 H), 7.21 (m, 2
H), 7.03 (d, J=9.1 Hz, 2H), 6.89 (d, J=8.7 Hz, 2H), 5.32 (s, 2H),
3.80 (s, 3H); MS: (M.sup.+H m/z=393.2).
EXAMPLE 38
2-[4-(1-Methyl-3-pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline
[0258] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline but
substituting methyl hydrazine provided the title compound and
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-4-yl)-phenoxymethyl]-quinoline.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.49 (bs, 2 H), 8.20 (d,
J=8.3 Hz, 1 H), 8.07 (d, J=8.3 Hz, 1 H), 7.83 (d, J=8.3 Hz, 1H),
7.74 (m, 2 H), 7.55 (t, J=7.1 Hz, 1 H), 7.42 (m, 2H), 7.38 (s, 1H),
7.17 (d, J=8.7 Hz, 2H) 7.00 (d, J=8.7Hz, 2H), 5.38 (s, 2H), 3.95
(s, 3H); MS: (M.sup.+H m/z=393.2).
EXAMPLE 39
2-Methyl-1-{4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-y-
l}-propan-2-ol
[0259] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting 1-Hydrazino-2-methyl-propan-2-ol provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.47 (d,
J=6.2 Hz, 2 H), 8.19 (d, J=8.7 Hz, 1 H), 8.07 (d, J=8.7 Hz, 1 H),
7.82 (d, J=7.9 Hz, 1H), 7.74 (t, J=8.3 Hz, 1H), 7.68 (d, J=8.7 Hz,
1 H), 7.62 (s,1H), 7.55 (t, J=7.1 Hz, 1 H), 7.39 (d, J=8.7 Hz, 2H),
7.17 (m, 2H), 7.01 (d, J=8.7 Hz, 2H), 5.39 (s, 2H) 4.09 (s, 2H),
1.23 (s, 2H); MS: (M.sup.+H m/z=451.2).
EXAMPLE 40
2-Methyl-1-{4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-y-
l}-propan-2-ol
[0260] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting 1-Hydrazino-2-methyl-propan-2-ol provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.37 (d,
J=5.8 Hz, 2 H), 8.24 (d, J=8.3 Hz, 1 H), 8.09 (d, J=9.1 Hz, 1 H),
7.87 (s, 1H), 7.85 (d, J=7.9 Hz, 1H), 7.76 (m, 1 H), 7.72 (m, 1H),
7.17 (m, 4 H), 7.00 (d, J=6.2 Hz, 2H), 5.42 (s, 2H) 3.89 (s, 2H),
1.04 (s, 6H); MS: (M.sup.+H m/z=451.2).
EXAMPLE 41
(R)-1-{4-Pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-pr-
opan-2-ol
[0261] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting (R)-1-Hydrazino-propan-2-ol provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.42 (m, 2 H),
8.18 (d, J=8.3 Hz, 1 H), 8.06 (d, J=8.4 Hz, 1 H), 7.81 (d, J=8.3
Hz, 1H), 7.73 (m, 1H), 7.66 (d, J=8.7 Hz, 1H), 7.61 (s, 1 H), 7.54
(m, 1H), 7.36 (d, J=9.1 Hz, 2 H), 7.12 (m, 2H), 6.99 (d, J=8.7 Hz,
2H) 5.37 (s, 2H), 4.30 (m, 1H), 4.21 (dd, J=13.6, 2.5 Hz, 1H), 4.03
(dd, J=13.6, 7.9 Hz, 1H), 1.26 (d, J=6.2 Hz, 3H); MS: (M.sup.+H
m/z=437.2).
EXAMPLE 42
(S)-1-{4-Pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-pyrazol-1-yl}-pr-
opan-2-ol
[0262] Following the procedure for the preparation of
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting (S)-1-Hydrazino-propan-2-ol provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.42 (m, 2 H),
8.18 (d, J=8.3 Hz, 1 H), 8.06 (d, J=8.4 Hz, 1 H), 7.81 (d, J=8.3
Hz, 1H), 7.73 (m, 1H), 7.66 (d, J=8.7 Hz, 1H), 7.61 (s, 1 H), 7.54
(m, 1H), 7.36 (d, J=9.1 Hz, 2 H), 7.12 (m, 2H), 6.99 (d, J=8.7 Hz,
2H) 5.37 (s, 2H), 4.30 (m, 1H), 4.21 (dd, J=13.6, 2.5 Hz, 1H), 4.03
(dd, J=13.6, 7.9 Hz, 1H), 1.26 (d, J=6.2 Hz, 3H), MS: (M.sup.+H
m/z=437.2).
EXAMPLE 43
2-[4-(1-Isopropyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0263] To a solution of
2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline
(0.075 g) in dimethyl formamide (2 ml) was added cesium carbonate
(0.098 g) and 2-iodo propane (0.030 ml) and the reaction mixture
heated at 60.degree. C. for 72 h. The reaction mixture was poured
into water and extracted with methylene chloride, dried magnesium
sulfate, filtered and concentrated. Purification via Prep TLC
eluting with 2% methanol/1% saturated ammonium hydroxide/67% ethyl
acetate/30% hexane provided the title compound (60 mg). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.43 (d, J=6.2 Hz, 2 H), 8.16 (d,
J=8.7 Hz, 1 H), 8.05 (d, J=9.1 Hz, 1 H), 7.80 (d, J=8.3 Hz, 1H),
7.70 (m, 1H), 7.65 (d, J=8.7 Hz, 1 H), 7.59 (s, 1H), 7.53 (t, J=7.1
Hz, 1 H), 7.38 (d, J=9.1 Hz, 2H), 7.15 (d, J=8.7 Hz, 2H), 6.99 (d,
J=8.7 Hz, 2H), 5.38 (s, 2H) 4.51 (m, 1H), 1.54 (d, J=6.6 Hz, 6H);
MS: (M.sup.+H m/z=421.2).
EXAMPLE 44
2-[4-(1-Isobutyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0264] Following the procedure for the preparation of
2-[4-(1-Isopropyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
but substituting 1-Iodo-2-methyl-propane provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.44 (m, 2H),
8.18 (d, J=8.7 Hz, 1H), 8.06 (d, J=8.3 Hz, 1 H), 7.83 (d, J=6.6 Hz,
1 H), 7.73 (t, J=6.6 Hz, 1H), 7.54 (s,1H), 7.52 (m, 1H), 7.38 (d,
J=9.1 Hz, 2 H), 7.15 (m, 2H), 7.00 (d, J=8.7 Hz, 2 H), 5.38 (s, 2H)
3.93 (d, J=7.5 Hz, 2 H), 4.29 (m, 1H), 0.95 (d, J=6.6 Hz, 6H); MS:
(M.sup.+H m/z=435.2).
EXAMPLE 45
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-[1.8]Naphthy-
ridine
[0265] To a solution of
4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenol (72 mg) in
dioxane 1.5 ml, was added triphenyl phosphine (121 mg),
[1,8]Naphthyridin-2-yl-methanol (69 mg) and
di-t-butyl-diazacarboxalate (106mg) and the reaction mixture heated
at 60.degree. C. for 24 h. The reaction mixture was poured into 1 N
NaOH, extracted with methylene chloride, dried magnesium sulfate
and concentrated. Purification via Prep TLC eluting with 15%
methanol/70%ethyl acetate/15% hexanes provided the title compound
(9.8 mg). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.13 (dd,
J=4.2, 1.7 Hz, 1H), 8.45 (d, J=5.8 Hz, 2H), 8.23 (d, J=8.3 Hz, 1H),
7.21 (dd, J=8.5, 2.1 Hz, 1 H), 7.79 (d, J=8.7 Hz, 1H), 7.57 (s,
1H), 7.52 (m, 1H), 7.37(d, J=9.1 Hz, 2 H), 7.16 (d, J=6.2 Hz, 2H),
7.01 (d, J=8.7 Hz, 2 H), 5.47 (s, 2H), 3.94 (s, 3 H); MS: (M.sup.+H
m/z=394.0).
Preparation 30
4-(2-Quinolin-2-yl-ethyl)-benzoic acid methyl ester
[0266] To a solution of 4-[Triphenyl-phophanyl)-methyl]-benzoic
acid methyl ester (1.87 g) in THF (16 ml) under N.sub.2 atmosphere
at 0.degree. C. was added sodium hydride (165 mg (60%)). After 30
min, quinoline-2-carbaldehyde (0.50 g) was added and the reaction
stirred at ambient temperature for 2 h. The reaction mixture was
quenched with brine, extracted with chloroform, dried magnesium
sulfate, filtered and concentrated to provide the crude alkene. The
crude product was placed on a parr shaker in ethanol (15 ml) with
palladium hydroxide (200 mg) as the catalyst under 10 PSI of
H.sub.2. After 40 min, the reaction mixture was filtered through
celite and concentrated. Biotage MPLC chromatography eluting with
10-20% ethyl acetate/hexane provided the title compound. MS:
(M.sup.+H m/z=292.1).
Preparation 31
4-(2-Quinolin-2-yl-ethyl)-benzoic acid
[0267] To a solution of 4-(2-Quinolin-2-yl-ethyl)-benzoic acid
methyl ester (680 mg) in THF (11 ml)/methanol (3 ml) was added 1N
sodium hydroxide solution (4.67 ml). The reaction mixture stirred
for 4 h. and the pH adjusted to 3. The white solid was filtered to
provide the title compound (550 mg, 86%). MS: (M.sup.+H
m/z=278.1).
Preparation 32
N-Methoxy-N-methyl-4-(2-quinolin-2-yl-ethyl)-benzamide
[0268] To a solution of 4-(2-Quinolin-2-yl-ethyl)-benzoic acid (530
mg) in dioxane 5 ml/acetonitrile 5 ml was added triethylamine (0.60
ml) and O,N-Dimethyl-hydroxylamine hydrogen chloride (240 mg).
After 72 h, the reaction mixture was poured into 1N sodium
hydroxide solution and extracted with chloroform, dried magnesium
sulfate, filtered and concentrated. Biotage MPLC chromatography
eluting with 20-50% ethyl acetate provided the title compound (516
mg, 88%). MS: (M.sup.+H m/z=321.1).
Preparation 33
2-Pyridin-4-yl-1-[4-(2-quinolin-2-yl-ethyl)-phenyl]-ethanone
[0269] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting N-Methoxy-N-methyl-4-(2-quinolin-2-yl-ethyl)-benzamide
provided the title compound. MS: (M.sup.+H m/z=353.1).
EXAMPLE 46
2-{2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline
[0270] To
2-Pyridin-4-yl-1-[4-(2-quinolin-2-yl-ethyl)-phenyl]-ethanone (53
mg) was added 3 ml of Diethoxymethyl-dimethyl-amine and the
reaction mixture heated at 100.degree. C. After 3 h, the reaction
mixture as concentrated and methanol (3 ml) and hydrazine (0.02 ml)
was added. The reaction mixture was heated at 60.degree. C. for 3 h
and concentrated. Biotage MPLC purification eluting with 1-3%
methanol/0.5% saturated ammonium hydroxide in chloroform provided
the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.47
(d, J=6.2 Hz, 2 H), 8.05 (d, J=8.3 Hz, 2 H), 7.80 (s, 1H), 7.78 (d,
J=8.3 Hz, 2 H), 7.70 (t, J=7.1 Hz, 1H), 7.51 (t, J=7.1 Hz, 1 H),
7.32 (d, J=8.3 Hz, 2 H), 7.24 (m, 3H), 7.19 (d, J=6.2 Hz, 2H), 3.31
(m, 2H), 3.22 (m, 2H), MS: (M.sup.+H m/z=377.1).
EXAMPLE 47
2-(2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenyl]-ethyl]-quinoline
[0271] Following the procedure for the preparation of
2-{2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline
but substituting methyl hydrazine provided the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.45 (d, J=6.2 Hz, 2 H),
8.06 (t, J=10.4 Hz, 2 H), 7.77 (d, J=7.1 Hz, 1 H), 7.70 (t, J=8.3
Hz, 1 H), 7.57 (s, 1H), 7.50 (t, J=9.1 Hz, 1 H), 7.35 (d, J=8.3 Hz,
2H), 7.24 (m, 3H), 7.20 (d, J=5.0 Hz, 2H), 3.97 (s, 3H), 3.31 (m,
2H), 3.18 (m, 2H); MS: (M.sup.+H m/z=391.0).
Preparation 34
2-(2-Chloro-pyridin-4-yl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
[0272] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting 2-chloro-4-methyl pyridine provided the title
compound. MS: (M.sup.+H m/z=389.0).
EXAMPLE 48
2-{4-[4-(2-Chloro-pyridin-4-yl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline
[0273] Following the procedure for the preparation of
2-{2-[4-(4-Pyridin4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline
but substituting
2-(2-Chloro-pyridin-4-yl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.23 (m, 2 H), 8.08 (d, J=8.7 Hz, 1 H), 7.83 (d, J=8.3 Hz,
1 H), 7.80 (s, 1H), 7.75 (t, J=7.1 Hz, 1 H), 7.67 (d, J=8.3 Hz,
1H), 7.57 (t, J=7.1 Hz, 1 H), 7.33 (d, J=9.1 Hz, 2H), 7.05 (m, 4H),
5.40 (s, 2H); MS: (M.sup.+H m/z=413.1).
EXAMPLE 49
2-[4-[4-(2-Chloro-pyridin-4-yl)-1-methyl-1H-pyrazol-3-yl]-phenoxymethyl}-q-
uinoline
[0274] Following the procedure for the preparation of
2-2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline
but substituting methyl hydrazine and
2-(2-Chloro-pyridin-4-yl)-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.19 (m, 2 H), 8.07 (d, J=8.3 Hz, 1 H), 7.83 (d, J=8.3 Hz,
1 H), 7.74 (t, J=8.3 Hz, 1H), 7.67 (d, J=8.3 Hz, 1 H), 7.58 (s,
1H), 7.55 (t, J=8.3 Hz, 1 H), 7.36 (d, J=8.7 Hz, 2H), 7.20 (s, 1H),
7.03 (m, 3H), 5.40 (s, 2H) 3.95 (s, 3H); MS: (M.sup.+H
m/z=427.0).
EXAMPLE 50
2-{4-[1-Methyl-4-(2-methyl-pyridin-4-yl)-1H-pyrazol-3-yl]-phenoxymethyl}-q-
uinoline
[0275] To a solution of
2-{4-[4-(2-Chloro-pyridin-4-yl)-1-methyl-1H-pyrazol-3-yl]-phenoxymethyl}--
quinoline (100 mg) in dioxane (1.2 ml) was added methyl boroxine
(0.066 ml), palladium tetrakis (41 mg) and 2N sodium carbonate
solution (0.234 ml). The reaction mixture was heated at 100.degree.
C. for 8 h, poured into 1 N NaOH, extracted with chloroform, dried
magnesium sulfate, filtered and concentrated. Prep TLC run with 3%
methanol/0.5% saturated ammonium hydroxide/80% ethyl acetate in
hexanes provided the free base material. The produce was stirred in
ethyl acetate and 2 eq. of succinic acid was added to give a white
precipitate which was filtered to provide the title compound as a
white solid succinate salt (20 mg). .sup.1H NMR (400 MHz, DMSO)
.delta. 8.40 (d, J=8.3 Hz, 2 H), 8.25 (d, J=5.0 Hz, 2 H), 8.07 (s,
1H), 8.00 (t, J=7.9 Hz, 2 H), 7.77 (t, J=6.6 Hz, 1 H), 7.67 (d,
J=8.7 Hz, 2H), 7.60 (t, J=6.6 Hz, 1 H), 7.29 (d, J=9.1 Hz, 2H),
7.03 (m, 3 H), 6.92 (m, 1H), 5.35 (s, 2H), 3.85 (s, 3H), 2.37 (s,
4H) 2.31 (s, 3H); MS: (M.sup.+H m/z=407.0).
EXAMPLE 51
Dimethyl-(4-{1-methyl-3-[4-(quinolin-2-ylmethoxy)-phenyl]-1H-pyrazol-4-yl}-
-pyridin-2-yl)-amine
[0276] To a solution of
2-{4-[4-(2-Chloro-pyridin-4-yl)-1-methyl-1H-pyrazol-3-yl]-phenoxymethyl}--
quinoline (100 mg) in dimethyl formamide (1 ml) was added
diethanolamine (0.035 ml) and the reaction mixture heated at
130.degree. C. for 72 h. The reaction mixture was poured into water
and extracted with ethyl ether, dried magnesium sulfate, filtered
and concentrated. Prep TLC eluting with 60% ethyl acetate/hexane
provided the title compound as a Free base. The product was stirred
in ethyl acetate and 1 eq. of succinic acid was added. After 18 h,
the white precipitate was filtered to provide the succinate salt
(24 mg). .sup.1H NMR (400 MHz, DMSO) .delta. 8.40 (d, J=8.3 Hz, 1
H), 8.03 (s, 1 H), 7.98 (m, 2 H), 7.90 (d, J=5.4 Hz, 1 H), 7.77 (m,
1H), 7.65 (d, J=8.3 Hz, 1 H), 7.59 (m, 1 H), 7.31 (d, J=6.6 Hz,
2H), 7.04 (d, J=9.1 Hz, 2 H), 6.37 (m, 2 H), 5.35 (s, 2H), 3.84 (s,
3H), 2.80 (s, 6H) 2.37 (s, 4H); MS: M.sup.+H m/z=436.0).
Preparation 35
3-Dimethylamino-1-pyridin-4-yl-propenone
[0277] To 1-Pyridin-4-yl-ethanone(1.62 g) was added
N,N-dimethylformamide diethylacetal (10 ml) and the reaction
mixture heated at 120.degree. C. for 2 h and concentrated to
provide the title compound. MS: (M.sup.+H m/z=177.0).
Preparation 36
4-[2-(4-Benzyloxy-phenyl-2H-pyrazol-3-yl]-pyridine
[0278] To a solution of 3-Dimethylamino-1-pyridin-4-yl-propenone
(590 mg) in methanol (10 ml) was added acetic acid (0.5 ml) and
(4-Benzyloxy-phenyl)-hydrazine hydrogen chloride (836 mg) and the
reaction mixture heated to 60.degree. C. for 6 h. The reaction
mixture was poured into saturated sodium bicarbonate, extracted
with ethyl acetate, dried magnesium sulfate, filtered and
concentrated. Purification via combiflash MPLC provided the title
compound (795 mg). MS: (M.sup.+H m/z=328.1).
Preparation 37
4-(5-Pyridin-4-yl-pyrazol-1-yl)-phenol
[0279] To a solution of
4-[2-(4-Benzyloxy-phenyl-2H-pyrazol-3-yl]-pyridine (610 mg) in
ethyl acetate (15 ml)/ethanol (15 ml) was added palladium hydroxide
(20%, 343 mg). The reaction mixture was placed on a parr shaker
under 45 psi of H.sub.2 gas for 18 h. The reaction mixture was
filtered through celite and concentrated. Purification via
chromatotron (2 mm silica, 5% methanol/chloroform) provided the
title compound (259 mg). MS: (M.sup.+H m/z=238.1).
EXAMPLE 52
2-[4-(5-Pyridin-4-yl-pyrazol-1-yl)-phenoxymethyl]-quinoline
[0280] To a solution of 4-(5-Pyridin-4-yl-pyrazol-1-yl)-phenol (82
mg) in acetone was added potassium carbonate (153 mg) and
2-Chloromethyl-quinoline (95 mg) and the reaction mixture heated at
60.degree. C. for 18 h. The reaction mixture was poured into brine
and extracted with ethyl acetate, dried magnesium sulfate, filtered
and concentrated. Purification via combiflash MPLC provided the
title compound (91 mg). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.51 (m, 2 H), 8.20 (d, J=8.7 Hz, 1 H), 8.06 (d, J=8.7 Hz, 1 H),
7.83 (d, J=7.1 Hz, 1H), 7.74 (m, 2H), 7.65 (d, J=8.7 Hz, 1 H), 7.57
(m, 1H), 7.20 (d, J=8.7 Hz, 2 H), 7.09 (d, J=5.8 Hz, 2H), 7.02 (d,
J=9.1 Hz, 2H), 6.60 (d, J=1.7 Hz, 1H), 5.39 (s, 2H); MS: (M.sup.+H
m/z=379.0).
EXAMPLE 53
2-[4-(3-Methyl-5-pyridin-4-yl-pyrazol-1-yl)-phenoxymethyl]-quinoline
[0281] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-pyrazol-1-yl)-phenoxymethyl]-quinoline but
substituting (1,1-Dimethoxy-ethyl)-dimethyl-amine provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.49 (d,
J=6.2 Hz, 2 H), 8.20 (d, J=8.3 Hz, 1 H), 8.06 (d, J=8.7 Hz, 1 H),
7.83 (d, J=8.3 Hz,1H), 7.74 (m,1H), 7.64 (d, J=8.3 Hz, 1 H), 7.54
(m, 1H), 7.18 (d, J=8.7 Hz, 2 H), 7.07 (d, J=6.2 Hz, 2H), 7.00 (d,
J=9.1 Hz, 2H), 6.40 (s, 1H), 5.38 (s, 2H), 2,35 (s, 3H); MS:
(M.sup.+H m/z=393.4).
Preparation 38
3-Chloro-4-(quinolin-2-ylmethoxy)-benzoic acid methyl ester
[0282] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
3-Chloro-4-hydroxy-benzoic acid methyl ester provided the title
compound. MS: (M.sup.+H m/z=328.0).
Preparation 39
3-Chloro-4-(quinolin-2-ylmethoxy)-benzoic acid
[0283] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid but substituting
3-Chloro-4-(quinolin-2-ylmethoxy)-benzoic acid methyl ester
provided the title compound. (M.sup.+H m/z=314.0).
Preparation 40
3-Chloro-N-methoxy-N-methyl4-(quinolin-2-ylmethoxy)-benzamide
[0284] Following the procedure for the preparation of
N-Methoxy-N-methyl-4-(2-quinolin-2-yl-ethyl)-benzamide but
substituting 3-Chloro4-(quinolin-2-ylmethoxy)-benzoic acid provided
the title compound. (M.sup.+H m/z=356.9).
Preparation 41
1-[3-Chloro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
[0285] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting
3-Chloro-N-methoxy-N-methyl-4-(quinolin-2-ylmethoxy)-benzamide
provided the title compound. (M.sup.+H m/z=389.0).
EXAMPLE 54
2-[2-Chloro4-(4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline
[0286] Following the procedure for the preparation of
2-{2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline
but substituting
1-[3-Chloro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.37 (m, 4 H), 8.02 (d, J=8.7 Hz, 2 H), 7.93 (d, J=8.3 Hz,
2H), 7.78 (m, 2 H), 7.61 (t, J=7.1 Hz, 1 H), 7.31 (m, 2H), 7.21 (m,
1 H), 5.44 (s, 2H); MS: (M.sup.+H m/z=413.0).
EXAMPLE 55
2-[2-Chloro-4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline
[0287] Following the procedure for the preparation of
2-{2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenyl]-ethyl}-quinoline
but substituting methyl hydrazine and
1-[3-Chloro-4-(quinolin-2-ylmethoxy)-phenyl]-2-pyridin-4-yl-ethanone
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.47 (d, J=6.2 Hz, 2 H), 8.21 (d, J=8.3 Hz, 1 H), 8.04 (d,
J=7.5 Hz, 1H), 7.83 (d, J=8.3 Hz, 1 H), 7.78 (d, J=8.7 Hz, 1 H),
7.72 (m, 1H), 7.56 (m, 3 H), 7.21 (m, 1H), 7.14 (d, J=6.2 Hz, 2 H),
6.97 (d, J=8.7 Hz, 1 H), 5.46 (s, 2H), 3.95 (s, 3H); MS: (M.sup.+H
m/z=427.1).
Preparation 42
4-(4-Pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-phenol
[0288] To a solution of 4-Methoxy-N-pyridin-4-yl-benzamide (75 mg)
in POCl.sub.3 (3 ml) was added PCl.sub.5 (68 mg) and the reaction
mixture heated at reflux for 5 h. The reaction mixture was
concentrated and dissolved in dimethyl formamide (2 ml) and Formic
acid hydrazide (5 eq, 100 mg) was added and stirred for 2 h. The
reaction mixture was concentrated and diluted with isopropanol (3
mL) and 0.25 ml of conc. HCl was added. The reaction mixture
stirred for 18 h, quenched with 1 NaOH, extracted with
dichloromethane, dried magenesium sulfate and concentrated. The
crude product dissolved in methylene chloride (2 mL) and boron
tribromide (0.63 mL 1.0M hexanes) was added at 0.degree. C. The
reaction mixture was warmed to ambient temperature and stirred for
18 h. The reaction mixture was quenched with 1 N NaOH and pH
adjusted to 9, extracted with dichloromethane, dried magnesium
sulfate, filtered and concentrated. Purification via Biotage MPLC
chromatography eluting with 0-20% methanol/methylene chlroride
provided the title compound (32 mg, 55%). MS: (M.sup.+H
m/z=239.2).
EXAMPLE 56
2-[4-(4-Pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-phenoxymethyl]-quinoline
[0289] To a solution of
4-(4-Pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-phenol (44 mg) in
dimethyl formamide (1 ml) in a 7 ml Teflon capped vial was added
cesium carbonate (185 mg) and 2-Chloromethyl-quinoline (37 mg) and
the reaction mixture heated on a shaker plate at 60.degree. C. for
18 h. The reaction mixture was poured into water and extracted with
methylene chloride, dried magnesium sulfate, filtered and
concentrated to provide the title compound (45 mg). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.87 (s, 1H), 8.65 (d, J=6.0 Hz, 2
H), 8.37 (d, J=8.3 Hz, 1 H), 8.03 (d, J=8.7 Hz, 1H), 7.94 (d, J=7.9
Hz, 1H), 7.78 (m, 1 H), 7.70 (d, J=8.3 Hz, 1 H), 7.61 (t, J=5.8 Hz,
1 H), 7.40 (m, 4H), 7.14 (d, J=9.1 Hz, 2 H), 5.38 (s, 2H); MS:
(M.sup.+H m/z=380.2).
Preparation 43
[4-(Quinolin-2-ylmethoxy)-phenyl]-hydrazine
[0290] To a suspension of 4-(Quinolin-2-ylmethoxy)-phenylamine
(1.73 g) in 30 mL of concentrated HCl at 0.degree. C. was added
sodium nitrite (531 mg). After 3 h, tin chlrodie (3.95 g) was
dissolved in 20 mL of concentrated HCl and added slowly dropwise
and the reaction mixture stirred at ambient temperature for 18 h.
The reaction mixture was filtered and the solid dried to provide
the title compound as the HCL salt (3.94 g). MS: (M.sup.+H
m/z=266.3).
EXAMPLE 57
2-[4-(5-Pyridin4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinoline
[0291] Isonicatinamide (4.15 g) was heated in 35 ml of
N,N-Dimethylformamide diethyl acetal at reflux for 3 h. The
reaction mixture was cooled to ambient temperature and concentrated
to give 5.02 g of N-Dimethylaminomethylene-isonicotinamide. To a
solution of [4-(Quinolin-2-ylmethoxy)-phenyl]-hydrazine (3.16 g) in
methanol (30 mL) and acetic acid (2.5 mL) was added
N-Dimethylaminomethylene-isonicotinamide (1.10 g) and the reaction
mixture heated at reflux for 72 h. The reaction mixture was
concentrated onto silica gel and purified by flash chromatography
to provided the title compound (514 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.60 (d, J=5.8 Hz, 2 H), 8.22 (d, J=8.7 Hz, 1
H), 8.10 (s, 1H), 8.07 (d, J=8.7 Hz, 1H), 7.85 (d, J=7.1 Hz, 1H),
7.76 (m, 1 H), 7.66 (d, J=8.3 Hz, 1 H), 7.56 (m, 1 H), 7.56 (m,
1H), 7.38 (d, J=6.2 Hz, 2 H), 7.26 (d, J=8.7Hz, 2H), 7.11 (d, J=9.1
Hz, 2H), 5.42 (s, 2H); MS: (M.sup.+H m/z=380.3).
Preparation 44
[4-(Quinolin-2-ylmethoxy)-phenyl]-hydrazine
[0292] Following the procedure for the preparation of
(4-(Quinolin-2-ylmethoxy)-phenyl]-hydrazine but substituting
4-(Quinolin-2-ylmethoxy)-phenylamine provided the title compound.
MS: (M.sup.+H m/z=266.2).
EXAMPLE 58
2-[4-(3-Methyl-5-pyridin-4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinolin-
e
[0293] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinoline
but substituting N,N-dimethylacetamide dimethyl acetal provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.58 (d,
J=6.2 Hz, 2 H), 8.22 (d, J=8.3 Hz, 1 H), 8.08 (d, J=8.3 Hz, 1H),
7.84 (d, J=7.7 Hz, 1H), 7.74 (m, 1 H), 7.65 (d, J=8.3 Hz, 1 H),
7.56 (m, 1 H), 7.36 (d, J=6.2 Hz, 2 H), 7.25 (d, J=9.1 Hz, 2H),
7.09 (d, J=8.7 Hz, 2H), 5.41 (s, 2H), 2.48 (s, 3H); MS: (M.sup.+H
m/z=394.4).
Preparation 45
4-(Quinolin-2-ylmethoxy)-benzamide
[0294] To a solution of 2-Chloromethyl-quinoline (1.57 g) and
4-Hydroxy-benzamide (995 mg) in dimethyl formamide (20 mL) was
added cesium carbonate (7.3 g) and the reaction mixture heated at
80.degree. C. for 18 h. The reaction mixture was poured into water
and extracted with chloroform, dried magnesium sulfate, filtered
and concentrated to provided the title compound (909 mg). MS:
(M.sup.+H -m/z=279.3).
EXAMPLE 59
2-[4-(2-Pyridin-4-yl-2H-[1,2,4]triazol-3-yl)-phenoxymethyl]-quinoline
[0295] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinoline
but substituting 4-(Quinolin-2-ylmethoxy)-benzamide and
Pyridin-4-yl-hydrazine provided the title compound. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.65 (d, J=6.2 Hz, 2 H), 8.21 (d,
J=8.3 Hz, 1 H), 8.08 (s, 1H), 8.07 (d, J=7.9 Hz, 1H), 7.84 (d,
J=8.3 Hz, 1H), 7.73 (m, 1 H), 7.65 (d, J=8.7 Hz, 1 H), 7.55 (m, 1
H), 7.43 (d, J=9.1 Hz, 2H), 7.32 (d, J=6.2 Hz, 2 H), 7.05 (d,
J=8.7Hz, 2H), 5.40 (s, 2H); MS: (M.sup.+H m/z=380.2).
EXAMPLE 60
2-[4-(5-Methyl-2-pyridin-4-yl-2H-[1,2,4]triazol-3-yl)-phenoxymethyl]-quino-
line
[0296] Following the procedure for the preparation of
2-[4-(5-Pyridin-4-yl-[1,2,4]triazol-1-yl)-phenoxymethyl]-quinoline
but substituting 4-(Quinolin-2-ylmethoxy)-benzamide,
Pyridin4-yl-hydrazine and N,N-dimethylacetamide dimethyl acetal
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.61 (d, J=6.2 Hz, 2 H), 8.21 (d, J=8.7 Hz, 1 H), 8.07 (d,
J=7.9 Hz, 1H, 7.83 (d, J=8.3 Hz, 1H), 7.75 (m, 1 H), 7.64 (d, J=8.3
Hz, 1 H), 7.55 (m, 1 H), 7.56 (m, 1H), 7.41 (d, J=9.1 Hz, 2 H),
7.29 (d, J=6.2 Hz, 2H), 7.05 (d, J=8.7 Hz, 2H), 5.40 (s, 2H), 2.47
(s, 3H); MS: (M.sup.+H m/z=394.3).
Preparation 46
4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyridine
[0297] To a solution of
1-(4-Benzyloxy-phenyl)-2-pyridin-4-yl-ethanone (1.58 g) was added
toluene (26 ml) and 1.6 g of Diethoxymethyl-dimethyl-amine and the
reaction mixture heated at reflux for 1 h. The reaction mixture was
concentrated, dissolved in methanol (26 ml) and hydrazine (0.64 g)
and the reaction mixture was heated at reflux for 1 h. The reaction
mixture was concentrated and purified via biotage MPLC eluting with
5% methanol/chloroform/0.5% ammonium hydroxide to provided the
title compound (0.89 g). MS: (M.sup.+H m/z=328.1).
Preparation 47
4-[3-(4-Benzyloxy-phenyl)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol4-yl]-pyridi-
ne
[0298] To a solution of
4-[3-(4-Benzyloxy-phenyl)-1H-pyrazol-4-yl]-pyridine (0.42 g) in
dimethyl formamide (7 ml) was added cesium carbonate (0.65 g) and
1,1,1-Trifluoro-2-iodo-ethane (0.29 ml). The reaction mixture was
heated at 60.degree. C. for 24 h, poured into water and extracted
3.times. with dichloromethane. Purification via biotage MPLC
chromatography, eluting with 5% methanol/0.5% ammonium
hydroxide/70% ethyl acetate/hexane provided the title compound. MS:
(M.sup.+H m/z=410.0).
Preparation 48
4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenol
[0299] Following the procedure for the preparation of
4-(1-Methyl4-pyridin4-yl-1H-pyrazol-3-yl)-phenol but substituting
4-[3-(4-Benzyloxy-phenyl)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4-yl]-pyri-
dine provided the title compound. MS: (M.sup.+H m/z=320.1)
EXAMPLE 61
2-4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymeth-
yl}-quinoxaline
[0300] To a solution of
4-[4-Pyridin4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenol
(79 mg) and Quinoxalin-2-yl-methanol (50 mg) in dioxane (2 ml) was
added triphenylphosphine (105 mg) and di-t-butyldiazacarboxalate
(92 mg) and the reaction mixture heated at 60.degree. C. After 18,
the reaction mixture was poured into 1N NaOH, extracted with
methylene chloride, dried magnesium sulfate, filtered and
concentrated. Purification with MPLC biotage eluting with 2%
methanol/0.5% ammonium hydroxide/60% ethyl acetate/hexanes provided
the title compound (54 mg). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.09 (s, 1 H), 8.52 (m, 2H), 8.13 (m, 1H), 8.10 (m, 1H),
7.79 (m, 2 H), 7.73 (s, 1 H), 7.40 (d, J=8.7, Hz, 2 H), 7.24 (m,
2H), 7.04 (d, J=8.7 Hz, 2 H), 5.32 (s, 2H), 4.79 (q, J=8.3 Hz, 2
H); MS: (M.sup.+H m/z=462.1).
EXAMPLE 62
8-Methoxy-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qu-
inoline
[0301] Following the procedure for the preparation of
2-{4-[4-Pyridin4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoxaline but substituting
4-(1-Methyl4-pyridin4-yl-1H-pyrazol-3-yl)-phenol and
(8-Methoxy-quinolin-2-yl)-methanol provided the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.45 (d, J=6.2 Hz, 2 H),
8.15 (d, J=8.7 Hz, 1H), 7.73 (d, J=8.3 Hz,1H), 7.55 (s, 1H), 7.44
(m, 1 H), 7.37 (m, 3 H), 7.15 (d, J=5.8, Hz, 2 H), 7.07 (d, J=7.5
Hz, 1H), 6.99 (d, J=8.7 Hz, 2 H), 5.46 (s, 2H), 4.08 (s, 3 H), 3.94
(s, 3H); MS: (M.sup.+H m/z=423.1).
EXAMPLE 63
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-pyrido[1,2-a-
]pyrimidin-4-one
[0302] Following the procedure for the preparation of
2-[4-(4-Pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-phenoxymethyl]-quinoline
but substituting 2-Chloromethyl-pyrido[1,2-a]pyrimidin4-one
provided the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 9.01 (d, J=7.1 Hz, 1 H), 8.43 (m, 2H), 7.72 (m, 1H), 7.59
(d, J=8.7 Hz, 1H), 7.53 (s, 1H), 7.37 (d, J=9.1 Hz, 2H), 7.12 (m,
3H), 6.93 (d, J=8.7Hz, 2H), 6.68 (s, 1 H), 5.05 (s, 2H), 3.92 (s,
3H); MS: (M.sup.+H m/z=410.1).
EXAMPLE 64
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinazoline
[0303] Following the procedure for the preparation of
2-[4-(4-Pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-phenoxymethyl]-quinoline
but substituting 2-Chloromethyl-quinazoline provided the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.43 (s, 1H),
4.43 (d, J=4.6 Hz, 2 H), 8.07 (d, J=8.3 Hz, 1H), 7.93 (d, 2H), 7.69
(t, J=7.9 Hz, 1H), 7.55 (s, 1 H), 7.36 (d, J=8.7 Hz, 2 H), 7.15 (d,
J=6.2, Hz, 2 H), 7.05 (d, J=8.7 Hz, 2H), 5.48 (s, 2H), 3.94 (s,
3H); MS: (M.sup.+H m/z=394.2)
Preparation 49
4-Benzyloxy-2-fluoro-benzoic acid benzyl ester
[0304] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid methyl ester but substituting
two equivalents of benzyl bromide and 2-Fluoro4-hydroxy-benzoic
acid provided the title compound. MS: (M.sup.+H m/z=337.2).
Preparation 50
4-Benzyloxy-2-fluoro-benzoic acid
[0305] Following the procedure for the preparation of
4-(Quinolin-2-ylmethoxy)-benzoic acid but substituting
4-Benzyloxy-2-fluoro-benzoic acid benzyl ester provided the title
compound. MS: (M.sup.+H m/z=247.1).
Preparation 51
4-Benzyloxy-2-fluoro-N-methoxy-N-methyl-benzamide
[0306] Following the procedure for the preparation of
N-Methoxy-N-methyl4-(quinolin-2-ylmethoxy)-benzamide but
substituting 4-Benzyloxy-2-fluoro-benzoic acid provided the title
compound. MS: (M.sup.+H m/z=290.2).
Preparation 52
1-(4-Benzyloxy-2-fluoro-phenyl)-2-pyridin-4-yl-ethanone
[0307] Following the procedure for the preparation of
2-pyridin-4-yl-1-[4-(quinolin-2-ylmethoxy)-phenyl]-ethanone but
substituting 4-Benzyloxy-2-fluoro-N-methoxy-N-methyl-benzamide
provided the title compound. MS: (M.sup.+H m/z=322.1).
Preparation 53
4-[3-(4-Benzyloxy-2-fluoro-phenyl)-l
-methyl-1H-pyrazol-4-yl]-pyridine
[0308] Following the procedure for the preparation of
4-[3-(4-Benzyloxy-phenyl)-1-methyl-1H-pyrazol4-yl]-pyridine but
substituting 1-(4-Benzyloxy-2-fluoro-phenyl)-2-pyridin4-yl-ethanone
provided the title compound. MS: (M.sup.+H m/z=360.1).
Preparation 54
3-Fluoro-4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenol
[0309] Following the procedure for the preparation of
4-(1-Methyl4-pyridin-4-yl-1H-pyrazol-3-yl)-phenol but substituting
4-[3-(4-Benzyloxy-2-fluoro-phenyl)-1-methyl-i
H-pyrazol4-yl]-pyridine provided the title compound. MS: (M.sup.+H
m/z=270.1).
EXAMPLE 65
2-[3-Fluoro-4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline
[0310] To a solution of
3-Fluoro-4-(1-methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenol (450 mg)
in dimethylformamide (10 ml) was added cesium carbonate (2 g) and
2-chloro methyl quinoline (481 mg) and the reaction mixture was
heated at 60.degree. C. for 18 h. The reaction mixture was poured
into 1N NaOH, extracted with methylene chloride, dried magnesium
sulfate, filtered and concentrated. Biotage MPLC purification
eluting with methanol 2%/0.5% ammonium hydroxide/70% ethyl
acetate/hexanes provided the title compound. The free base was
stirred in ethyl acetate and 1.1 equivalents of succinic acid was
added. The white precipitate was filtered and dried to provide the
title compound as the succinate salt (280 mg). .sup.1H NMR (400
MHz, DMSO) .delta. 8.43 (d, J=8.3 Hz, 1 H), 8.37 (d, J=6.2 Hz, 2H),
8.26 (s, 1H), 8.00 (m, 2H), 7.78 (t, J=7.1 Hz, 1H), 7.70 (d, J=8.3
Hz, 1 H), 7.61 (t, J=6.6 Hz, 1 H), 7.38 (t, J=8.3, Hz, 1 H), 7.10
(d, J=6.2 Hz, 2H), 7.00 (m, 2H), 5.40 (s, 2H), 3.88 (s, 3 H), 2.38
(s, 4H), MS: (M.sup.+H m/z=411.1).
Preparation 55
4-[3-(4-Benzyloxy-2-fluoro-phenyl)-1H-pyrazol-4-yl]-pyridine
[0311] Following the procedure for the preparation of
2-[4-(4-Pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline but
substituting
1-(4-Benzyloxy-2-fluoro-phenyl)-2-pyridin-4-yl-ethanone provided
the title compound. MS: (M.sup.+H m/z=346.3).
Preparation 56
4-[3-(4-Benzyloxy-2-fluoro-phenyl)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4--
yl]-pyridine
[0312] Following the procedure for the preparation of
2-{4-[-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoline but substituting
4-[3-(4-Benzyloxy-2-fluoro-phenyl)-1H-pyrazol4-yl]-pyridine
provided the title compound. MS: (M.sup.+H m/z=428.4).
Preparation 57
3-Fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phen-
ol
[0313] To
4-[3-(4-Benzyloxy-2-fluoro-phenyl)-1-(2,2,2-trifluoro-ethyl)-1H-
-pyrazol-4-yl]-pyridine (900 mg) was added trifluoroacetic acid
(5.25 ml) and anisole (1.15 ml) and the reaction mixture heated at
reflux for 18 h. The reaction mixture was quenched with with 1N
NaOH, extracted 3.times. tetrahydrofuran, dried magnesium sulfate,
filtered and concentrated. Purification via Biotage MPLC eluting
with 5% methanol/1% ammonium hydroxide/ethyl acetate provided the
title compound (552 mg). MS: (M.sup.+H m/z=338.2).
EXAMPLE 66
2-{3-Fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-p-
henoxymethyl}-quinoline
[0314] Following the procedure for the preparation of
2-[3-Fluoro4-(1-methyl4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quin-
oline but substituting
3-Fluoro4-[4-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phen-
ol and acetone as the solvent provided the title compound. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.46 (m, 2 H), 7.80 (s, 1H), 7.31
(t, J=8.3 Hz, 1H), 7.24 (m, 5 H), 6.72 (dd, J=8.3, 2.5 Hz, 1 H),
6.50 (dd, J=11.6, 2.1 Hz, 1 H), 4.81 (q, J=8.4 Hz, 2H); MS:
(M.sup.+H m/z=479.2).
EXAMPLE 67
2-{3-Fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-p-
henoxymethyl}-quinoxaline
[0315] Following the procedure for the preparation of
2-[3-Fluoro4-(1-methyl4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quin-
oline but substituting
3-Fluoro4-[4-pyridin4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-pheno-
l, 2-Chloromethyl-quinoxaline and acetone as the solvent provided
the title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.09
(s, 1 H), 8.46 (m, 2H), 8.15 (m, 1H), 8.09 (m, 1 H), 7.81 (m, 3H),
7.43 (t, J=8.7Hz, 1H), 7.12 (d, J=6.2 Hz, 2H), 6.93 (dd, J=7.9, 2.0
Hz, 1 H), 6.81 (dd, J=11.6, 2.5 Hz, 1 H), 5.43 (s, 2H), 4.80 (q,
J=8.3 Hz, 2H); MS: (M.sup.+H m/z=480.1).
EXAMPLE 68
4-Chloro-2-[4-(1-methyl4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quin-
oline
[0316] Following the procedure for the preparation of
2-{4-[4-Pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxyme-
thyl}-quinoxaline but substituting
4-(1-Methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenol and
(4-Chloro-quinolin-2-yl)-methanol provided the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.43 (d, J=4.6 Hz, 2 H),
8.18 (d, J=8.7 Hz, 1H), 8.04 (d, J=7.9 Hz, 1H), 7.73 (m, 2H), 7.60
(t, J=7.1 Hz, 1 H), 7.52 (s, 1 H), 7.37 (d, J=9.1, Hz, 2 H), 7.12
(d, J=6.2 Hz, 2H), 6.98 (d, J=8.7 Hz, 2 H), 5.30 (s, 2H), 3.90 (s,
3 H); MS: (M.sup.+H m/z=427.1).
EXAMPLE 69
4-Methoxy-2-[4-(1-methyl-4-pyridin4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline
[0317] To a solution of
4-Chloro-2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qu-
inoline (125 mg) in methanol (4 mL) was added phenanthroline (78
mg), cesium carbonate (143 mg) and copper iodide (5 mg). The
reaction mixture was heated in a microwave reactor at 165.degree.
C. with 50 W of power for 20 min. The reaction mixture was filtered
through celite and concentrated. Purification via MPLC biotage
chromatography, eluting with 5% methanol/1% ammonium
hydroxide/methylene chloride provided the title compound (74 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.45 (d, J=5.4 Hz, 2 H),
8.18 (d, J=8.3 Hz, 1H), 7.97 (d, J=8.3 Hz, 1H), 7.68 (m, 1H), 7.55
(s, 1H), 7.49 (t, J=7.1 Hz, 1 H), 7.37 (d, J=9.1, Hz, 2 H), 7.15
(d, J=6.2 Hz, 2H), 7.01 (m, 3H), 5.32 (s, 2H), 4.02 (s, 3 H), 3.95
(s, 3H); MS: (M.sup.+H m/z=423.3).
EXAMPLE 70
Dimethyl{2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
nolin-4-yl}-amine
[0318] To a solution of
4-Chloro-2-[4-(1-methyl4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-qui-
noline (135 mg) in tetrahydrofuran (4 mL) was added dimethylamine
(2N in methanol, 0.32 mL), cesium fluoride (5 mg), diisopropyl
ethyl amine (62 mg) and tetrabutyl ammonium iodide (12 mg). The
reaction mixture was heated in a microwave reactor at 180.degree.
C. with 100 W of power for 40 min. The reaction mixture was
filtered through celite and concentrated. Purification via MPLC
biotage chromatography, eluting with 5% methanol/1% ammonium
hydroxide/methylene chloride provided the title compound (36 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.45 (d, J=6.2Hz, 2 H),
8.04 (d, J=8.3 Hz, 1H), 7.99 (d, J=8.3 Hz, 1H), 7.62 (m, 1H), 7.56
(s, 1H), 7.42 (m, 1 H), 7.38 (d, J=9.1 Hz, 2 H), 7.15 (d, J=6.2 Hz,
2H), 7.01 (m, 3H), 5.29 (s, 2H), 3.95 (s, 3 H), 3.03 (s, 6H); MS:
(M.sup.+H m/z=436.3).
Preparation 58
N-Methoxy-N-methyl-4-triisopropylsilanyloxymethyl-benzamide
[0319] Following the procedure for the preparation of
4-benzyloxy-N-methoxy-N-methyl-benzamide but substituting
4-Triisopropylsilanyloxymethyl-benzoic acid provided the title
compound. MS: (M.sup.+H m/z=352.1).
Preparation 59
2-Pyridin-4-yl-1-(4-triisopropylsilanyloxymethyl-phenyl)-ethanone
[0320] Following the procedure for the preparation of
1-(4-Benzyloxy-phenyl)-2-pyridin-4-yl-ethanone but substituting
N-Methoxy-N-methyl-4-triisopropylsilanyloxymethyl-benzamide
provided the title compound. MS: (M.sup.+H m/z=384.1).
Preparation 60
4-[1-Methyl-3-(4-triisopropylsilanyloxymethyl-phenyl)-1H-pyrazol-4-yl]-pyr-
idine
[0321] Following the procedure for the preparation of
4-[3-(4-Benzyloxy-phenyl)-1-methyl-1H-pyrazol-4-yl]-pyridine but
substituting
2-Pyridin-4-yl-1-(4-triisopropylsilanyloxymethyl-phenyl)-ethanone
provided the title compound. MS: (M.sup.+H m/z=422.2).
Preparation 61
[4-(l -Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenyl]-methanol
[0322] To a solution of
4-[1-Methyl-3-(4-triisopropylsilanyloxymethyl-phenyl)-1H-pyrazol-4-yl]-py-
ridine (1.75 g) in THF (16.2 mL) was added TBAF (1.0M THF, 5.2 mL)
and the reaction mixture stirred at ambient temperature under inert
atmosphere for 1 h. The reaction mixture was poured into saturated
sodium bicarbonate, extracted 3.times. with chloroform, dried
magnesium sulfate filtered and concentration. Purification via MPLC
biotage chromatography eluting with 2% methanol/0.5% saturated
ammonium hydroxide/50% ethyl acetate/hexanes provided the title
compound (920 mg, 84%). MS: (M.sup.+H m/z=266.1).
EXAMPLE 71
2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-benzyloxy]-quinoline
di succinic acid
[0323] Following the procedure for the preparation of
2-{4-[4-Pyridin4-yl-1-(2,212-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymet-
hyl}-quinoxaline but substituting
[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenyl]-methanol and
Quinolin-2-ol provided the title compound. .sup.1H NMR (400 MHz,
DMSO) .delta. 8.42 (d, J=5.0 Hz, 2 H), 8.25 (d, J=8.7 Hz, 1H), 8.14
(s, 1H), 7.88 (d, J=7.9 Hz, 1H), 7.78 (d, J=7.9 Hz, 1H), 7.66 (t,
J=7.1 Hz, 1 H), 7.51 (d, J=7.5 Hz, 2 H), 7.40 (m, 3 H), 7.19 (d,
J=4.6 Hz, 2H), 7.07 (d, J=8.7 Hz, 1H), 5.49 (s, 2H), 2.38 (s, 8 H);
MS: (M.sup.+H m/z=393.1).
Preparation 62
N-((4-(Benzyloxy)phenyl)(tosyl)methyl)formamide
[0324] A mixture of 4-methylbenzenesulfinic acid (3.1 g, 19.9
mmol), 4-(benzyloxy)benzaldehyde (4.2 g, 19.9 mmol), and formamide
(4.5 mL ) was heated at 60.degree. C. for 20 h. The mixture was
diluted with methanol and stirring was continued for 1 h at rt. The
resultant solid was filtered and dried to give 3.81 g (49%) of a
white solid. The product was used in the next step without future
purification.
Preparation 63
1-((4-(Benzyloxy)phenyl)isocyanomethylsulfonyl)-4-methylbenzene
[0325] To a solution of
N-((4-(Benzyloxy)phenyl)(tosyl)methyl)formamide (3.2 g, 8.1 mmol)
in 43 mL of DME (dimethoxy ethane) at 0.degree. C. was added
POCl.sub.3 (2.27 mL) followed by the dropwise addition of
triethylamine (5.6 mL ). The resultant solution was then stirred at
0.degree. C. for 3 h and finally poured into cooled water. The
precipitate was collected and dried to give 3.3 g of pale yellow
solid. MS m/z: 378 [M+1].sup.+.
Preparation 64
4-(4-(4-(Benzyloxy)phenyl)oxazol-5-yl)pyridine
[0326] A mixture of
1-((4-(Benzyloxy)phenyl)isocyanomethylsulfonyl)4-methylbenzene (4.3
g, 11.4 mmol), isonicotinaldehyde (1.34 g, 12.5 mmol) and K.sub.2CO
3 (3.15 g, 22.8 mmol) in methanol (96 mL ) and DME (30 mL) was
heated at reflux for 5 h. After removal of solvent, the residue was
purified by silica gel chromatography (2:1 hexane/EtOAc) to provide
2.29 g (84%) of a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta.: 5.12v (s, 2H), 7.03 (d, 2H), 7.46 (m, 6H), 7.56 (d, 2H),
7.61 (d, 2H), 8.02 (s, 1H), 8.58 (d, 2H). MS m/z: 329
[M+1].sup.+.
Preparation 65
4-(5-(pyridin-4-yl)oxazol-4-yl)phenol
[0327] To a solution of
4-(4-(4-(Benzyloxy)phenyl)oxazol-5-yl)pyridine (300 g, 0.91 mmol)
was added 20% Pd(OH).sub.2/C (30 mg) and ammonium formate (115 mg,
1.83 mmol) in methanol (8 mL ). The solution was heated at
60.degree. C. for 20 min. The catalyst was removed by filtration
and the filtrate was concentrated to give 208 mg (96%) of the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 6.92 (m, 2H),
7.46 (m, 2H), 7.57 (d, 2H), 8.02 (s, 1H), 8.58 (m, 2H). MS m/z: 239
[M+1].sup.+.
EXAMPLE 72
2-((4-(5-(pyridin-4-yl)oxazol-4-yl)phenoxy)methyl)quinoline
[0328] To a solution of compound
4-(5-(pyridin4-yl)oxazol4-yl)phenol (90 mg, 0.38 mmol) in 1 mL of
dry DMF was added CsF (115 mg, 0.76 mmol). After stirring for 0.5
h, 2-(chloromethyl)quinoline (67 mg, 0.38 mmol) was added and the
reaction was heated at 80.degree. C. for 48 h. Upon removal of DMF
under vacuum, the residue was purified by PTLC (1:2 hexane/EtOAc)
to give 29 mg (20%) of the title compound as a white solid. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta.: 5.47 (s, 2H), 7.11 (m, 2H), 7.56
(m, 5H), 7.70 (d, 1H), 7.78 (t, 1H), 7.86 (d, 1H), 8.01 (s, 1H),
8.12 (d, 1H), 8.26 (d, 1H), 8.57 (d, (2H). MS m/z: 380
[M+1].sup.+.
Preparation 66
1-(4-(benzyloxy)phenyl)-2-bromo-2-(pyridin-4-yl)ethanone
[0329] To a solution of
1-(4-(benzyloxy)phenyl)-2-(pyridin-4-yl)ethanone (1.39 g, 4.58
mmol) in acetic acid was added a solution of bromine (0.72 g, 4.58
mmol) in acetic acid (3 mL). After stirring 2 h, the solid was
collected via filtration and washed with acetic acid to provide
1.67 g (96%) of the title compound as a pale yellow solid. .sup.1H
NMR (400 MHz, DMSO) .delta.: 5.21 (s, 1H), 7.15 (d, 2H), 7.42 (m,
3H), 7.87 (m, 1H), 8.06 (d, 2H), 8.77 (m, 1H). MS m/z: 382
[M+1].sup.+.
Preparation 67
4-(4-(4-(benzyloxy)phenyl)-2-methyloxazol-5-yl)pyridine
[0330] To a mixture of sodium acetate (323 mg, 2.38 mmol) and
ammonium acetate (304 mg, 3.95 mmol) in acetic acid (10 mL) was
added 1-(4-(benzyloxy)phenyl)-2-bromo-2-(pyridin-4-yl)ethanone (302
mg, 0.79 mmol). The resulting mixture was then refluxed for 48 h.
After removal of the solvent under vacuum, the residue was
dissolved in ethyl acetate and the solution was washed with satd
NaHCO3. The organic phase was dried and concentrated in vacuum to
give an oil, which was purified via silica gel chromatography (1:3
EtOAc/n-hexane) to provide 111 mg (41%) of the title compound.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 2.58 (s, 3H), 5.15 (s,
2H), 7.01 (d, 2H), 7.39 (m, 7H), 7.56 (d, 2H), 8.57 (d, 2H). MS
m/z: 343 [M+1].sup.+.
Preparation 68
4-(2-methyl-5-(pyridin-4-yl)oxazol-4-yl)phenol
[0331] 4-(4-(4-(Benzyloxy)phenyl)-2-methyloxazol-5-yl)pyridine was
hydrogenated in the presence of ammonium formate and Pd(OH).sub.2
in methanol for 1 h at 50.degree. C. The catalyst was removed via
filtration and the filtrate was concentrated. The resultant residue
was dissolved in methylene chloride and dried with
Na.sub.2SO.sub.4. Evaporation of the solvent gave 69 mg (86%) of
the title compound as a brown solid. MS m/z: 253.
EXAMPLE 73
2-((4-(2-methyl-5-(pyridin-4-yl)oxazol-4-yl)phenoxy)methyl)quinoline
[0332] To a solution of
4-(2-methyl-5-(pyridin-4-yl)oxazol-4-yl)phenol (21 mg, 0.083 mmol)
in 2.5 mL of dry DMF was added Cs.sub.2CO.sub.3 (54 mg, 0.17 mmol).
After stirring for 0.5 h, 2-(chloromethyl)quinoline (17.8 mg, 0.100
mmol) was added and the mixture was stirred at 85.degree. C. for 12
h. After removal of the DMF under vacuum, the residue was purified
by PTLC (1:2 hexane/EtOAc) to give 13 mg (40%) of the title
compound as a pale yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta.: 2.54 (s, 3H), 5.41 (s, 2H), 7.06 (m, 2H), 7.41 (m, 2H),
7.53 (m, 3H), 7.68 (d, 1H), 7.80 (t, 1H), 7.83 (d, 1H), 8.05 (d,
1H), 8.20 (d, 1H), 8.53 (m, 2H). MS m/z: 394 [M+1].sup.+.
Preparation 69
4-(4-((quinolin-2-yl)methoxy)phenyl)-3-(pyridin-4-yl)but-3-en-2-one
[0333] A mixture of 4-((quinolin-2-yl)methoxy)benzaldehyde (2.5 g,
9.5 mmol), 1-(pyridin-4-yl)propan-2-one (1.3 g, 9.5 mmol) and
piperidine (162 mg, 1.9 mmol) in toluene (50 mL) was heated at
reflux for 18 h, concentrated, and the residue chromatographed on
silica eluting with a gradient of ethyl acetate in hexanes giving
impure title substance (2.4 g) as a yellow solid which was
chromatographed again on silica eluted with 1% and 2% methanol in
dichloromethane containing 0.5% concentrated ammonium hydroxide
giving a 3:1 mixture of the title substance contaminated with the
pyridyl starting material. Yield 2.0 g, 55%. The title substance
appeared to be a 10:1 mixture of two isomers by NMR. .sup.1H NMR
(CDCl.sub.3, 400 mHz, partial) .delta. 2.35 (s, 3H, major isomer),
2.23 (s, 3H, minor isomer). HPLC-MS 6.09 min, m/e 381 (MH+).
EXAMPLE 74
2-((4-(3-Methyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline
[0334] A mixture of
4-(4-((quinolin-2-yl)methoxy)phenyl)-3-(pyridin-4-yl)but-3-en-2-one
(1.00 g, 2.60 mmol) and p-toluensulfonylhydrazine (484 mg, 2.6
mmol) in acetic acid (14 mL) was heated at reflux for 10 h.
Additional p-toluenesulfonylhydrazine (242 mg, 0.5 mmol) was added
and the mixture heated at reflux 2 h. The mixture was concentrated,
the residue dissolved in dichloromethane and the resulting solution
washed with water (2.times.25 mL), dried and concentrated. The
residue was chromatographed on silica eluted with 1%, 2%, and 3%
methanol in dichloromethane containing 0.5% concentrated ammonium
hydroxide giving a solid which was triturated with ether and dried.
Yield 293 mg, 29%. .sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.51
(m, 2H), 8.18 (d, 1H, J=8.7 Hz), 8.06 (d, 1H, J=7.9 Hz), 7.81 (d,
1H, J=8.3 Hz), 7.72 (m, 1H), 7.64 (d, 1H, J=8.3 Hz), 7.54 (m, 1H),
7.24 (m, 2H), 7.13 (m, 2H), 6.96 (m, 2H), 5.36 (s, 2H), 2.33 (s,
3H). HPLC-MS (system 1) 4.65 min, m/e 393 (MH+).
EXAMPLE 75
2-((4-(1,3-dimethyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinol-
ine
[0335] A solution of
2-((4-(3-methyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline
(150 mg, 0.38 mmol) in anhydrous dimethylformamide (2 mL) was
treated at 0.degree. C. with sodium hydride dispersion (30 mg, 0.76
mmol of 60% NaH in oil) followed after 20 min with methyl iodide
(54 mg, 0.38 mmol), and the stirred mixture was allowed to warm to
RT overnight. Water was added and the mixture extracted with
dichloromethane (3.times.20 mL). The organic layer was dried,
concentrated, and the residue chromatographed on silica eluted with
an ethyl acetate-hexane gradient containing 1% triethylamine,
giving fractions containing two isomeric substances. The less polar
isomer (18 mg) was thus obtained (methylation regiochemistry
tentatively assigned by NMR). .sup.1H NMR (CDCl.sub.3, 400 mHz)
.delta. 8.41 (m, 2H), 8.21 (d, 1H, J=8.7 Hz), 8.07 (d, 1H, J=8.3
Hz), 7.84 (d, 1H, J=9.5 Hz), 7.74 (ddd, 1H), 7.67 (d, 1H, J=8.3
Hz), 7.55 (ddd, 1H), 7.12 (m, 2H), 7.05 (m, 2H), 7.0 (m, 2H), 5.40
(s, 2H), 3.71 (s, 3H), 2.37 (s, 3H). HPLC-MS 4.81 min, m/e 407
(MH+).
EXAMPLE 76
2-((4-(1,5-dimethyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinol-
ine
[0336] The more polar fractions obtained from the sodium
hydride/methyl iodide alkylation of
2-((4-(3-methyl-4-(pyridin-4-yl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline
gave 26 mg of impure title substance which was recrystallized from
10:1 ethyl acetate-hexanes giving isomerically pure material whose
methylation regiochemistry was tentatively assigned by NMR. .sup.1H
NMR (CDCl.sub.3, 400 mHz) .delta. 8.51 (m, 2H), 8.17 (d, 1H, J=8.7
Hz), 8.05 (d, 1H, J=8.3 Hz), 7.85 (d, 1H, J=8.3 Hz), 7.72 (ddd,
1H), 7.65 (d, 1H, J=8.7 Hz), 7.53 (t, 1H, J=7.5 Hz), 7.27 (m, 2H),
7.12-7.11 (m, 2H), 6.93 (m, 2H), 5.36 (s, 2H), 3.87 (s, 3H), 2.30
(s, 3H), HPLC-MS 4.78 min, m/e 407 (MH+).
Preparation 69a
1-(quinolin-2-yl)ethanol
[0337] A solution of methylmagnesium bromide (17.6 mL of 1.4 M in
toluene, 24.7 mmol) was added at <10.degree. C. to a solution of
quinoline-2-carboxaldehyde (3.0 g, 19 mmol) in anhydrous
tetrahydrofuran (50 mL). The mixture was stirred at RT for 1 h and
poured into saturated aqueous ammonium chloride (100 mL), and the
resulting mixture was extracted with ethyl acetate (3.times.150
mL). The extracts were dried, concentrated, and the residue
chromatographed on silica eluted with 30% and 40% ethyl
acetate-hexanes giving a yellow solid. Yield 2.46 g, 75%. .sup.1H
NMR (CDCl.sub.3, 400 mHz) .delta. 8.15 (d, 1H, J=8.7 Hz), 8.07 (d,
1H, J =8.7 Hz), 7.81 (dd, 1H, J=1, 8 Hz), 7.71 (ddd, 1H, J=1, 7,
8.5 Hz), 7.51 (ddd, 1H, J=1, 7, 8.3 Hz), 7.33 (d, 1H, J=8.3 Hz),
5.07-4.99 (m, 2H), 1.56 (d, 3H, J=6.2 Hz).
EXAMPLE 77
2-(1-(4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)ethyl)quinoline
[0338] A mixture of
4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (75 mg, 0.30
mmol) and 1-(quinolin-2-yl)ethanol (78 mg, 0.45 mmol) in p-dioxane
(2 mL) was treated sequentially at RT with triphenylphosphine (126
mg, 0.48 mmol) and di-t-butyldiazodicarboxylate (110 mg, 0.48 mmol)
and the mixture was heated at 60.degree. C. for 4 h. Aqueous 2N
NaOH was added and the mixture extracted with dichloromethane. The
organic layers were dried, concentrated, and the residue purified
on silica gel eluted with a gradient of ethyl acetate-hexanes
giving a yellow solid. Yield 36 mg, 29%. .sup.1H NMR (CDCl.sub.3,
400 mHz) .delta. 8.40 (m, 2H), 8.10 (d, 1H, J=8.7 Hz), 8.06 (d, 1H,
J=7.5 Hz), 7.77 (d, 1H, J=8.3 Hz), 7.71 (ddd, 1H), 7.55 (d, 1H,
J=8.3 Hz), 7.53-7.49 (m, 2H), 7.25 (m, 2H), 7.10 (m, 2H), 6.88 (m,
2H), 5.59 (q, 1H, J=6.6 Hz), 3.91 (s, 3H), 1.75 (d, 3H, J=6.6 Hz).
HPLC-MS (system 1) 4.73 min, m/e 407 (MH+).
Preparation 70
2-((4-(2-(pyridin-4-yl)ethynyl)phenoxy)methyl)quinoline
[0339] A mixture of 4-(2-(pyridin-4-yl)ethynyl)phenol (335 mg, 1.72
mmol), 2-(chloromethyl)quinoline hydrochloride (385 mg, 1.8 mmol),
and cesium carbonate (2.2 g, 6.87 mmol) was stirred in
dimethylformamide (8 mL) at 65.degree. C. for 3 h. Water (20 mL)
was added and the mixture was extracted with dichloromethane
(3.times.15 mL). The organic layers were dried, concentrated, and
the residue chromatographed on silica eluted with a gradient of 10%
to 80% ethyl acetate-hexanes giving 450 mg (78%) of a yellow solid.
.sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.56 (m, 2H), 8.20 (d,
1H, J=8.7 Hz), 8.08 (d, 1H, J=8.3 Hz), 7.82 (d, 1H, J=7.9 Hz), 7.74
(ddd, 1H, J=8.4, 7, 1Hz), 7.63 (d, 1H, J=8.7 Hz), 7.55 (ddd, 1H,
J=8, 7, 1 Hz), 7.47 (m, 2H), 7.35 (m, 2H), 7.01 (m, 2H), 5.41 (s,
2H). MS (AP+) m/e 337 (MH+).
Preparation 71
4-(2-(pyridin-4-yl)ethynyl)phenol
[0340] Boron tribromide (1M in dichloromethane, 9.7 mL, 9.7 mmol)
was added at 0.degree. C. to a solution of
4-(2-(4-methoxyphenyl)ethynyl)pyridine (810 mg, 3.88 mmol) in
dichloromethane (10 mL) and the mixture was stirred at RT for 5 h.
Aqueous 1 N sodium hydroxide (20 mL) was added and after 40 min the
pH was brought between 7 and 8 by addition of 1 N HCl. The
resulting mixture was extracted with 4:1 dichloromethane:2-propanol
(3.times.30 mL). The organic layers were dried, concentrated and
evaporated and the residue chromatographed on silica in a gradient
from 25% to 80% ethyl acetate-hexanes giving a brown solid. Yield
450 mg, 60%. .sup.1H NMR (CDCl.sub.3 containing CD.sub.3OD, 400
mHz) .delta. 8.50 (br, 2H), 7.38 (br, 2H), 7.37 (d, 2H, J=8.7 Hz),
6.77 (d, 2H, J=8.7 Hz), 3.11 (br, 2H, OH+H2O). MS (AP+) m/e 196
(MH+).
Preparation 72
4-(2-(4-methoxyphenyl)ethynyl)pyridine
[0341] A mixture of 4-methoxyphenylacetylene (2.86 g, 21.7 mmol),
4-iodopyridine (4.44 g, 21.7 mmol), cuprous iodide (206 mg, 1.08
mmol), bis(triphenylphosphine)palladium(II) dichloride (758 mg,
1.08 mmol) in tetrahydrofuran (40 mL) and triethylamine (20 mL) was
heated at reflux for 2 h. The mixture was filtered, concentrated,
and the residue chromaptographed on silica in 1:1 ethyl
acetate-hexanes giving 2.45 g (54%) of a yellow solid. .sup.1H NMR
(CDCl.sub.3, 400 mHz) .delta. 9.2 (very broad, 2H), 7.57 (br, 2H),
7.48 (d, 2H, J=8.7 Hz), 6.88 (d, 2H, J=8.7 Hz), 3.82 (s, 3H). MS
(AP+) m/e 210 (MH+).
EXAMPLE 78
2-((4-(5-(pyridin-4-yl)-1,2,3-triazol-4-yl)phenoxy)methyl)quinoline
[0342] Trimethylsilylazide (730 mg, 6.4 mmol) and
2-((4-(2-(pyridin-4-yl)ethynyl)phenoxy)methyl)quinoline (360 mg)
were combined in a screw cap sealed tube and heated behind a safety
shield in a 150.degree. C. bath for 72 h. The mixture was
concentrated and the yellow residue triturated with ether
(2.times.10 mL) leaving a yellow solid (346 mg) which was
chromatographed on silica eluted with a gradient of 0.5%-2%
methanol in dichloromethane giving a yellow solid (210 mg,52%).
.sup.1H NMR (CDCl.sub.3 with a drop of CD.sub.3OD, 400 mHz) .delta.
8.54 (d, 2H, J=6.2 Hz), 8.23 (d, 1H, J=8.7 Hz), 8.07 (d, 1H, J=8.7
Hz), 7.84 (d, 1H, J=7.9 Hz), 7.74 (ddd, 1H, J=8.4, 7, 1Hz), 7.69
(d, 1H, J=8.7 Hz), 7.63 (d, 2H, J=6.2 Hz), 7.56 (ddd, 1H), 7.41 (m,
2H), 7.09 (m, 2H), 5.41 (s, 2H). MS (AP+) m/e 380 (MH+).
Preparation 73
4-(2-methyl-5-(pyridin-4-yl)-2H-1,2,3-triazol-4-yl)phenol
[0343] A solution of
4-(5-(4-methoxyphenyl)-2-methyl-2H-1,2,3-triazol-4-yl)pyridine (203
mg, 0.76 mmol) in dichloromethane (5 mL) was treated at 0.degree.
C. with boron tribromide (2.3 mL of 1M in dichloromethane) and the
mixture stirred 18 h at RT. Methanol (3 mL) was added and the
mixture was concentrated and extracted using dichloromethane and
aqueous sodium bicarbonate. The organic extracts were dried and
concentrated giving a yellow solid which was chromatographed on
silica (gradient of 0.5%-3% methanol in dichloromethane) giving two
substances. The more polar substance (88 mg) was assigned
4-(2-methyl-5-(pyridin4-yl)-2H-1,2,3-triazol-4-yl)phenol. .sup.1H
NMR (CDCl.sub.3, 400 mHz, partial) .delta. 8.57 (br, 2H), 7.59 (d,
2H, J=5.2 Hz), 7.32 (m, 2H), 6.90 (m, 2H), 4.26 (s, 3H). HPLC-MS
(system 1) 3.96 min, m/e 253 (MH+). The less polar substance (80
mg) was assigned to be the corresponding boronate as it was found
to convert on treatment with aqueous NaOH to the less polar
substance.
Preparation 74
4-(5-(4-methoxyphenyl)-2-methyl-2H-1,2,3-triazol-4-yl)pyridine,
4-(5-(4-methoxyphenyl)-1-methyl-1H-1,2,3-triazol-4-yl)pyridine, and
4-(5-(4-methoxyphenyl)-3-methyl-3H-1,2,3-triazol-4-yl)pyridine
[0344] Sodium hydride (240 mg of 60% oil dispersion, 6.0 mmol) was
added to a solution of
4-(5-(4-methoxyphenyl)-1,2,3-triazol-4-yl)pyridine (755 mg, 3.0
mmol) in dimethylformamide (10 mL) at 0.degree. C. and the mixture
was stirred 30 min. Methyl iodide (425 mg) was added and the
mixture was stirred at 0.degree. C. for 2.5 h, quenched with water
(20 mL), and extracted with dichloromethane (3.times.20 mL). The
organic layers were dried over magnesium sulfate and concentrated.
The residue was chromatographed on silica eluted with a gradient of
50% to 100% ethyl acetate-hexanes providing three isomeric
substances of increasing polarity. Each showed a mass of m/e 267
(MH+) by HPLC-MS. Each structure was assigned by single crystal
X-ray on crystals grown from either ethyl acetate or acetonitrile.
The least polar substance (454 mg of yellow solid),
4-(5-(4-methoxyphenyl)-2-methyl-2H-1,2,3-triazol-4-yl)pyridine,
.sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.59 (br, 2H), 7.52 (br,
2H), 7.41 (m, 2H), 6.93 (m, 2H), 4.26 (s, 3H), 3.84 (s, 3H). The
middle-polarity substance (235 mg yellow solid),
4-(5-(4-methoxyphenyl)-1-methyl-1H-1,2,3-triazol-4-yl)pyridine,
.sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.49 (d, 2H, J=6.22),
7.52 (m, 2H), 7.24 (m, 2H), 7.06 (m, 2H), 3.91 (s, 3H), 3.89 (s,
3H). The most polar substance (50 mg yellow solid),
4-(5-(4-methoxyphenyl)-3-methyl-3H-1,2,3-triazol-4-yl)pyridine,
.sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.59 (br, 2H), 7.52 (br,
2H), 7.41 (m, 2H), 6.93 (m, 2H), 4.26 (s, 3H), 3.84 (s, 3H).
Preparation 75
4-(5-(4-methoxyphenyl)-1,2,3-triazol-4-yl)pyridine
[0345] 4-(2-(4-methoxyphenyl)ethynyl)pyridine (1.48 g, 7.1 mmol)
and trimethylsilylazide (2.5 g, 21.3 mmol) were combined in a
sealed tube which was heated 48 h in a 150.degree. C. oil bath. The
mixture was chromatographed on silica using an ethyl
acetate-hexanes gradient giving a yellow solid (950 mg, 53%).
.sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.50 (d, 2H, J=5.8 Hz),
7.60 (d, 2H, J=5.8 Hz), 7.36 (d, 2H, J=8.7 Hz), 6.92 (d, 2H, J=8.7
Hz), 3.81 (s, 3H), 2.80 (br, 1H). MS (AP+) m/e 253 (MH+).
EXAMPLE 79
2-((4-(2-methyl-5-(pyridin-4-yl)-2H-1,2,3-triazol-4-yl)phenoxy)methyl)quin-
oline
[0346] A mixture of
4-(2-methyl-5-(pyridin-4-yl)-2H-1,2,3-triazol-4-yl)phenol (80 mg,
0.32 mmol), 2-(chloromethyl)quinoline hydrochloride (71 mg, 0.33
mg), and cesium carbonate (414 mg, 1.27 mmol) in dimethylformamide
was heated at 65.degree. C. for 20 h, filtered, the filtrate
concentrated and chromatographed on silica eluted with ethyl
acetate-hexanes providing material containing starting phenol. This
was dissolved in ethyl acetate, washed with aqueous NaOH, dried and
concentrated giving a colorless solid (100 mg, 80%). .sup.1H NMR
(CDCl.sub.3, 400 mHz) .delta. 8.56 (d, 2H, J=6.2 Hz), 8.24 (d,1H,
J=8.3 Hz), 8.12 (d, 1H, J=8.3 Hz), 7.85 (d, 1H, J=8.3 Hz), 7.75
(ddd, 1H, J=8.5, 7, 1.6 Hz), 7.70 (d, 1H, J=8.7 Hz), 7.65 (d, 2H,
J=6.2 Hz), 7.57 (m, 1H), 7.41 (m, 2H), 7.08 (m, 2H), 5.45 (s, 2H),
4.27 (s, 3H). MS (AP+) m/e 394 (MH+).
Preparation 76
4-(3-methyl-5-(pyridin-4-yl)-3H-1,2,3-triazol-4-yl)phenol
[0347] A solution of
4-(5-(4-methoxyphenyl)-1-methyl-1H-1,2,3-triazol-4-yl)pyridine (170
mg, 0.64 mmol) in dichloromethane (5 mL) was treated at RT With
boron tribromide (1.27 mL of 1M in dichloromethane) and the mixture
was stirred overnight. Aqueous 1N NaOH (10 mL) was added, and after
being stirred 1 h the mixture was extracted with dichloromethane
(20 mL). The aqueous layer was acidified to pH 7 with 2N HCl, and
extracted with ethyl acetate (2.times.15 mL). The extracts were
dried with sodium sulfate and concentrated giving a yellow solid
(142 mg, 88%). .sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. .sup.1H
NMR (CDCl.sub.3, 400 mHz) .delta. 8.39 (d, 2H, J=5-6 Hz), 7.49 (d,
2H, J=5-6 Hz), 7.09 (d, 2H, J=8.7 Hz), 6.95 (d, 2H, J=8.7 Hz), 3.87
(s, 3H). MS (AP-) 351 (M-H).
EXAMPLE 80
2-((4-(3-methyl-5-(pyridin-4-yl)-3H-1,2,3-triazol-4-yl)
phenoxy)methyl)quinoline
[0348] A mixture of
4-(3-methyl-5-(pyridin-4-yl)-3H-1,2,3-triazol-4-yl)phenol (88 mg,
0.35 mmol), 2-(chloromethyl)quinoline hydrochloride (82 mg, 0.38
mmol), and cesium carbonate (455 mg, 1.4 mmol) in dimethylformamide
was stirred at 65.degree. C. for 20 h, filtered, and concentrated.
The residue was chromatographed on silica eluting with a gradient
of 50% to 100% ethyl acetate in hexanes giving a light yellow solid
(100 mg, 73%). .sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.48 (d,
2H, J=6.2 Hz), 8.24 (d, 1H, J=8.3 Hz), 8.09 (d, 1H, J=8.3 HZ), 7.85
(d, 1H, J=7.9 Hz), 7.76 (ddd, 1H, J=8.5, 7, 1Hz), 7.70 (d, 1H,
J=8.7 Hz), 7.57 (m, 1H), 7.54 (m, 2H), 7.24 (m, 2H), 7.20 (m, 2H).
5.46 (s, 2H), 3.90 (s, 3H). MS (AP+) m/e 394 (MH+).
Preparation 77
4-(1-(pyridin-4-yl)-1H-imidazol-2-yl)phenol
[0349] According to the procedure for preparation of
4-(3-methyl-5-(pyridin-4-yl)-3H-1,2,3-triazol-4-yl)phenol, except
that 4:1 dichloromethane:2-propanol was used in place of ethyl
acetate to extract the product,
4-(2-(4-methoxyphenyl)-1H-imidazol-1-yl)pyridine (125 mg, 0.5 mmol)
was treated with 1.25 mmol of boron tribromide to give 90 mg of a
colorless solid. .sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.52 (d,
2H, J=6 Hz), 7.14 (m, 2H), 7.11-7.08 (m, 4H), 6.79 (m, 2H), 2.94
(br, 1 H).
Preparation 78
4-(2-(4-methoxyphenyl)-1H-imidazol-1-yl)pyridine
[0350] Phosphorus pentachloride (572 mg, 2.75 mmol) was added to a
mixture of 4-methoxy-N-(pyridin-4-yl)benzamide (626 mg, 2.75 mmol)
in phosphorus oxychloride (3 mL) and the mixture was heated a
105.degree. C. oil bath for 4 h. The mixture was concentrated to
dryness. To the residue was added 2,2-dimethoxyethylamine (3.1 g)
in methanol, and the mixture was stirred at RT. After more than one
hour the mixture was partially concentrated to remove most of the
methanol, stirred at RT overnight and concentrated to dryness.
Isopropyl alcohol (10 mL) and conc. HCl (15 mL) were added and the
mixture was heated at 80.degree. C. for 24 h. Solid sodium
bicarbonate was added to bring the pH to 7-8, and the mixture was
extracted with dichloromethane (3.times.50 mL) which was dried
(sodium sulfate) and concentrated. Chromatography on silica eluted
with 25% to 100% ethyl acetate-hexanes gave 130 mg (20%) of a
yellow solid. .sup.1H NMR (CDCl.sub.3, 400 mHz) .delta. 8.55 (d,
2H, J=6 Hz), 7.22 (d, 2H, J=9Hz), 7.17 (s, 1H), 7.12 (s, 1H), 7.05
(d, 2H, J=6 Hz), 6.75 (d, 2H, J=9 Hz), 3.72 (s, 3H).
Preparation 79
4-methoxy-N-(pyridin-4-yl)benzamide
[0351] 4-Aminopyridine (1.94 g, 20.6 mmol) was added to a solution
of p-anisoyl chloride (3.5 g, 20.6 mmol) and triethylamine (8.6 mL,
62 mmol) in dichloromethane (100 mL) at 0.degree. C. The mixture
was stirred 3 h at RT, and then extracted successively with 1N
NaOH, water and brine, dried over sodium sulfate, and concentrated.
Chromatography on silica (gradient of 30% to 100% ethyl
acetate-hexanes) gave 3.8 g (81%) of a colorless solid. .sup.1H NMR
(CDCl.sub.3, 400 mHz) .delta. 8.49 (m, 2H), 8.19 (br, 1H), 7.85 (m,
2H), 7.59 (m, 2H), 6.95 (m, 2H), 3.85 (s, 3H), MS (AP+) 229
(MH+).
EXAMPLE 81
2-((4-(1-(pyridin-4-yl)-1H-imidazol-2-yl)phenoxy)methyl)quinoline
[0352] According to the procedure for preparation of
2-((4-(3-methyl-5-(pyridin-4-yl)-3H-1,2,3-triazol-4-yl)phenoxy)methyl)qui-
noline, 4-(1-(pyridin-4-yl)-1H-imidazol-2-yl)phenol (90 mg),
2-(chloromethyl)quinoline hydrochloride (81 mg) and cesium
carbonate (495 mg) gave 120 mg as an off-white solid (84%). .sup.1H
NMR (CDCl.sub.3, 400 mHz) .delta. 8.59 (m, 2H), 8.16 (d, 1H, J =8.3
Hz), 8.04 (d, 1H, J=8.3 Hz), 7.79 (d, 1H, J=7.9 Hz), 7.70 (ddd,
1H), 7.60 (d, 1H, J=8.3 Hz), 7.52 (ddd, 1H), 7.28 (m, 2H), 7.22 (d,
1H, J=1 Hz), 7.15 (d, 1H, J=1 Hz), 7.11 (m, 2H), 6.94 (m, 2H), 5.34
(s, 2H). HPLC-MS (system 1) 4.53 min, m/e 379 (MH+).
Preparation 80
4-(1-(4-methoxyphenyl)-1H-imidazol-5-yl)pyridine
[0353] 4-Methoxyaniline (2.46 g, 20 mmol) and
pyridine-4-carboxaldehyde (1.9 mL, 10 mmol) in toluene (110 mL) in
a flask attached to a Dean-Stark trap and reflux condensor was
heated at reflux. After 40 hours, the reaction was complete by
infrared spectral analysis and mass spectral analysis. The toluene
was removed via distillation through the Dean-Stark sidearm, the
residue was dissolved in methanol (100 mL) and ca. 1/2 of the crude
imine (ca. 10 mmol, 50 mL of methanol solution) was diluted with
methanol (20 mL) and 1,2-dimethoxyethane (20 mL). The solution was
then treated with potassium carbonate (2.76 g, 20 mmol) and
tosylmethylisocyanide (TOSMIC, 2.93 g, 15 mmol) and was heated at
reflux for 3 hours. After cooling to room temperature, the solvent
was removed in vacuo, and the residue was dissolved in methylene
chloride and was washed with brine. The brine layer was extracted
with methylene chloride and the combined organic layers were dried
(MgSO.sub.4), were filtered, and were concentrated in vacuo. The
residue was purified by silica gel chromatography with ethyl
acetate--hexanes--methanol (80:20:0 to 76:19:5) to afford 1.4 g
(56% yield) of the title compound; diagnostic .sup.13C NMR signals
(100 MHz, CDCl.sub.3) .delta. 160.039, 150.161, 141.009, 137.240,
130.839, 129.179, 127.287, 121.597, 115.106, 55.801; MS (AP/Cl)
252.4 (M.sup.+H)+.
Preparation 81
4-(1-(4-(benzyloxy)phenyl)-1H-imidazol-5-yl)pyridine
[0354] The title compound was prepared using the method described
for Preparation 80, substituting 4-benzyloxyaniline for
4-methoxyaniline, and afforded
4-(1-(4-(benzyloxy)phenyl)-1H-imidazol-5-yl)pyridine in 54% yield;
diagnostic .sup.13C NMR signals (100 MHz, CDCl.sub.3) .delta.
159.195, 150.132, 141.001, 137.263, 136.403, 130.892, 130.735,
129.389, 128.932, 128.521, 127.751, 127.317, 121.627, 116.078,
70.637; MS (AP/Cl) 328.4 (M+H)+.
Preparation 82
4-(1-(4-methoxyphenyl)-2-methyl-1H-imidazol-5-yl)pyridine
[0355] A solution of diisopropyl amine (0.51 mL, 3.6 mmol) in
tetrahydrofuran (12 mL) at -20.degree. C., was treated with n-butyl
lithium (2.5 M in hexanes, 1.45 mL, 3.6 mmol) and the solution was
stirred for 10 minutes. A solution of Preparation 80
(4-(1-(4-methoxyphenyl)-1H-imidazol-5-yl)pyridine, 730 mg, 2.9
mmol) in tetrahydrofuran was added and the solution became dark
orange. The solution was stirred for 30 minutes as the temperature
was allowed to rise to 0.degree. C. After cooling to -20.degree.
C., methyl iodide (0.54 mL, 8.7 mmol) in tetrahydrofuran (12 mL)
was added and the solution was stirred for 30 min at -20.degree. C.
and for 2 hr at 23.degree. C. The solvent was removed in vacuo, the
residue was diluted with brine and was extracted with ethyl
acetate. The organic layer was then dried (MgSO.sub.4), was
filtered, and was concentrated in vacuo. The residue was purified
by silica gel chromatography using ethyl acetate-hexanes-methanol
(63:32:5 to 72:18:10) to afford 555 mg (72% yield) of the title
compound; diagnostic .sup.13C NMR signals (100 MHz, CDCl.sub.3)
.delta. 160.144, 150.034, 149.197, 137.749, 131.265, 129.463,
128.985, 128.828, 120.849, 115.233, 55.78, 14.203; MS (AP/Cl) 266.4
(M+H)+.
Preparation 83
4-(2-ethyl-1-(4-methoxyphenyl)-1H-imidazol-5-yl)pyridine
[0356] The title compound was prepared using the method described
for Preparation 82 with ethyl iodide used in the place of methyl
iodide and afforded 83% yield of
4-(2-ethyl-1-(4-methoxyphenyl)-1H-imidazol-5-yl)pyridine;
diagnostic .sup.13C NMR signals (100 MHz, CDCl.sub.3) .delta.
160.144, 150.147, 149.990, 137.786, 129.239, 129.037, 128.992,
121.597, 120.909, 115.181, 55.771,21.097,12.348; MS (AP/Cl) 280.5
(M+H)+.
Preparation 84
4-(5-(pyridin-4-yl)-1H-imidazol-1-yl)phenol
[0357] A solution of Preparation 81
(4-(1-(4-(benzyloxy)phenyl)-1H-imidazol-5-yl)pyridine, 2 g, 6.1
mmol) and anisole (13 mL, 122 mmol) in trifluoracetic acid (50 mL)
was heated at 75.degree. C. for 24 h. The solvent was removed in
vacuo and the residue was purified via silica gel chromatography
with chloroform-methanol-ammonium hydroxide (94:5:1) to afford 1.27
g (88%) of the title compound; diagnostic .sup.13C NMR signals (100
MHz, CDCl.sub.3) .delta. 158.402, 149.145, 141.061, 138.018,
120.600, 129.822, 127.482, 127.370, 121.933, 116.497; MS (AP/Cl)
238.3 (M+H)+.
Preparation 85
4-(2-methyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)phenol
[0358] A solution of boron tribromide (1 M in methylene chloride,
2.1 mL, 2.1 mmol) was added dropwise to a solution of Preparation
82 (4-(1-(4-methoxyphenyl)-2-methyl-1H-imidazol-5-yl)pyridine, 220
mg, 0.83 mmol) in methylene chloride (5 mL) at 0.degree. C. After
stirring at 23.degree. C. for 24 h, aqueous sodium hydroxide
solution (1 N, 15 mL) was added and the mixture was stirred at
23.degree. C. for 1 h. The pH was adjusted to 7 by the addition of
aqueous hydrochloric acid (1N), the mixture was extracted with
methylene chloride/isopropanol (4:1, 3.times.30 mL), the combined
organic layers were dried (MgSO.sub.4), were filtered, and were
concentrated in vacuo. The residue was purified by silica gel
chromatography using chloroform-methanol (20:1 to 10:1) to afford
150 mg (72% yield ) of the title compound; diagnostic .sup.13C NMR
signals (100 MHz, CDCl.sub.3) .delta. 159.337, 149.548, 149.302,
138.302, 131.131, 128.760, 128.170, 127.310, 121.163, 117.237,
13.881; MS (AP/Cl) 252.4 (M+H)+.
Preparation 86
4-(2-ethyl-5-(pyridin-4-yl)-l H-imidazol-1-yl)phenol
[0359] The title compound was prepared using Preparation 4 as the
starting material and the method for Preparation 85. This yielded
4-(2-ethyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)phenol in 70% yield;
diagnostic .sup.13C NMR signals (100 MHz, CD.sub.3OD/CDCl.sub.3)
.delta. 158.574, 149.182, 149.002, 138.511, 130.877, 128.895,
128.200, 127.340, 121.253, 116.692, 20.656, 12.020; MS (AP/Cl)
266.4 (M+H)+.
EXAMPLE 82
2-((4-(5-(pyridin-4-yl)-1H-imidazol-1-yl)phenoxy)methyl)quinoline
[0360] A mixture of Preparation 84
(4-(5-(pyridin-4-yl)-1H-imidazol-1-yl)phenol, 95 mg, 0.4 mmol),
2-chloromethylquinoline hydrochloride (128 mg, 0.6 mmol), and
cesium carbonate (391 mg, 1.2 mmol) in dimethylsulfoxide (2 mL) was
stirred at 23.degree. C. for 24 h. The mixture was diluted with
ethyl acetate/n-butanol (100 mL/5 mL), was washed with water and
then brine, and the organic layer was dried (MgSO.sub.4), was
filtered, and was concentrated in vacuo. The residue was purified
by silica gel chromatography using chloroform/methanol (50:1) to
afford 150 mg (99% yield) of the title compound; diagnostic
.sup.13C NMR signals (100 MHz, CDCl.sub.3) .delta. 158.940,
157.116, 149.990, 147.836, 141.054, 137.405, 130.989, 130.204,
129.650, 129.239, 127.953, 127.871, 127.392, 127.011, 121.627,
119.324, 116.198, 71.990; MS (AP/Cl) 379.4 (M+H)+.
EXAMPLE 83
2-((4-(2-methyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)phenoxy)methyl)quinoline
[0361] The title compound was prepared using Preparation 85 and the
method described in Example 82; 88% yield; diagnostic .sup.13C NMR
signals (100 MHz, CDCl.sub.3) .delta. 159.060, 157.078, 150.004,
147.836, 137.689, 137.397, 130.204, 129.934, 129.239, 128.962,
127.968, 127.871, 127.385, 127.011, 120.886, 119.354, 116.273,
71.975, 14.225; MS (AP/Cl) 393.49 (M+H)+.
EXAMPLE 84
2-((4-(2-ethyl-5-(pyridin-4-yl)-1H-imidazol-1-yl)phenoxy)methyl)quinoline
[0362] The title compound was prepared using Preparation 86 and the
method described in Example 82; 92% yield; diagnostic .sup.13C NMR
signals (100 MHz, CDCl.sub.3) .delta. 159.090, 157.078, 150.147,
149.930, 147.836, 137.734, 137.405, 130.211, 129.680, 129.232,
129.127, 128.970, 127.968, 127.886, 127.392, 127.018, 120.961,
119.354, 116.243, 71.968, 21.090, 12.333; MS (AP/Cl) 407.5
(M+H)+.
Preparation 87
N-(4-methoxyphenyl)isonicotinamide
[0363] A solution of p-anisidine (2.46 g, 20 mmol) and
triethylamine (13.9 mL, 100 mmol) in ethyl acetate (200 mL) was
treated with isonicotinic acid (2.46 g, 20 mmol) followed by
1-propanephosphonic acid cyclic anhydride (50% in ethyl acetate,
15.1 mL, 24 mmol). After stirring at 23.degree. C. for 4 h, the
reaction mixture was diluted with ethyl acetate, was washed with
water and with brine, and the organic layer was dried (MgSO.sub.4),
was filtered, and was concentrated in vacuo. Purification by silica
gel chromatography with chloroform-methanol (40:1) gave 4 g (88%
yield) of the title compound; diagnostic .sup.13C NMR signals (100
MHz, CD.sub.3OD/CDCl.sub.3) .delta. 164.825, 157.213, 149.758,
143.349, 130.989, 123.085, 122.068, 55.285; MS (AP/Cl) 229.3
(M+H)+.
Preparation 88
4-(1-(4-methoxyphenyl)-1H-imidazol-2-yl)pyridine
[0364] Preparation 87 (N-(4-methoxyphenyl)isonicotinamide, 1 g,
4.39 mmol) was dissolved in phosphorous oxychloride (POCl.sub.3) (5
mL) then phosphorous pentachloride (913 mg, 4.39 mmol) was added.
The mixture was heated at 120.degree. C. for 4 h. The POCl.sub.3
was removed in vacuo, aminoacetaldehyde dimethyl acetal (9.5 mL,
87.8 mmol) and isopropanol (10 mL) were added, and the mixture was
stirred at 23.degree. C. for ca. 16 h. The reaction mixture was
concentrated in vacuo and concentrated hydrochloric acid (36.5%, 25
mL) in isopropanol (15 mL) was added. The reaction mixture was
heated at 90.degree. C. for 24 h. After cooling to 23.degree. C.,
aqueous sodium hydroxide (1N) and aqueous sodium bicarbonate were
added to obtain pH=8. The mixture was extracted with methylene
chloride, was dried (MgSO.sub.4), and was filtered and concentrated
in vacuo. The residue was purified by silica gel chromatography
with ethyl acetate/hexanes/methanol (80:20:0 to 76:19:5) to afford
811 mg (74% yield) of the title compound; diagnostic .sup.13C NMR
signals (100 MHz, CDCl.sub.3) .delta. 160.069, 149.952, 144.142,
137.853, 131.004, 129.882, 127.414, 124.977, 122.195, 115.114,
55.808; MS (AP/Cl) 252.4 (M+H)+.
Preparation 89
4-(2-(pyridin-4-yl)-1H-imidazol-1-yl)phenol
[0365] The title compound was prepared using the method outlined in
Preparation 85 with the substitution of Preparation 88 for
Preparation 82; 86% yield; diagnostic .sup.13C NMR signals (100
MHz, CD.sub.3OD/CDCl.sub.3) .delta. 158.372, 149.145, 143.641,
138.257, 129.232, 128.985, 127.347, 125.418, 122.666, 116.505; MS
(AP/Cl) 238.4 (M+H)+.
EXAMPLE 85
[0366]
2-((4-(2-(pyridin-4-yl)-1H-imidazol-1-yl)phenoxy)methyl)quinoline
[0367] The title compound was prepared using the method outlined in
Example 82 with the substitution of Preparation 89 for Preparation
84; 98% yield; diagnostic .sup.13C NMR signals (100 MHz,
CDCl.sub.3) .delta. 158.948, 157.108, 149.847, 147.814, 137.868,
137.420, 131.445, 130.226, 129.942, 127.968, 127.871, 127.534,
127.026, 124.954, 122.247, 119.339, 116.190, 71.968; MS (AP/Cl)
379.4 (M+H)+.
[0368] The invention described and claimed herein is not to be
limited in scope by the specific embodiments herein disclosed,
since these embodiments are intended as illustrations of several
aspects of the invention. Any equivalent embodiments are intended
to be within the scope of this invention. Indeed, various
modifications of the invention in addition to those shown and
described herein will become apparent to those skilled in the art
from the foregoing description. Such modifications are also
intended to fall within the scope of the appended claims.
* * * * *